WO2017212012A1 - New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them - Google Patents

New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them Download PDF

Info

Publication number
WO2017212012A1
WO2017212012A1 PCT/EP2017/064067 EP2017064067W WO2017212012A1 WO 2017212012 A1 WO2017212012 A1 WO 2017212012A1 EP 2017064067 W EP2017064067 W EP 2017064067W WO 2017212012 A1 WO2017212012 A1 WO 2017212012A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
pyrimidin
group
carbonyl
pyrrolo
Prior art date
Application number
PCT/EP2017/064067
Other languages
French (fr)
Inventor
András Kotschy
Csaba WÉBER
Attila Vasas
Balázs MOLNÁR
Árpád KISS
Alba Macias
James Brooke MURRAY
Elodie LEWKOWICZ
Olivier Geneste
Maïa CHANRION
Didier DEMARLES
Original Assignee
Les Laboratoires Servier
Vernalis (R&D) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2018564356A priority Critical patent/JP6928005B2/en
Priority to MYPI2018002416A priority patent/MY196562A/en
Priority to KR1020197000834A priority patent/KR20190016106A/en
Priority to TNP/2018/000410A priority patent/TN2018000410A1/en
Priority to ES17727927T priority patent/ES2775789T3/en
Priority to US16/306,933 priority patent/US11046681B2/en
Priority to RS20200266A priority patent/RS60029B1/en
Priority to CU2018000145A priority patent/CU20180145A7/en
Priority to LTEP17727927.0T priority patent/LT3468974T/en
Priority to RU2018147430A priority patent/RU2743163C2/en
Priority to MX2018015216A priority patent/MX2018015216A/en
Priority to CA3027014A priority patent/CA3027014C/en
Priority to AU2017277734A priority patent/AU2017277734B2/en
Priority to CR20180564A priority patent/CR20180564A/en
Priority to MA45222A priority patent/MA45222B1/en
Priority to DK17727927.0T priority patent/DK3468974T3/en
Application filed by Les Laboratoires Servier, Vernalis (R&D) Limited filed Critical Les Laboratoires Servier
Priority to SI201730260T priority patent/SI3468974T1/en
Priority to UAA201900217A priority patent/UA123794C2/en
Priority to SG11201810629QA priority patent/SG11201810629QA/en
Priority to CN201780035584.8A priority patent/CN109311888B/en
Priority to EA201892838A priority patent/EA037211B1/en
Priority to MDE20190460T priority patent/MD3468974T2/en
Priority to EP17727927.0A priority patent/EP3468974B1/en
Priority to PE2018003159A priority patent/PE20220567A1/en
Priority to PL17727927T priority patent/PL3468974T3/en
Priority to BR112018075433-1A priority patent/BR112018075433A2/en
Priority to MEP-2020-47A priority patent/ME03670B/en
Publication of WO2017212012A1 publication Critical patent/WO2017212012A1/en
Priority to PH12018502515A priority patent/PH12018502515A1/en
Priority to IL263463A priority patent/IL263463B/en
Priority to ECSENADI201890144A priority patent/ECSP18090144A/en
Priority to CONC2018/0013210A priority patent/CO2018013210A2/en
Priority to HRP20200361TT priority patent/HRP20200361T1/en
Priority to CY20201100414T priority patent/CY1122870T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Definitions

  • the present invention relates to new piperidinyl derivatives, to a process for their preparation and to pharmaceutical compositions containing them.
  • Ubiquitination is a process controlling essential cellular functions such as protein turnover and homeostasis, protein activation and localisation.
  • Ubiquitin is a 76 amino acids polypeptide which is covalently attached to postranslationnaly modified protein substrates via an isopeptide bond.
  • Deubiquinating enzymes are in majority cysteine proteases that cleave the ubiquitin-ubiquitin bond or ubiquitin-protein bond at the Cter glycine of Ubiquitin. Approximately 100 DUBs regulate the thousands ubiquitinated proteins and then some redundancy of deubiquitinase substrates regulation are observed.
  • Dysregulation of DUBs have been associated with several diseases such as neurodegenerative and infectious diseases (Edelman et al, Expert Rev. Mol. Med. 2011, 13, 1-17) and human malignancies (Pal et al, Cancer Res. 2014, 74, 4955-4966). Accordingly, overexpression of DUBs or increase of their activity have been associated to numerous types of cancers (Luise et al, Plos One 2011, 6, el5891; Rolen et al, Mol. Carcinog. 2006, 45, 260-269) and poor prognosis.
  • Ubiquitin Specific Protease 7 (USP7), also known as Herpes-virus-Associated Ubiquitin- Specific Protease (HAUSP), belongs to the deubiquitinating family. USP7 has been reported to stabilize numerous oncogenes involved in survival and proliferations via cell cycle progression, apoptosis, DNA repair, DNA replication and epigenetic factors regulation (Nicholson et al, Cell Biochem. Biophys. 2011, 60, 61-68). In addition, USP7 has been shown to regulate immune response via inflammation and Treg modulation (Van Loosdregt et al, Immunity 2013, 39, 259-27; Colleran et al, Proc. Natl. Acad. Sci.
  • HUSP7 Herpes-virus-Associated Ubiquitin- Specific Protease
  • USP7 has also been implicated in other pathologic states such as neurodevelopmental disorder (Hao et al, Mol. Cell 2015, 59, 956-969) and viral infection (Holowaty et al, Biochem. Soc. Trans. 2004, 32, 731-732).
  • USP7 overexpression has been associated with late stages of cancers and poor prognosis in lung, neuroblastoma, myeloma, prostate, colon and breast cancers. Although some inhibitors have been published in the literature, most of them were not selective and, to date, no USP7 inhibitors have entered the clinic (Kemp et al, Progress in Medicinal Chemistry 2016, 55, 149-192). There is, therefore, a therapeutic need for compounds that inhibit the activity of the protein USP7.
  • the compounds of the present invention have pro-apoptotic and/or anti-proliferative properties making it possible to use them in pathologies involving a defect in apoptosis, such as, for example, in the treatment of cancer and of immune and auto-immune diseases.
  • the present invention relates more especially to compounds of formula (I):
  • ⁇ P i represents an aryl group or a heteroaryl group
  • ⁇ P 2 represents a hydrogen atom or a halogen atom
  • ⁇ P 3 represents a hydrogen atom, a linear or branched (Ci-Ce)alkyl group, a linear or branched halo(Ci-C6)alkyl, a -C(0)-Rs group, a -C(0)-ORs group,
  • ⁇ n is an integer equal to 0, 1 or 2
  • ⁇ W represents the group wherein:
  • A represents a heteroaryl ring
  • X represents a carbon atom or a nitrogen atom
  • R4 represents a hydrogen atom, a halogen atom, a linear or branched (Ci-C 6 )alkyl group, a linear or branched (C 2 -C 6 )alkenyl group, a linear or branched (C2-Ce)alkynyl group, a -Y1-NR6R7 group, a -Y1-OR5 group, a linear or branched halo(Ci-C 6 )alkyl group, an oxo group, a -Yi-Cyi group, a -Cyi-R 7 group, a -Cyi-OR 7 group, or a -Yi-NR 6 -C(0)-R 7 group,
  • ⁇ R 5 represents a hydrogen atom, a halogen atom, a linear or branched (Ci-C 6 )alkyl group, a cyano group, or a -hydroxy(Ci-Ce)alkyl group, ⁇ 5 represents a hydrogen atom, a linear or branched (Ci-Ce)alkyl group, or a -Y 2 -Si[(Ci-C 4 )alkyl] 3 group,
  • ⁇ R 7 represents a hydrogen atom, a linear or branched (Ci-Ce)alkyl group, or a -Y 2 -Cy 2 group,
  • ⁇ Yi and Y 2 independently of one another represent a bond or a linear or branched (Ci-C 4 )alkylene group
  • ⁇ Rs represents a hydrogen atom or a linear or branched (Ci-Ce)alkyl group
  • Cyi and Cy 2 independently of one another, represent a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, it being understood that:
  • aryl means a phenyl, naphthyl, or indanyl group
  • heteroaryl means any mono- or fused bi-cyclic group composed of from 5 to 10 ring members, having at least one aromatic moiety and containing from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen,
  • cycloalkyl means any mono- or fused bi-cyclic non-aromatic carbocyclic group containing from 3 to 7 ring members
  • heterocycloalkyl means any non-aromatic mono- or fused bi-cyclic group containing from 3 to 10 ring members, and containing from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, it being possible for the aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups so defined to be substituted by from 1 to 4 groups selected from linear or branched (Ci-Ce)alkyl, linear or branched (C 2 -C 6 )alkenyl, linear or branched (C 2 -C 6 )alkynyl, linear or branched halo(Ci-C 6 )alkyl, -Yj-OR', -Yi-NR'R", -Yi-S(0) m -R', oxo (or N-oxide where appropriate), nitro, cyano, -C(0)-R', -C(0)-OR', -0-C(0)-R', -C
  • the substituents of the pair (R', R' ') form together with the nitrogen atom carrying them a non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen a second heteroatom selected from oxygen and nitrogen, it being understood that the nitrogen in question may be substituted by from 1 to 2 groups representing a hydrogen atom, or a linear or branched (Ci-Ce)alkyl group, and it being understood that m is an integer equal to 0, 1 and 2, their enantiomers, diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.
  • heteroaryl groups there may be mentioned, without implying any limitation, pyrrolyl, furyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, pyridinonyl, indolyl, dihydroindolyl, dihydroisoindolyl, indazolyl, dihydrocyclopentathienyl, benzothienyl, tetrahydrobenzothienyl, benzofuranyl, imidazopyridinyl, benzotriazolyl, benzodioxolyl, dihydrobenzodioxinyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, tetrahydroisoquinol,
  • cycloalkyl groups there may be mentioned, without implying any limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.
  • heterocycloalkyl groups there may be mentioned, without implying any limitation, pyrrolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, etc.
  • W advantageously represents the group
  • R4, R 5 and A are as defined for formula (I).
  • W advantageously represents the group mula (I).
  • Ri advantageously represents a phenyl group.
  • the compounds of formula (I) display a trans configuration as follows:
  • the compounds of formula (I) display a trans configuration as follows:
  • R 2 represents a hydrogen atom.
  • R 3 represents a hydrogen atom, a methyl group, a -CH 2 -CH(CH 3 ) 2 group, a -CH 2 -CF 3 group, a -C(0)-CH 3 group, a -C(0)-CH(CH 3 ) 2 group, a -C(0)-CH 2 -C(CH 3 ) 3 group, or a -C(0)-OC(CH 3 ) 3 group.
  • R4 represents a hydrogen atom, a linear or branched (Ci-Ce)alkyl group, a linear or branched (C 2 -C 6 )alkenyl group, a linear or branched (C 2 -C 6 )alkynyl group, a -Y 1 -NR 6 R 7 group, a -Y 1 -OR 6 group, a linear or branched halo(Ci-C6)alkyl group, a -Yi-Cyi group, a -Cyi-R 7 group, or a -Cyi-OR 7 group.
  • Cyi represents a phenyl group, a naphthyl group, a thienyl group, a thiazolyl group, a pyrazolyl group, an imidazolyl group, a pyridinyl group, a pyrimidinyl group, a pyridinonyl group, a benzodioxolyl group, a dihydrobenzodioxinyl group, a cyclopropyl group, a cyclobutyl group, or a piperidinyl group.
  • R 5 represents a hydrogen atom, an iodine atom, a chlorine atom, a methyl group or a -CH 2 -OH group.
  • R ⁇ represents a hydrogen atom, a methyl group, or a -(CH 2 ) 2 -Si(CH 3 ) 3 group.
  • R 7 preferably represents a hydrogen atom, a methyl group, or a -CH 2 -Cy 2 group.
  • Cy 2 represents a phenyl group.
  • the invention relates also to a process for the preparation of compounds of formula (I), which process is characterized in that there is used as starting material the compound of formula (II):
  • W is as defined for formula (I), to yield the compound of formula (I-a), a particular case of the compounds of formula (I): wherein R l s R 2 , R 3 ', n and W are as defined hereinbefore, which compound of formula (I/a) may then, if required, be subjected to a reaction removing the R 3 ' group, to yield the compound of formula (I-b), a particular case of the compounds of formula (I):
  • R l s R 2 , n and W are as defined hereinbefore, which compound of formula (I/b) may then, if required, be subjected to a coupling reaction with compound of formula R 3 "-C1 wherein R 3 " represents a linear or branched (Ci-C 6 )alkyl group, a linear or branched halo(Ci-C6)alkyl, or a -C(0)-Rs group wherein R 8 is as defined for formula (I), to yield the compound of formula (I-c), a particular case of the compounds of formula (I):
  • the present invention relates also to pharmaceutical compositions comprising at least one compound of formula (I) in combination with one or more pharmaceutically acceptable excipients.
  • compositions according to the invention there may be mentioned more especially those that are suitable for oral, parenteral, nasal, per- or trans-cutaneous, rectal, perlingual, ocular or respiratory administration, especially tablets or dragees, sublingual tablets, sachets, paquets, capsules, glossettes, lozenges, suppositories, creams, ointments, dermal gels, and drinkable or injectable ampoules.
  • compositions according to the invention comprise one or more excipients or carriers selected from diluents, lubricants, binders, disintegration agents, stabilisers, preservatives, absorbents, colorants, sweeteners, flavourings etc.
  • ⁇ as diluents: lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, glycerol,
  • ⁇ as lubricants silica, talc, stearic acid and its magnesium and calcium salts, polyethylene glycol,
  • binders magnesium aluminium silicate, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidone,
  • ⁇ as disintegrants agar, alginic acid and its sodium salt, effervescent mixtures.
  • the dosage varies according to the sex, age and weight of the patient, the administration route, the nature of the therapeutic indication, or of any associated treatments, and ranges from 0.01 mg to 1 g per 24 hours in one or more administrations.
  • the present invention relates also to the combination of a compound of formula (I) with anti-cancer agents selected from genotoxic agents, mitotic poisons, antimetabolites, proteasome inhibitors, kinase inhibitors, protein-protein interaction inhibitors, immunomodulators, E3 ligase inhibitors, chimeric antigen receptor T-cell therapy and antibodies, and also to pharmaceutical compositions comprising that type of combination and their use in the manufacture of medicaments for use in the treatment of cancer.
  • the combination of a compound of formula (I) with an anticancer agent may be administered simultaneously or sequentially.
  • the administration route is preferably the oral route, and the corresponding pharmaceutical compositions may allow the instantaneous or delayed release of the active ingredients.
  • the compounds of the combination may moreover be administered in the form of two separate pharmaceutical compositions, each containing one of the active ingredients, or in the form of a single pharmaceutical composition, in which the active ingredients are in admixture.
  • the compounds of formula (I) may also be used in combination with radiotherapy in the treatment of cancer.
  • Thin layer chromatography was conducted with 5 x 10 cm plates coated with Merck Type 60 F254 silica-gel.
  • Microwave heating was performed in an Anton Parr MonoWave or CEM Discover® instrument.
  • Preparative HPLC purifications were performed on an HANBON NP7000 Liquid Chromatography system with a Gemini-NX ® 5 ⁇ C18, 250 mm x 50 mm i.d. column running at a flow rate of 99.9 mL min "1 with UV diode array detection (210 - 400 nm) using 5 mM aqueous NH 4 HCO 3 solution and MeCN as eluents unless specified otherwise.
  • Analytical LC-MS The compounds of the present invention were characterized by high performance liquid chromatography-mass spectroscopy (HPLC-MS) on Agilent HP 1200 with Agilent 6140 quadrupole LC/MS, operating in positive or negative ion electrospray ionisation mode. Molecular weight scan range is 100 to 1350. Parallel UV detection was done at 210 nm and 254 nm. Samples were supplied as a 1 mM solution in ACN, or in THF/H 2 0 (1 : 1) with 5 ⁇ , loop injection. LCMS analyses were performed on two instruments, one of which was operated with basic, and the other with acidic eluents.
  • Acidic LCMS ZORBAX Eclipse XDB-C18, 1.8 ⁇ , 50 mm x 4.6 mm i.d. column at 40 °C, at a flow rate of 1 mL min "1 using 0.02 % v/v aqueous formic acid (Solvent A) and 0.02 % v/v formic acid in acetonitrile (Solvent B) with a gradient starting from 100% Solvent A and finishing at 100 % Solvent B over various/certain duration of time.
  • Solvent A 0.02 % v/v aqueous formic acid
  • Solvent B 0.02 % v/v formic acid in acetonitrile
  • 1H-NMR measurements were performed on Bruker Avance III 500 MHz spectrometer and Bruker Avance III 400 MHz spectrometer, using DMSO-d 6 or CDC1 3 as solvent.
  • 1H NMR data is in the form of delta values, given in part per million (ppm), using the residual peak of the solvent (2.50 ppm for DMSO-d 6 and 7.26 ppm for CDC1 3 ) as internal standard.
  • Splitting patterns are designated as: s (singlet), d (doublet), t (triplet), q (quartet), quint (quintet), sept (septet), m (multiplet), brs (broad singlet), brd (broad doublet), brt (broad triplet), brq (broad quartet), brm (broad multiplet), vbrs (very broad singlet), dd (doublet of doublets), td (triplet of doublets), dt (doublet of triplets), dq (doublet of quartet), ddd (doublet of doublet of doublets), dm (doublet of multiplets), tm (triplet of multiplets), qm (quartet of multiplets).
  • the mixture was diluted with water (200 ml) (or. 25 % aq. NH 3 ) and cooled to r.t.
  • the mixture was filtered, and washed with water (3x30 ml), aq. NH 3 solution (40 ml, 25 %), water (3 x 50 ml), heptane (50 then 30 ml), dried in vacuum.
  • reaction mixture was evaporated to Celite, then purified by flash chromatography (heptane :EEO, gradient).
  • Step 2 The corresponding 4-methoxy-7-aryl-pyrrolo[2,3-d]pyrimidine (61.3 mmol, 1 eq.), cc. HC1 aqueous solution (10 ml, -12.2 M, 122.5 mmol, 2 eq.) and PDO (70 ml) was stirred at 100 °C for 0.5-2 hours. After the reaction completed, the mixture was partially evaporated. The formed suspension was filtered and the solid on the filter was washed with water and dried.
  • the reaction mixture was filtered, the solid was washed with DMF.
  • the resulted filtrate was purified by preparative LC (on C-18 Gemini-NX 5 ⁇ column, 5 mM aqueous NH 4 HC0 3 -MeCN, gradient).
  • the mixture was purified by preparative LC (on C-18 Gemini-NX 5 ⁇ column, 5 mM aqueous NH 4 HC0 3 -MeCN, gradient, resulted as free base).
  • reaction mixture was evaporated, the residue was taken in DMF and injected to preparative LC (on C-18 Gemini-NX 5 ⁇ column, 5 mM aqueous NH 4 HC03-MeCN, gradient).
  • reaction mixture was evaporated and the residue was trituated with water. The resulted solid was filtered off.
  • Step 1 tert-butyl (3R,4R)-4-(4-oxopiperidine-l -carbonyl)-3-phenyl-piperidine- 1 - carboxylate
  • Preparation R21 7-(cyclopropylmethyl)-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4-one Using General Procedure 1 starting from Preparation Rla and cyclopropylmethyl bromide as reagents, Preparation R21 was obtained. HRMS calculated for C10H11N3O: 189.0902; found 190.0980 [(M+H) + form].
  • N-amino compound 300 mg, 1.83 mmol
  • acetylacetone 206 ⁇ , 201 mg 2.01 mmol
  • TFA 5 ml
  • 1 ml water and 10 ml methanol were added, then it was evaporated.
  • the residue was purified by preparative LC (on C-18 Gemini-NX 5 ⁇ column, 5 mM aqueous NH 4 HCO 3 - MeCN, gradient) to give Preparation R2t.
  • HRMS calculated for CnHi 0 N 4 O: 214.0855; found 215.0935 [(M+H) + form] .
  • Preparation R2x 7-(2,2,2-trifluoroethyl)-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4-one Using General Procedure 1 starting from Preparation Rla and 2,2,2-trifluoroethyl trifluoromethanesulfonate as reagents, Preparation R2x was obtained. HRMS calculated for CsHgNsOFs: 217.0463; found 218.0543 [(M+H) + form].
  • Preparation R2an 7-(3,5-dichlorophenyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one Using General Procedure 2 starting from Preparation Rla and 3,5-dichlorophenylboronic acid as reagents, Preparation R2an was obtained. HRMS calculated for C12H7CI2N3O: 278.9966; found 280.0040 [(M+H) + form].
  • Preparation R2au 4- ⁇ 4-oxo-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-7-yl ⁇ benzonitrile Using General Procedure 3 starting from Preparation Rib and 4-iodobenzonitrile as reagents, Preparation R2au was obtained. HRMS calculated for C 13 H 8 N 4 O: 236,0698; found 237.0775 [(M+H) + form].
  • EXAMPLE 1 ⁇ tert-butyl (3R,4R)-4- [4-hydroxy-4- [(7-methyl-4-oxo-pyrrolo [2,3-d] pyrimidin-3- yl)methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 1) Using General Procedure 5 starting from Preparation R2g and Preparation Rlc as reagents, EXAMPLE 1 was obtained. HRMS calculated for C30H39N5O5 : 549.2951; found 550.3021 [(M+H) form].
  • EXAMPLE 2 ⁇ tert-butyl (3R,4R)-4- [4-hydroxy-4- [(4-oxothieno [2,3-d] pyrimidin-3- yl)methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 2) Using General Procedure 5 starting from 3H-thieno[2,3-d]pyrimidin-4-one and Preparation Rlc as reagents, EXAMPLE 2 was obtained. HRMS calculated for C 29 H 36 N 4 0 5 S: 552.2406; found 553.2479 [(M+H) form].
  • EXAMPLE 10 ⁇ tert-butyl (3R,4R)-4- [4-hydroxy-4- [(9-methyl-4-oxo-pyrimido [4,5-b] indol-3- yl)methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 10) Using General Procedure 5 starting from Preparation R2n and Preparation Rlc as reagents, EXAMPLE 10 was obtained. HRMS calculated for C 34 H 4 iN 5 0 5 : 599.3108; found 600.3181 [(M+H) form].
  • EXAMPLE 36 ⁇ tert-butyl (3R,4R)-4- [4- [(7-bromo-4-oxo-thieno [3,2-d] yrimidin-3-yl)methyl] -4- hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 36) Using General Procedure 5 starting from 7-bromo-3H-thieno[3,2-d]pyrimidin-4-one and Preparation Rlc as reagents, EXAMPLE 36 was obtained. HRMS calculated for C 2 9H3 5 BrN 4 0 5 S: 630.1511; found 653.1419 [(M+Na) form].
  • EXAMPLE 65 Using General Procedure 5 starting from Preparation R2at and Preparation Rlc as reagents, EXAMPLE 65 was obtained. HRMS calculated for C 37 H 45 N 5 0 7 : 671.3319; found 672.3396 [(M+H) form].
  • EXAMPLE 74 was dissolved in PDO and copper cyanide (4.2 eq), tetraethylammonium cyanide (1.05 eq.), Pd 2 (dba) 3 (0.1 eq.), and 1 , -bis(diphenylphosphino)ferrocene (0.4 eq.) were added. The mixture was heated and stirred at 1 10 °C till the reaction was completed. The residue was purified by flash chromatography in DCM-MeOH gradient to give EXAMPLE 82. HRMS calculated for CseHsoNgOgSi: 690.3561; found 691.3637 [(M+H) form].
  • EXAMPLE 62 (610 mg, 0.92 mmol) was dissolved in 12 ml DCM, then TFA (211 ⁇ , 2.73 mmol, 3 eq.) and formic acid (399 ⁇ , 10.6 mmol, 1 1.5 eq.) were added. The mixture was stirred at r.t. for 118 hours, then potassium carbonate (2.22g 16.1 mmol) was added. The solution was extrated with DCM (2x70 ml) and organic phase was dried (MgS0 4 ) and evaporated.
  • EXAMPLE 121 Using General Procedure 7 starting from EXAMPLE 101 and methyl iodide as reagents, EXAMPLE 121 was obtained as HC1 salt. HRMS calculated for C31H35N5O3 : 525.274; found 526.2802 [(M+H) form].
  • EXAMPLE 12-7 EXAMPLE 6 (370 mg, 0.63 mmol) was dissolved in 2 ml THF and 2 ml water, then phenyl boronic acid (308 mg, 2.52 mmol, 4 eq.), AtaPhos*PdCl 2 (8.6 mg, 0.012 mmol, 0.2 eq.), cesium carbonate (617 mg, 1.89 mmol, 3 eq.) were added.
  • EXAMPLE 62 (1.6 g, 2.4 mmol) was dissolved in 30 ml DCM, then TFA (3 ml) and formic acid (550 ⁇ , 7.2 mmol, 3 eq.) were added. The mixture was stirred at r.t. for 4 days, then potassium carbonate (15 g, 108 mmol) was added. The solution was extrated with DCM and organic phase was dried (MgS0 4 ) and evaporated to give EXAMPLE 162. HRMS calculated for C 3 oH43N 5 0 4 Si: 565.3084; found 566.3138 [(M+H) form].
  • EXAMPLE 191 was obtained. HRMS calculated for C 30 H 32 N 4 O 3 S: 528.2195; found 529.2265 [(M+H) form]. ⁇ 3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -6- iodo-7-(2-trimethylsilylethoxymethyl)pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 192) EXAMPLE 74 (647 mg, 0.82 mmol) was dissolved in 13 ml DCM, then TFA (188 ⁇ , 2.46 mmol, 3 eq.) and formic acid (356 ⁇ , 9.43 mmol, 11.5 eq.) were added.
  • USP7 activity was measured using Rhodamine-110 c-terminal labelled Ubiquitin as a substrate (Viva Biosciences). Incubation with USP7 results in the release of Rhodamine-110 leading to an increase in fluorescence which can be used in the continuous measurement of USP7 activity.
  • the USP7 reactions were performed in a 50 ⁇ , volume, in 384 well black solid low binding plates (Corning #3575).
  • the reaction buffer consisted of 100 mM Bicine pH 8.0, 0.01 % TritonXlOO, 1 mM TCEP, and 10 % DMSO.
  • nM His-His-USP7 0.25 nM His-His-USP7 (aa208-560, [C315A]) was incubated with compound (final concentration 10 % DMSO) for 60 minutes at 30 °C. The reaction was then initiated by the addition of 500 nM Ubiquitin- Rhodamine-110 substrate and the plate read every 3 minutes for 21 minutes to measure the release of Rhodamine-110. Fluorescence Intensity (FLINT) readings were measured using a Biomek Neo plate reader (Ex.485 nm, Em.535 nm).
  • the inhibition of increasing doses of compound was expressed as a percentage reduction in kinetic rate compared to the kinetic rates established between 'DMSO only' and 'total inhibition' controls (no USP7).
  • the inhibitory concentrations that gave a 50 % reduction in kinetic rate (IC 50 ) were determined, from 11 -point dose response curves, in XL-Fit using a 4-Parameter Logistic Model (Sigmoidal Dose-Response Model).
  • the cytotoxicity studies were carried out on the MM IS multiple myeloma tumour cell line.
  • the cells are distributed onto microplates and exposed to the test compounds for 96 hours.
  • the cell viability is then quantified by a colorimetric assay, the Microculture Tetrazolium Assay (Cancer Res., 1987, 47, 939-942).
  • IC 50 the concentration of compound that inhibits cell viability by 50%
  • Table 1 ICsn of USP7 inhibition and of cytotoxicity for MM1S cells
  • the anti-tumour activity of the compounds of the invention is evaluated in a xenograft model of multiple myeloma and/or acute lymphoblastic leukaemia cells.
  • Human tumour cells are grafted subcutaneously into immunosuppressed mice.
  • tumour volume When the tumour volume (TV) reaches about 200 mm 3 , the mice are treated per os with the various compounds once a day for 5 days on/2 days off during 3 weeks. The tumour mass is measured twice weekly from the start of treatment.
  • the compounds of the invention display anti-tumour activities represented by the TGI (tumor growth inhibition) at the end of the treatment period.
  • TGI tumor growth inhibition

Abstract

Compounds of formula (I) wherein R1, R2, R3, n and W are as defined in the description. Medicaments.

Description

NEW PIPERIDINYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION
AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
The present invention relates to new piperidinyl derivatives, to a process for their preparation and to pharmaceutical compositions containing them.
The compounds of the present invention are new and have very valuable pharmacological characteristics in the field of apoptosis and oncology. Ubiquitination is a process controlling essential cellular functions such as protein turnover and homeostasis, protein activation and localisation. Ubiquitin is a 76 amino acids polypeptide which is covalently attached to postranslationnaly modified protein substrates via an isopeptide bond. Deubiquinating enzymes (DUBs) are in majority cysteine proteases that cleave the ubiquitin-ubiquitin bond or ubiquitin-protein bond at the Cter glycine of Ubiquitin. Approximately 100 DUBs regulate the thousands ubiquitinated proteins and then some redundancy of deubiquitinase substrates regulation are observed.
Dysregulation of DUBs have been associated with several diseases such as neurodegenerative and infectious diseases (Edelman et al, Expert Rev. Mol. Med. 2011, 13, 1-17) and human malignancies (Pal et al, Cancer Res. 2014, 74, 4955-4966). Accordingly, overexpression of DUBs or increase of their activity have been associated to numerous types of cancers (Luise et al, Plos One 2011, 6, el5891; Rolen et al, Mol. Carcinog. 2006, 45, 260-269) and poor prognosis.
Ubiquitin Specific Protease 7 (USP7), also known as Herpes-virus-Associated Ubiquitin- Specific Protease (HAUSP), belongs to the deubiquitinating family. USP7 has been reported to stabilize numerous oncogenes involved in survival and proliferations via cell cycle progression, apoptosis, DNA repair, DNA replication and epigenetic factors regulation (Nicholson et al, Cell Biochem. Biophys. 2011, 60, 61-68). In addition, USP7 has been shown to regulate immune response via inflammation and Treg modulation (Van Loosdregt et al, Immunity 2013, 39, 259-27; Colleran et al, Proc. Natl. Acad. Sci. USA 2013, 110, 618-623). USP7 has also been implicated in other pathologic states such as neurodevelopmental disorder (Hao et al, Mol. Cell 2015, 59, 956-969) and viral infection (Holowaty et al, Biochem. Soc. Trans. 2004, 32, 731-732).
USP7 overexpression has been associated with late stages of cancers and poor prognosis in lung, neuroblastoma, myeloma, prostate, colon and breast cancers. Although some inhibitors have been published in the literature, most of them were not selective and, to date, no USP7 inhibitors have entered the clinic (Kemp et al, Progress in Medicinal Chemistry 2016, 55, 149-192). There is, therefore, a therapeutic need for compounds that inhibit the activity of the protein USP7.
In addition to being new, the compounds of the present invention have pro-apoptotic and/or anti-proliferative properties making it possible to use them in pathologies involving a defect in apoptosis, such as, for example, in the treatment of cancer and of immune and auto-immune diseases.
The present invention relates more especially to compounds of formula (I):
Figure imgf000003_0003
Figure imgf000003_0001
wherein:
♦ P i represents an aryl group or a heteroaryl group,
♦ P2 represents a hydrogen atom or a halogen atom,
♦ P 3 represents a hydrogen atom, a linear or branched (Ci-Ce)alkyl group, a linear or branched halo(Ci-C6)alkyl, a -C(0)-Rs group, a -C(0)-ORs group,
♦ n is an integer equal to 0, 1 or 2,
♦ W represents the group wherein:
Figure imgf000003_0002
A represents a heteroaryl ring,
X represents a carbon atom or a nitrogen atom,
R4 represents a hydrogen atom, a halogen atom, a linear or branched (Ci-C6)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-Ce)alkynyl group, a -Y1-NR6R7 group, a -Y1-OR5 group, a linear or branched halo(Ci-C6)alkyl group, an oxo group, a -Yi-Cyi group, a -Cyi-R7 group, a -Cyi-OR7 group, or a -Yi-NR6-C(0)-R7 group,
■ R5 represents a hydrogen atom, a halogen atom, a linear or branched (Ci-C6)alkyl group, a cyano group, or a -hydroxy(Ci-Ce)alkyl group, ■ 5 represents a hydrogen atom, a linear or branched (Ci-Ce)alkyl group, or a -Y2-Si[(Ci-C4)alkyl]3 group,
■ R7 represents a hydrogen atom, a linear or branched (Ci-Ce)alkyl group, or a -Y2-Cy2 group,
■ Yi and Y2 independently of one another represent a bond or a linear or branched (Ci-C4)alkylene group,
♦ Rs represents a hydrogen atom or a linear or branched (Ci-Ce)alkyl group,
♦ Cyi and Cy2 independently of one another, represent a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, it being understood that:
- "aryl" means a phenyl, naphthyl, or indanyl group,
- "heteroaryl" means any mono- or fused bi-cyclic group composed of from 5 to 10 ring members, having at least one aromatic moiety and containing from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen,
- "cycloalkyl" means any mono- or fused bi-cyclic non-aromatic carbocyclic group containing from 3 to 7 ring members,
- "heterocycloalkyl" means any non-aromatic mono- or fused bi-cyclic group containing from 3 to 10 ring members, and containing from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, it being possible for the aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups so defined to be substituted by from 1 to 4 groups selected from linear or branched (Ci-Ce)alkyl, linear or branched (C2-C6)alkenyl, linear or branched (C2-C6)alkynyl, linear or branched halo(Ci-C6)alkyl, -Yj-OR', -Yi-NR'R", -Yi-S(0)m-R', oxo (or N-oxide where appropriate), nitro, cyano, -C(0)-R', -C(0)-OR', -0-C(0)-R', -C(0)-NR'R", -Yi-NR'-C(0)-R", -Yi-NR'-C(0)-OR", halogen, cyclopropyl, and pyridinyl which can be substituted by a linear or branched (Ci-C6)alkyl group, it being understood that R' and R" independently of one another represent a hydrogen atom, a linear or branched (Ci-Ce)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (Ci-Ce)alkoxy group, a linear or branched halo(Ci-C6)alkyl, a linear or branched hydroxy(Ci-C6)alkyl group, a linear or branched (Ci-C6)alkoxy(Ci-C6)alkyl group, a phenyl group, a cyclopropylmethyl group, a tetrahydropyranyl group,
or the substituents of the pair (R', R' ') form together with the nitrogen atom carrying them a non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen a second heteroatom selected from oxygen and nitrogen, it being understood that the nitrogen in question may be substituted by from 1 to 2 groups representing a hydrogen atom, or a linear or branched (Ci-Ce)alkyl group, and it being understood that m is an integer equal to 0, 1 and 2, their enantiomers, diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.
Among the pharmaceutically acceptable acids there may be mentioned, without implying any limitation, hydrochloric acid, hydrobromic acid, sulphuric acid, phosphonic acid, acetic acid, trifluoroacetic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, tartaric acid, maleic acid, citric acid, ascorbic acid, oxalic acid, methanesulphonic acid, camphoric acid etc.
Among the pharmaceutically acceptable bases there may be mentioned, without implying any limitation, sodium hydroxide, potassium hydroxide, triethylamine, tert-butylamine etc.
Among the heteroaryl groups there may be mentioned, without implying any limitation, pyrrolyl, furyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, pyridinonyl, indolyl, dihydroindolyl, dihydroisoindolyl, indazolyl, dihydrocyclopentathienyl, benzothienyl, tetrahydrobenzothienyl, benzofuranyl, imidazopyridinyl, benzotriazolyl, benzodioxolyl, dihydrobenzodioxinyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, quinoxalinyl, dihydroquinoxalinyl, dihydrothienodioxinyl, quinazolinonyl, pyrrolopyridazinyl, dihydropyrrolizinyl, tetrahydroindolizinyl, etc.
Among the cycloalkyl groups there may be mentioned, without implying any limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.
Among the heterocycloalkyl groups there may be mentioned, without implying any limitation, pyrrolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, etc.
In another embodiment of the invention, W advantageously represents the group
wherein R4, R5 and A are as defined for formula (I).
Figure imgf000006_0001
Figure imgf000006_0002
Figure imgf000007_0001
In another embodiment of the invention, W advantageously represents the group mula (I).
Figure imgf000008_0001
Ri advantageously represents a phenyl group.
Advantageously, the compounds of formula (I) display a trans configuration as follows:
Figure imgf000008_0002
or
Figure imgf000008_0003
More preferably, the compounds of formula (I) display a trans configuration as follows:
Figure imgf000009_0001
Preferably, R2 represents a hydrogen atom.
In some preferred embodiment of the invention, R3 represents a hydrogen atom, a methyl group, a -CH2-CH(CH3)2 group, a -CH2-CF3 group, a -C(0)-CH3 group, a -C(0)-CH(CH3)2 group, a -C(0)-CH2-C(CH3)3 group, or a -C(0)-OC(CH3)3 group.
In the preferred compounds of the invention, R4 represents a hydrogen atom, a linear or branched (Ci-Ce)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, a -Y1-NR6R7 group, a -Y1-OR6 group, a linear or branched halo(Ci-C6)alkyl group, a -Yi-Cyi group, a -Cyi-R7 group, or a -Cyi-OR7 group.
Advantageously, Cyi represents a phenyl group, a naphthyl group, a thienyl group, a thiazolyl group, a pyrazolyl group, an imidazolyl group, a pyridinyl group, a pyrimidinyl group, a pyridinonyl group, a benzodioxolyl group, a dihydrobenzodioxinyl group, a cyclopropyl group, a cyclobutyl group, or a piperidinyl group.
Advantageously, R5 represents a hydrogen atom, an iodine atom, a chlorine atom, a methyl group or a -CH2-OH group.
In the preferred compounds of the invention, R^ represents a hydrogen atom, a methyl group, or a -(CH2)2-Si(CH3)3 group.
R7 preferably represents a hydrogen atom, a methyl group, or a -CH2-Cy2 group.
Preferably, Cy2 represents a phenyl group.
Among the preferred compounds of the invention there may be mentioned: - tert-butyl (3S,4S)-4-( {4-hydroxy-4 (4-oxothieno[2,3-60p imidin-3(4H)- yl)methyl]piperidin- 1 -yl} carbonyl)-3-phenylpiperidine- 1 -carboxylate;
- tert-butyl (3i?,4i?)-4-[(4-hydroxy-4- {[4-oxo-7-(pyridin-2-yl)-4,7-dihydro-3H- pyrrolo[2,3-(i]pyrimidin-3-yl]methyl}piperidin- 1 -yl)carbonyl]-3-phenylpiperidine- 1 - carboxylate;
- tert-butyl (3i?,4i?)-4-[(4-hydroxy-4- {[7-(4-methoxyphenyl)-4-oxo-4,7-dihydro-3H- pyrrolo[2,3-(i]pyrimidin-3-yl]methyl}piperidin- 1 -yl)carbonyl]-3-phenylpiperidine- 1 - carboxylate;
- tert-butyl (3i?,4i?)-4-[(4-hydroxy-4- { [ 1 -(4-methoxyphenyl)-4-oxo- 1 ,4-dihydro-5H- pyrazo lo [3 ,4- ]pyrimidin-5 -yljmethyl} piperidin- 1 -yl)carbonyl] -3 -phenylpiperidine- 1 carboxylate;
- tert-butyl (3R,4R)-4-[(4- {[7-(4-fluoro-3-methoxyphenyl)-4-oxo-4,7-dihydro-3H- pyrrolo[2,3-d]pyrimidin-3-yl]methyl} -4-hydroxypiperidin- 1 -yl)carbonyl]-3- phenylpiperidine- 1 -carboxylate;
- tert-butyl (3R,4R)-4-[(4- { [ 1 -(2,3-dihydro- 1 ,4-benzodioxin-6-yl)-4-oxo- 1 ,4-dihydro- 5H-pyrazo lo [3 ,4- ]pyrimidin-5 -yljmethyl} -4-hydroxypiperidin- 1 -yl)carbonyl] -3 - phenylpiperidine- 1 -carboxylate;
- 3-[(4-hydroxy-l-{[(3i?,4i?)-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl] 7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-(i]pyrimidin-4-one;
- 5-[(4-hydroxy-l-{[(3i?,4i?)-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl] l-phenyl-l,5-dihydro-4H-pyrazolo[3,4-(i]pyrimidin-4-one;
- 3-[(4-hydroxy-l-{[(3i?,4i?)-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl] 7-(pyridin-2-yl)-3,7-dihydro-4H-pyrrolo[2,3-(i]pyrimidin-4-one;
- 3-[(4-hydroxy- 1 - { [(3i?,4i?)-3-phenyl- 1 -(2,2,2-trifluoroethyl)piperidin-4- yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3- ]pyrimidin-4-one;
- 3-[(4-hydroxy-l-{[(3i?,4i?)-l-methyl-3-phenylpiperidin-4-yl]carbonyl}piperidin-4- yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-(i]pyrimidin-4-one;
- 7-(4-fluorophenyl)-3-[(4-hydroxy-l-{[(3i?,4i?)-3-phenylpiperidin-4- yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3- ]pyrimidin-4-one;
- 3-[(4-hydroxy-l-{[(3i?,4i?)-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl] 7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-(i]pyrimidin-4-one; - 3-[(4-hydroxy-l-{[(3i?,4i?)-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]- 7-(3-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-(i]pyrimidin-4-one;
- 7-(4-fluorophenyl)-3- [(4-hydroxy- 1 - {[(3R,4R)- 1 -methyl-3 -phenylpiperidin-4- yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3- ]pyrimidin-4-one;
- 7-(3-chlorophenyl)-3-[(4-hydroxy-l-{[(3i?,4i?)-3-phenylpiperidin-4- yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3- ]pyrimidin-4-one;
- 7-(4-chlorophenyl)-3-[(4-hydroxy-l-{[(3i?,4i?)-3-phenylpiperidin-4- yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3- ]pyrimidin-4-one;
- 3-[( 1 - { [(3R,4R)- 1 -acetyl-3-phenylpiperidin-4-yl]carbonyl} -4-hydroxypiperidin-4- yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-(i]pyrimidin-4-one;
- 3-[(4-hydroxy-l-{[(3i?,4i?)-l-methyl-3-phenylpiperidin-4-yl]carbonyl}piperidin-4- yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3- ]pyrimidin-4-one;
- 7-(3-chlorophenyl)-3-[(4-hydroxy-l-{[(3i?,4i?)-l-methyl-3-phenylpiperidin-4- yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3- ]pyrimidin-4-one;
- 7-(4-chlorophenyl)-3-[(4-hydroxy-l-{[(3i?,4i?)-l-methyl-3-phenylpiperidin-4- yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3- ]pyrimidin-4-one;
- 7-(4-fluoro-3-methoxyphenyl)-3-[(4-hydroxy-l-{[(3i?,4i?)-3-phenylpiperidin-4- yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3- ]pyrimidin-4-one;
- 3-[(4-hydroxy-l-{[(3i?,4i?)-l-(2-methylpropyl)-3-phenylpiperidin-4- yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3- ]pyrimidin- 4-one;
- 1 -(2,3-dihydro- 1 ,4-benzodioxin-6-yl)-5- [(4-hydroxy- 1 - {[(3i?,4i?)-3-phenylpiperidin- 4-yl]carbonyl}piperidin-4-yl)methyl]-l,5-dihydro-4H-pyrazolo[3,4- ]pyrimidin-4-one
- 3-[( 1 - { [(3R,4R)- 1 -acetyl-3-phenylpiperidin-4-yl]carbonyl} -4-hydroxypiperidin-4- yl)methyl]-7-(4-fluorophenyl)-3,7-dihydro-4H-pyrrolo[2,3-(i]pyrimidin-4-one;
- (3i?,4i?)-4-[(4-hydroxy-4- { [ 1 -(4-methoxyphenyl)-4-oxo- 1 ,4-dihydro-5H- pyrazolo[3,4-(i]pyrimidin-5-yl]methyl}piperidin- 1 -yl)carbonyl]- 1 , 1 -dimethyl-3- phenylpiperidinium;
- 3-[(4-hydroxy-l-{[(3i?,4i?)-l-(2-methylpropanoyl)-3-phenylpiperidin-4- yl]carbonyl}piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3- ]pyrimidin- 4-one; - 3-[( 1 - { [(3R,4R)- 1 -acetyl-3-phenylpiperidin-4-yl]carbonyl} -4-hydroxypiperidin-4- yl)methyl]-7-(4-methoxyphenyl)-3,7-dihyd
- 3-[( 1 - { [(3R,4R)- 1 -acetyl-3-phenylpiperidin-4-yl]carbonyl} -4-hydroxypiperidin-4- yl)methyl]-7-(3-methoxyphenyl)-3,7-dihydro^
- 3-[( 1 - { [(3R,4R)- 1 -acetyl-3-phenylpiperidin-4-yl]carbonyl} -4-hydroxypiperidin-4- yl)methyl]-7-(3-chlorophenyl)-3,7-dihydro-4H-pyrrolo[2,3- ]pyrimidin-4-one;
- 3-[( 1 - { [(3R,4R)- 1 -acetyl-3-phenylpiperidin-4-yl]carbonyl} -4-hydroxypiperidin-4- yl)methyl]-7-(4-chlorophenyl)-3,7-dihydro-4H-pyrrolo[2,3- ]pyrimidin-4-one;
- 3-[( 1 - { [(3R,4R)- 1 -(2,2-dimethylpropanoyl)-3-phenylpiperidin-4-yl] carbonyl} -4- hydroxypiperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3- ]pyrimidin-4- one;
- 3-[( 1 - { [(3R,4R)- 1 -(3 ,3-dimethylbutanoyl)-3-phenylpiperidin-4-yl]carbonyl} -4- hydroxypiperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3- ]pyrimidin-4- one;
The invention relates also to a process for the preparation of compounds of formula (I), which process is characterized in that there is used as starting material the compound of formula (II):
Figure imgf000012_0001
wherein R2 and n are as defined for formula (I), which is subjected to coupling with a compound of formula (III):
Figure imgf000012_0002
wherein Ri is as defined for formula (I), and R3' represents a -C(0)-ORs group wherein R8 is as defined for formula (I), to yield the compound of formula (IV):
Figure imgf000013_0001
wherein Rl s R2, R3' and n are as defined hereinbefore, compound of formula (IV) which is further converted to an epoxide compound of formula (V):
Figure imgf000013_0002
wherein Rl s R2, R3' and n are as defined hereinbefore, compound of formula (V) which is further subjected to coupling with compound of formula (VI):
Figure imgf000013_0003
wherein W is as defined for formula (I), to yield the compound of formula (I-a), a particular case of the compounds of formula (I):
Figure imgf000014_0001
wherein Rl s R2, R3', n and W are as defined hereinbefore, which compound of formula (I/a) may then, if required, be subjected to a reaction removing the R3' group, to yield the compound of formula (I-b), a particular case of the compounds of formula (I):
Figure imgf000014_0002
wherein Rl s R2, n and W are as defined hereinbefore, which compound of formula (I/b) may then, if required, be subjected to a coupling reaction with compound of formula R3"-C1 wherein R3" represents a linear or branched (Ci-C6)alkyl group, a linear or branched halo(Ci-C6)alkyl, or a -C(0)-Rs group wherein R8 is as defined for formula (I), to yield the compound of formula (I-c), a particular case of the compounds of formula (I):
(I-c)
Figure imgf000014_0003
wherein Rl s R2, R3", n and W are as defined hereinbefore, which compounds of formulae (I/a) to (I/c), which constitute the totality of the compounds of formula (I), may then be purified according to a conventional separation technique, which is converted, if desired, into its addition salts with a pharmaceutically acceptable acid or base and which is optionally separated into its isomers according to a conventional separation technique,
it being understood that at any moment considered appropriate during the course of the process described above, some groups (hydroxy, amino...) of the starting reagents or of the synthesis intermediates can be protected, subsequently deprotected and functionalized, as required by the synthesis.
The compounds of formulae (II), (III), (VI) and R3"-C1 are either commercially available or can be obtained by the person skilled in the art using conventional chemical reactions described in the literature.
Pharmacological studies of the compounds of the invention have shown pro-apoptotic and/or anti-proliferative properties. The ability to reactivate the apoptotic process in cancerous cells is of major therapeutic interest in the treatment of cancers and of immune and auto-immune diseases.
Among the cancer treatments envisaged there may be mentioned, without implying any limitation, treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukemia, cancer of the colon, esophagus and liver, lymphoblastic leukemia, acute myeloid leukemia, lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer. More especially, the compounds according to the invention will be useful in the treatment of chemo-, targeted therapy- or radio -resistant cancers. The present invention relates also to pharmaceutical compositions comprising at least one compound of formula (I) in combination with one or more pharmaceutically acceptable excipients. Among the pharmaceutical compositions according to the invention there may be mentioned more especially those that are suitable for oral, parenteral, nasal, per- or trans-cutaneous, rectal, perlingual, ocular or respiratory administration, especially tablets or dragees, sublingual tablets, sachets, paquets, capsules, glossettes, lozenges, suppositories, creams, ointments, dermal gels, and drinkable or injectable ampoules.
The pharmaceutical compositions according to the invention comprise one or more excipients or carriers selected from diluents, lubricants, binders, disintegration agents, stabilisers, preservatives, absorbents, colorants, sweeteners, flavourings etc.
By way of non-limiting example there may be mentioned:
♦ as diluents: lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, glycerol,
♦ as lubricants: silica, talc, stearic acid and its magnesium and calcium salts, polyethylene glycol,
♦ as binders: magnesium aluminium silicate, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidone,
♦ as disintegrants: agar, alginic acid and its sodium salt, effervescent mixtures.
The dosage varies according to the sex, age and weight of the patient, the administration route, the nature of the therapeutic indication, or of any associated treatments, and ranges from 0.01 mg to 1 g per 24 hours in one or more administrations.
Furthermore, the present invention relates also to the combination of a compound of formula (I) with anti-cancer agents selected from genotoxic agents, mitotic poisons, antimetabolites, proteasome inhibitors, kinase inhibitors, protein-protein interaction inhibitors, immunomodulators, E3 ligase inhibitors, chimeric antigen receptor T-cell therapy and antibodies, and also to pharmaceutical compositions comprising that type of combination and their use in the manufacture of medicaments for use in the treatment of cancer. The combination of a compound of formula (I) with an anticancer agent may be administered simultaneously or sequentially. The administration route is preferably the oral route, and the corresponding pharmaceutical compositions may allow the instantaneous or delayed release of the active ingredients. The compounds of the combination may moreover be administered in the form of two separate pharmaceutical compositions, each containing one of the active ingredients, or in the form of a single pharmaceutical composition, in which the active ingredients are in admixture.
The compounds of formula (I) may also be used in combination with radiotherapy in the treatment of cancer.
The following Preparations and Examples illustrate the invention but do not limit it in any way. General Procedures
All reagents obtained from commercial sources were used without further purification. Anhydrous solvents were obtained from commercial sources and used without further drying.
Flash chromatography was performed on ISCO CombiFlash Rf 200i with pre-packed silica-gel cartridges (RediSe/?®i?f Gold High Performance).
Thin layer chromatography was conducted with 5 x 10 cm plates coated with Merck Type 60 F254 silica-gel.
Microwave heating was performed in an Anton Parr MonoWave or CEM Discover® instrument. Preparative HPLC purifications were performed on an HANBON NP7000 Liquid Chromatography system with a Gemini-NX® 5μΜ C18, 250 mm x 50 mm i.d. column running at a flow rate of 99.9 mL min"1 with UV diode array detection (210 - 400 nm) using 5 mM aqueous NH4HCO3 solution and MeCN as eluents unless specified otherwise. Analytical LC-MS: The compounds of the present invention were characterized by high performance liquid chromatography-mass spectroscopy (HPLC-MS) on Agilent HP 1200 with Agilent 6140 quadrupole LC/MS, operating in positive or negative ion electrospray ionisation mode. Molecular weight scan range is 100 to 1350. Parallel UV detection was done at 210 nm and 254 nm. Samples were supplied as a 1 mM solution in ACN, or in THF/H20 (1 : 1) with 5 μΐ, loop injection. LCMS analyses were performed on two instruments, one of which was operated with basic, and the other with acidic eluents.
Basic LCMS: Gemini-NX, 3 μιη, CI 8, 50 mm x 3.00 mm i.d. column at 23 °C, at a flow rate of 1 mL min 1 using 5 mM ammonium bicarbonate (Solvent A) and acetonitrile (Solvent B) with a gradient starting from 100 % Solvent A and finishing at 100 % Solvent B over various/certain duration of time.
Acidic LCMS: ZORBAX Eclipse XDB-C18, 1.8 μιη, 50 mm x 4.6 mm i.d. column at 40 °C, at a flow rate of 1 mL min"1 using 0.02 % v/v aqueous formic acid (Solvent A) and 0.02 % v/v formic acid in acetonitrile (Solvent B) with a gradient starting from 100% Solvent A and finishing at 100 % Solvent B over various/certain duration of time.
1H-NMR measurements were performed on Bruker Avance III 500 MHz spectrometer and Bruker Avance III 400 MHz spectrometer, using DMSO-d6 or CDC13 as solvent. 1H NMR data is in the form of delta values, given in part per million (ppm), using the residual peak of the solvent (2.50 ppm for DMSO-d6 and 7.26 ppm for CDC13) as internal standard. Splitting patterns are designated as: s (singlet), d (doublet), t (triplet), q (quartet), quint (quintet), sept (septet), m (multiplet), brs (broad singlet), brd (broad doublet), brt (broad triplet), brq (broad quartet), brm (broad multiplet), vbrs (very broad singlet), dd (doublet of doublets), td (triplet of doublets), dt (doublet of triplets), dq (doublet of quartet), ddd (doublet of doublet of doublets), dm (doublet of multiplets), tm (triplet of multiplets), qm (quartet of multiplets).
Combination gas chromatography and low resolution mass spectrometry were performed on Agilent 6850 gas chromatograph and Agilent 5975C mass spectrometer using 15 m x 0.25 mm column with 0.25 μιη HP-5MS coating and helium as carrier gas. Ion source: EI+, 70 eV, 230 °C, quadrupole: 150 °C, interface: 300 °C. HRMS were determined on a Shimadzu IT-TOF, ion source temperature 200 °C, ESI +/-, ionization voltage: (+-)4.5 kV. Mass resolution min. 10000.
Elementary analyses were performed on a Thermo Flash EA 1112 Elemental Analyzer.
List of abbreviations Abbreviation Name
abs. absolute
aq. aqueous
Ar argon
AtaPhos*PdCi2 bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)
dichloropalladium(II)
Boc tert-butoxycarbonyl
cc. concentrated
DCM dichloromethane
DEE diethyl ether
DIPO diisopropyl oxide
disp. dispersion
DMEDA N^-dimethylethylenediamine
DMF dimethylformamide
EDC.HC1 ^-(S-dimethylaminopropy^-N'-ethylcarbodiimide
hydrochloride
EEO ethyl ethanoate
eq. equivalent
iPr2NH isopropylamine
LC liquid chromatography
LDA lithium diisopropylamide
MeCN acetonitrile
MSM methylsulfinylmethane
MTBE tert-butyl methylether PDO p-dioxane
Pd2(dba)3 tris(dibenzylideneacetone)dipalladium
r.t. room temperature
sat. saturated
TFA trifluoroacetic acid
THF tetrahydrofuran
General Procedure 1
Step 1:
To a stirred solution of 4-chloro-7H-pyrrolo[2,3-d]pyrimidine (Preparation Rla; 1.84 g, 12 mmol, 1 eq.) in abs. DMF (15 ml) sodium-hydride (720 mg, 60 % disp. in mineral oil, 18 mmol, 1.5 eq.) was added, and stirred for 10 minutes at r.t. under Ar. Alkylating agent (13.18 mmol) was added to the reaction mixture and stirred for 1-6 hours at r.t. The mixture was poured into water (150 ml), then it was extracted with EEO (3 x 150 ml). The combined organic layer was washed with water, brine, dried over MgSC^, and evaporated. Step 2:
A part of this residue (1.36 mmol) and lithium-hydroxide monohydrate (571 mg, 13.62 mmol, 10 eq.) were stirred in PDO-water (40 ml, 1 : 1 v/v) mixture at 110 °C for 7-36 hours. The reaction mixture was neutralized with 1 N aq. HCl solution. The resulted precipitate was filtered off, washed with water and dried. General Procedure 2
Step 1:
Preparation Rla (460 mg, 3 mmol, 1 eq.), heteroaryl/aryl-boronic acid (7.5 mmol) and copper(II)-acetate (817 mg, 4.5 mmol) were stirred in pyridine (10 ml) at 50-60 °C for 16-72 hours. Work-up 1 : The mixture was evaporated to Celite, purified by flash chromatography (heptane-EEO, gradient).
Work-up 2:
The mixture was filtered, the resulted filtrate was purified by preparative LC (on C-18 Gemini-NX 5μιη column, 5 mM aqueous NH4HC03-MeCN, gradient).
Step 2:
The resulted compound (1.36 mmol) and lithium- hydroxide monohydrate (571 mg, 13.62 mmol, 10 eq.) were stirred in PDO-water (40 ml, 1 : 1 v/v) mixture at 110 °C for 7-24 hours. The reaction mixture was neutralized with 1 N aq. HCl solution. The resulted precipitate was filtered off, washed with water and dried.
General Procedure 3
Step 1:
Preparation Rib (746 mg, 5 mmol, 1 eq.), heteroaryl/aryl-iodide (10 mmol), Cul ( 286 mg, 1.5 mmol, 0.3 eq.), i?J?-diaminocyclohexane (171 mg, 1.5 mmol, 0.3 eq.), anhydrous K3P04 (4.24 g, 20 mmol, 4 eq.) was stirred in diglyme (15 ml) for 6-16 hours at 120 °C under N2 atmosphere.
Work-up 1 :
After the reaction completed, the mixture was diluted with water (200 ml) (or. 25 % aq. NH3) and cooled to r.t. The mixture was filtered, and washed with water (3x30 ml), aq. NH3 solution (40 ml, 25 %), water (3 x 50 ml), heptane (50 then 30 ml), dried in vacuum.
Work-up2:
The reaction mixture was evaporated to Celite, then purified by flash chromatography (heptane :EEO, gradient).
Step 2: The corresponding 4-methoxy-7-aryl-pyrrolo[2,3-d]pyrimidine (61.3 mmol, 1 eq.), cc. HC1 aqueous solution (10 ml, -12.2 M, 122.5 mmol, 2 eq.) and PDO (70 ml) was stirred at 100 °C for 0.5-2 hours. After the reaction completed, the mixture was partially evaporated. The formed suspension was filtered and the solid on the filter was washed with water and dried.
General procedure 4
Step 1:
Preparation Rla (154 mg, 1 mmol, 1 eq.), di-tert-butyl-diazodicarboxylate (690 mg, 3 mmol, 3 eq.), triphenylphosphine (786 mg, 3 mmol, 3 eq.) and corresponding alcohol (3 mmol, 3 eq.) were stirred in abs. toluene (10 ml) under Ar atmosphere at 50 °C for 2 hours. The reaction mixture was evaporated, taken in THF and purified by preparative LC (on C-18 Gemini-NX 5μιη column, 5 mM aqueous NH4HC03-MeCN, gradient).
Step 2:
A part of this residue (4-chloro-7-aryl/alkyl-pyrrolo[2,3-<i]pyrimidine) (1.36 mmol) and lithium- hydroxide monohydrate (571 mg, 13.62 mmol) were stirred in PDO-water (40 ml, 1 : 1 v/v) mixture at 110 °C for 7-24 hours. The reaction mixture was neutralized with 1 N aq. HC1 solution. The resulted precipitate was filtered off, washed with water and dried.
General procedure 5
Pyrimidine-4-one derivative (1 mmol), epoxide compound Preparation Rlc (400.5 mg, 1 mmol, 1 eq.) and K2C03 (276.4 mg, 2 mmol, 2 eq.) were stirred in DMF (5 ml) at 75 °C for 2-8 hours.
Work-up 1 :
The mixture was poured into ice-water mixture. The resulted precipitate was filtered off, washed with water, and dried. Work-up 2:
The reaction mixture was filtered, the solid was washed with DMF. The resulted filtrate was purified by preparative LC (on C-18 Gemini-NX 5μιη column, 5 mM aqueous NH4HC03-MeCN, gradient).
General procedure 6
Compound obtained in General Procedure 5 (~ 1 mmol) was stirred in aq. HC1 solution (1 N, 10 ml, 10 mmol, 10 eq.) and PDO (5 ml) for 1-3 hours at 75 °C.
Work-up 1 :
The mixture was cooled to about 0-5 °C with ice bath and the white precipitate was filtered off, dried in vacuum (resulted HC1 salt).
Work-up2:
The mixture was totally evaporated, and was used to the further step (resulted HC1 salt). Work-up3 :
The mixture was purified by preparative LC (on C-18 Gemini-NX 5μιη column, 5 mM aqueous NH4HC03-MeCN, gradient, resulted as free base).
General procedure 7
Compound obtained in General Procedure 6 (1 mmol, 1 eq.), alkyl-X (1 mmol, 1 eq.) and K2C03 (483 mg, 3.5 mmol, 3.5 eq.) were stirred in DMF (10 ml) at r.t. for 4-16 hours.
Work-up 1 :
The mixture was poured into ice-water mixture. The resulted precipitate was filtered off, washed with water, and dried. Work-up2:
The mixture was filtered and the filtrate was injected to preparative LC (on C-18 Gemini- NX 5μιη column, 5 mM aqueous NH4HC03-MeCN, gradient).
General procedure 8 Compound obtained in General Procedure 6 (2.7 mmol), EDC.HC1 (1.183 g, 6.172 mmol) and corresponding carboxylic acid (2.7 mmol) were stirred in pyridine (25 ml) at r.t. for 16 hours.
Work-up 1 :
The reaction mixture was evaporated, the residue was taken in DMF and injected to preparative LC (on C-18 Gemini-NX 5μιη column, 5 mM aqueous NH4HC03-MeCN, gradient).
Work-up2:
The reaction mixture was evaporated and the residue was trituated with water. The resulted solid was filtered off.
Preparation Rib: 4-methoxy-7H-pyrrolo [2,3-i ] yrimidine
Preparation Rla (100 g, 0,651 mol, 1 eq.), NaOH (31,26 g, 0,781 mol, 1.2 eq.) and MeOH (400 ml) was stirred at 90 °C for 24 hours. The mixture was quenched with water (1200 ml) and cooled to r.t. with ice bath. The mixture was stirred for 30 minutes, and filtered through a glass filter. The precipitate was washed with water (3 x 100 ml) then dried and Preparation Rib is obtained as white solid. HRMS calculated for C7H7N3O: 149.0589; found 150.0667 [(M+H)+ form].
1H-NMR (400 MHz, MSM-d6): δ = 12.02 (vbrs, 1 H), 8.37 (s, 1 H), 7.35 (d, 1 H), 6.47 (d, 1 H), 4.02 (s, 3 H).
13C-NMR (100 MHz, MSM-d6): δ ppm 162.6, 152.9, 150.8, 124.6, 104.8, 98.3, 53.7.
Preparation Rlc: tert-butyl (3R,4R)-4-(2-oxa-6-azaspiro [2.5] octane-6-carbonyl)-3- phenyl-piperidine-l-carboxylate
Step 1: tert-butyl (3R,4R)-4-(4-oxopiperidine-l -carbonyl)-3-phenyl-piperidine- 1 - carboxylate
4-piperidone hydrochloride hydrate (0.969 g, 6.3 mmol), EDC.HC1 (3.623 g, 18.9 mmol) and (3i?,4i?)-l-tert-butoxycarbonyl-3-phenyl-piperidine-4-carboxylic acid (1.928 g, 6.3 mmol) were dissolved in pyridine (10 mL) and stirred at r.t. for 16 hours. The reaction mixture was evaporated to Celite, purified by flash chromatography (DCM:MeOH, gradient) to give the product of the title. HRMS calculated for C22H30N2O4: 386.2206; found 409.2093 [(M+Na)+ form].
1H-NMR (500 MHz, MSM-d6): δ = 1.42 (s, 9 H), 4.14-1.50 (m, 16 H), 7.32-7.15 (m, 5 H).
Step 2: Preparation Rlc
tert-Butyl (3R,4R)-4-(4-oxopiperidine- 1 -carbonyl)-3-phenylpiperidine- 1 -carboxylate) (60 g, 155 mmol 1 eq.) and trimethylsulfoxonium-iodide (85.41 g, 388 mmol, 2.5 eq.) was charged into a round bottom flask and dissolved/suspended in MeCN (150 ml) and MTBE (150 ml). NaOH (15.5 g, 388 mmol, 2.5 eq.) was dissolved in water (21.6 ml) (-40 % solution). The aq. NaOH solution was added to the mixture and stirred at 60 °C for 2 hours. After the reaction completed, the mixture was cooled to r.t., filtered through a Celite bed, the filter cake was washed with MTBE (2 x 60 ml). Water (150 ml) was added to the organic layer and after extraction the layers were separated. The aq. layer was extracted with further MTBE (2 x 60 ml). The combined organic layers were dried over MgSC"4, and after filtration evaporated to give Preparation Rlc as beige solid foam. HRMS calculated for C23H32N2O4: 400.2362; found 423.2247 [(M+Na)+ form].
1H-NMR (500 MHz, MSM-d6): δ = 1.41 (s, 9 H), 1.79-0.86 (m, 6 H), 2.61-2.51 (m, 2 H), 4.16-2.73 (m, 10 H), 7.33-7.18 (m, 5 H).
Preparation R2b: 7-(pyridin-2-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one
Using General Procedure 3 starting from Preparation Rib and 2-iodopyridine as reagents, Preparation R2b was obtained. HRMS calculated for CnH8N40: 212.0698; found 213.0774 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.29 (s, 1 H), 8.55 (dd, 1 H), 8.47 (dd, 1 H), 8.06 (brs, 1 H), 8.03 (t, 1 H), 7.9 (d, 1 H), 7.4 (t, 1 H), 6.7 (d, 1 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 149.1, 145, 139.4, 122.5, 122, 116.9, 104.
15N-NMR (50.6 MHz, MSM-d6): δ (ppm) 171.2.
Preparation R2c: 7-(4-methoxyphenyl)-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4-one Using General Procedure 3 starting from Preparation Rib and 4-iodoanisole as reagents, Preparation R2c was obtained. HRMS calculated for C13H11N3O2: 241.0851; found 242.0929 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.04 (brs, 1 H), 7.92 (d, 1 H), 7.58 (dd, 1 H), 7.4 (d, 1 H), 7.08 (d, 1 H), 6.65 (d, 1 H), 3.81 (s, 3 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 158.8, 158.8, 147.3, 144.4, 130.9, 126.1, 124.4, 114.8, 109.4, 103.1, 55.9.
Preparation R2e: 7-(4-fluoro-3-methoxyphenyl)-3H,4H,7H-pyrrolo [2,3-d] pyrimidin- 4-one
Using General Procedure 3 starting from Preparation Rib and l-fluoro-4-iodo-2- methoxybenzene as reagents, Preparation R2e was obtained. HRMS calculated for C13H10N3O2F: 259.0757; found 260.0818 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.1 (s, 1 H), 7.95 (s, 1 H), 7.51 (d, 1 H), 7.48 (dd, 1 H), 7.38 (dd, 1 H), 7.27 (ddd, 1 H), 6.68 (d, 1 H), 3.9 (s, 3 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 144.7, 124.5, 117, 116.5, 111, 103.4, 56.8.
Preparation R2g: 7-methyl-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4-one
Using General Procedure 1 starting from Preparation Rla and iodomethane as alkylating agent, Preparation R2g was obtained. HRMS calculated for C7H7N3O: 149.0589; found 150,0668 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 11.85 (brs, 1 H), 7.88 (brs, 1 H), 7.09 (d, 1 H), 6.44 (d, 1 H), 3.70 (m, 1 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 158.7, 147.7, 143.8, 125.1, 108.1, 101.7, 31.8.
Preparation R2h: 7-ethyl-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4-one
Using General Procedure 1 starting from Preparation Rla and iodoethane as reagents, Preparation R2h was obtained. HRMS calculated for C8H9N30: 163.0746; found 164.0823 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 1 1.38 (brs., 1 H), 7.87 (d, J=2.0 Hz, 1 H), 7.16 (d, J=3.4 Hz, 1 H), 6.45 (d, J=3.4 Hz, 1 H), 4.14 (q, J=7.1 Hz, 2 H), 1.34 (t, J=7.1 Hz, 3 H). Preparation R2i: 7-(prop-2-yn- l-yl)-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4-one
Using General Procedure 1 starting from Preparation Rib (instead of Preparation Rla) and 3-bromoprop-l-yne as reagents (without the hydrolysis step), the crude methoxypyrimidine product (400 mg, 2.3 mmol) was dissolved in PDO (4 ml) and aqueous HC1 solution (37 %, 0.18 ml) was added. The mixture was heated for 100 °C for 30 minutes in a Schlenk tube. After cooling, DIPO (4 ml) was added to the reaction mixture and the resulted precipitate was filtered off and dried to give Preparation R2i. HPvMS calculated for C9H7N3O: 173.0589; found 174.0665 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 11.98 (brs, 1 H), 7.93 (s, 1 H), 7.19 (d, 1 H), 6.5 (d, 1 H), 4.98 (d, 2 H), 3.42 (t, 1 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 158.6, 147.3, 144.3, 123.6, 102.5, 79.4, 76, 34.1.
Preparation R2j: 7-cyclopr opyl-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4-one
Using General Procedure 2 starting from Preparation Rla and cyclopropylboronic acid as reagents, Preparation R2j was obtained. HRMS calculated for C9H9N3O: 175.0746; found 176.0819 [(M+H)+ form] .
1H-NMR (500 MHz, MSM-d6): δ (ppm) 11.88 (brs., 1 H), 7.89 (brs., 1 H), 7.05 (d, 1 H), 6.4 (d, 1 H), 3.53 (m, 1 H), 1.06-0.92 (m, 4 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 158.7, 148.9, 143.8, 123.4, 108.8, 101.6, 27.5, 6.6. Preparation R2k: 7-(buta-2,3-dien-l-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one
Using General Procedure 1 starting from Preparation Rib (instead of Preparation Rla) and 4-bromobuta-l,2-diene as reagents (without the hydrolysis step), the crude methoxypyrimidine product (300 mg, 1.65 mmol) was dissolved in PDO (4 ml) and aq. HC1 solution (37 %, 0.18 ml) was added. The mixture was heated for 100 °C for 30 minutes in a Schlenk tube. After cooling, the reaction mixture was evaporated to give Preparation R2k. HRMS calculated for Ci0H9N3O: 187.0745; found 188.0821 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 11.91 (brs, 1 H), 7.89 (s, 1 H), 7.12 (d, 1 H), 6.46 (d, 1 H), 5.48 (m, 1 H), 4.87 (m, 2 H), 4.73 (m, 2 H). 13C-NMR (125 MHz, MSM-d6): δ (ppm) 208.3, 158.7, 147.4, 143.9, 123.9, 108.2, 102.1, 88.3, 78.1, 43.
Preparation R21: 7-(cyclopropylmethyl)-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4-one Using General Procedure 1 starting from Preparation Rla and cyclopropylmethyl bromide as reagents, Preparation R21 was obtained. HRMS calculated for C10H11N3O: 189.0902; found 190.0980 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 11.84 (s, 1 H), 7.87 (s, 1 H), 7.2 (d, 1 H), 6.45 (d, 1 H), 3.97 (d, 2 H), 1.21 (m, 1 H), 0.52-0.35 (m, 4 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 158.7, 147.3, 143.7, 124, 108.1, 101.7, 49, 12.3, 4.07.
Preparation R2m: 7-(2-methylpropyl)-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4-one
Using General Procedure 1 starting from Preparation Rla and l-bromo-2- methylpropane as reagents, Preparation R2m was obtained. HRMS calculated for C10H13N3O: 191.1059; found 192.1132 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 11.84 (brs, 1 H), 7.86 (s, 1 H), 7.12 (d, 1 H), 6.45 (d, 1 H), 3.92 (d, 2 H), 2.1 (sept., 1 H), 0.82 (d, 6 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 158.8, 147.7, 143.7, 124.5, 108, 101.6, 52, 29.6, 20.2.
Preparation R2n: 9-methyl-3H-pyrimido [4,5-b] indol-4-one
Preparation Rib (500 mg, 3.06 mmol) and 2,5-dimethoxytetrahydrofurane (810 mg, 6.13 mmol, d= 1.02, 795 μΐ) in 5 ml 1,4-dioxane were heated up to 100 °C for 102 hours, then 5ml IN HC1 was added. It was dissolved in DMF and purified by preparative LC (on C-18 Gemini-NX 5μιη column, 5 mM aqueous NH4HC03-MeCN, gradient) to give Preparation R2n. HRMS calculated for CnH9N30: 199.0746; found 200.0827 [(M+H)+ form].
1H-NMR(500 MHz, dmso-d6) δ ppm 12.33 (brs, 1 H), 8.21 (s, 1 H), 7.63 (dm, 1 H), 7.41 (ddd, 1 H), 7.29 (td, 1 H), 3.86 (s, 3 H)
13C-NMR(500 MHz, dmso-d6) δ ppm 158.5, 153.5, 148.1, 137, 124.6, 122, 121.8, 121, 110.7, 100.1, 28.5 Preparation R2o: 7-(cyclobutylmethyl)-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4-one Using General Procedure 1 starting from Preparation Rla and
(bromomethyl)cyclobutane as reagents, Preparation R2o was obtained. HRMS calculated for C1 1H13N3O: 203.1059; found 204.1134 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 1 1.83 (brs, 1 H), 7.87 (d, 1 H), 7.12 (d, 1 H), 6.43 (d, 1 H), 4.13 (d, 2 H), 2.72 (m, 1 H), 1.92/1.74 (m+m, 4 H), 1.82 (m, 2 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 143.7, 124.2, 101.7, 49.6, 36, 25.6, 18.
Preparation R2p: 7- [2-(dimethylamino)ethyl] -3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4- one
Using General Procedure 1 starting from Preparation Rla and 2-bromo-N,N- dimethylethylamine hydrobromide as reagents, Preparation R2p was obtained. HRMS calculated for C10H14N4O: 206.1168; found 207.1242 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 11.84 (brs, 1 H), 7.88 (brd, 1 H), 7.16 (d, 1 H), 6.44 (d, 1 H), 4.19 (t, 2 H), 2.6 (t, 2 H), 2.16 (s, 6 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 158.7, 147.5, 143.7, 124.4, 108.1, 101.7, 59.2, 45.5, 42.6.
Preparation R2q: 7-phenyl-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4-one
Using General Procedure 3 starting from Preparation Rib and iodobenzene as reagents, Preparation R2q was obtained. HRMS calculated for C12H9N3O: 211.0746; found 212.083 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.1 (brs, 1 H), 7.95 (d, 1 H), 7.71 (m, 2 H), 7.54 (m, 2 H), 7.5 (d, 1 H), 7.4 (m, 1 H), 6.69 (d, 1 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 158.8, 147.3, 144.6, 137.8, 129.7, 127.4, 124.6, 124.1, 109.8, 103.6. Preparation R2s: 7-(pyrimidin-2-yl)-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4-one
Preparation Rib (300 mg, 2.011 mmol, 1 eq.), 2-chloropyrimidine (2.413 mmol, 1.2 eq.) and anhydrous K2CO3 (417 mg, 3.017 mmol, 1.5 eq.) was heated in DMF (10 ml) at 150 °C for 2 hours. The reaction mixture was filtered and purified by preparative LC (on C-18 Gemini-NX 5μιη column, 5 mM aqueous NH4HCO3-MCN, gradient) to give 4-methoxy-7-pyrimidin-2-yl-pyrrolo[2,3-(i]pyrimidine.
Then the obtained product (0.633 mmol, 1 eq.), 1M HC1 aqueous solution (3 ml) and PDO (60 ml) were stirred at 100 °C for 1 hour. After the reaction completed, the mixture was evaporated and purified by preparative LC (on C-18 Gemini-NX 5μιη column, 5 mM aqueous NH4HCO3-MCN, gradient) to give Preparation R2cj . HRMS calculated for CioHyNsO: 213.0651 ; found 214,0735 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.19 (brs, 1 H), 8.94 (d, 1 H), 8.01 (s, 1 H), 7.78 (d, 1 H), 7.54 (t, 1 H), 6.71 (d, 1 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 159.7, 158.7, 156, 148.1 , 145.2, 123.3, 120.1 , 1 1 1.4, 104.5.
Preparation R2t: 6,8-dimethylpyrimido [5,4-6] indolizin-4(3H)-one
Preparation Rib (1.74 g, 1 1.67 mmol) was dissolved in DMF (80 ml) and cooled to 0 °C.
Sodium hydride (60 % disp., 1.87 g, 46.67 mmol) was slowly added and the solution was stirred for 30 minutes at 0 °C. Hydroxylamine-O-sulfonic acid (2.1 1 g, 18.67 mmol) was added to the reaction mixture and allowed to warm up to r.t. and stirred for 20 hours. Water (100 ml) was added to the reaction mixture and extracted with DCM (4 x 50 ml). The combined organic layers were washed with water, dried over MgS04 and evaporated.
A part of the resulted N-amino compound (300 mg, 1.83 mmol) and acetylacetone (206 μΐ, 201 mg 2.01 mmol) were dissolved in 5 ml acetic acid and heated up to 120 °C for 2 hours and 30 minutes, then TFA (5 ml) was added. It was heated at 120 °C for more 18 hours. Then 1 ml water and 10 ml methanol were added, then it was evaporated. The residue was purified by preparative LC (on C-18 Gemini-NX 5μιη column, 5 mM aqueous NH4HCO3- MeCN, gradient) to give Preparation R2t. HRMS calculated for CnHi0N4O: 214.0855; found 215.0935 [(M+H)+ form] .
1H-NMR(500 MHz, dmso-d6) δ ppm 12.16 (s, 1 H), 8 (s, 1 H), 6.89 (s, 1 H), 6.68 (d, 1 H), 2.45 (d, 3 H), 2.44 (s, 3 H)
13C-NMR(500 MHz, dmso-d6) δ ppm 159.7, 152.5, 143.4, 141.2, 138.9, 127.7, 1 15.5, 109.8, 91.2, 21.9, 17.4 Preparation R2u: 7-(l-methyl-lH-imidazol-4-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin- 4-one
Using General Procedure 3 starting from Preparation Rib and 4-iodo-l -methyl- 1H- imidazole as reagents, Preparation R2u was obtained. HRMS calculated for C10H9N5O: 215.0807; found 216.0879 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 9.24-7.3 (vbrs, 3 H), 7.51 (d, 1 H), 6.72 (brs, 1 H), 3.77 (s, 3 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 121.7, 103.5, 35.
15N-NMR (50.6 MHz, MSM-d6): δ (ppm) 153. Preparation R2v: 7-(thiophen-3-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one
Using General Procedure 2 starting from Preparation Rla and thiophene-3-boronic acid pinacol ester as reagents, Preparation R2v was obtained. HRMS calculated for CioH7N3OS: 217.0310; found 218.0390 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.14 (s, 1 H), 7.99 (d, 1 H), 7.92 (dd, 1 H), 7.71 (dd, 1 H), 7.68 (dd, 1 H), 7.57 (d, 1 H), 6.66 (d, 1 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 158.6, 147, 144.8, 136.3, 127, 123.8, 123.3, 1 15.1 , 109.5, 103.5.
Preparation R2w: 7-(thiophen-2-yl)-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4-one
Using General Procedure 3 starting from Preparation Rib and 2-iodothiophene as reagents, Preparation R2w was obtained. HRMS calculated for C10H7N3OS: 217.0310; found 218.0384 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.2 (brs, 1 H), 8.03 (s, 1 H), 7.58 (d, 1 H), 7.43 (dd, 1 H), 7.39 (dd, 1 H), 7.07 (dd, 1 H), 6.69 (d, 1 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 158.5, 147.2, 145.3, 138.7, 126, 124.3, 122.8, 1 19.2, 109.4, 104.2.
Preparation R2x: 7-(2,2,2-trifluoroethyl)-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4-one Using General Procedure 1 starting from Preparation Rla and 2,2,2-trifluoroethyl trifluoromethanesulfonate as reagents, Preparation R2x was obtained. HRMS calculated for CsHgNsOFs: 217.0463; found 218.0543 [(M+H)+ form]. Ή-NMR (500 MHz, MSM-d6): δ (ppm) 12.08 (brs, 1 H), 7.97 (s, 1 H), 7.19 (d, 1 H), 6.57 (d, 1 H), 5.06 (q, 2 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 158.5, 148.4, 144.9, 124.7, 124.4, 108.8, 103.2, 45.1.
19F-NMR (376.5 MHz, MSM-d6): δ (ppm) -70.3.
Preparation R2y: 7-(l,3-thiazol-2-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one
Using General Procedure 3 starting from Preparation Rib and 2-iodothiazole as reagents, Preparation R2ck was obtained. HRMS calculated for C9H6N4OS: 218.0262; found 219.0335 [(M+H)+ form].
1H-NMR (500 MHz, MeCN-d3) δ ppm 8.5 (s, 1 H), 7.62 (d, 1 H), 7.52 (d, 1 H), 7.22 (d, 1 H), 6.51 (d, 1 H).
13C-NMR (125 MHz, MeCN-d3) δ ppm 154.5, 137.9, 1 16.8, 1 14.8, 104.2.
Preparation R2z: 7- [3-(dimethylamino)propyl] -3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4- one
Using General Procedure 1 starting from Preparation Rla and 3-dimethylaminopropyl chloride hydrochloride as reagents, Preparation R2z was obtained. HRMS calculated for Ci iHi6N40: 220.1324; found 221.1401 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 1 1.84 (brs, 1 H), 7.88 (s, 1 H), 7.13 (d, 1 H), 6.44 (d, 1 H), 4.12 (t, 2 H), 2.15 (t, 2 H), 2.1 (s, 6 H), 1.85 (p, 2 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 158.8, 147.4, 143.8, 124.2, 108.2, 101.7, 56.4, 45.6, 43, 28.6.
Preparation R2aa: 7-(3-methylphenyl)-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4-one
Using General Procedure 3 starting from Preparation Rib and 3-iodotoluene as reagents, Preparation R2aa was obtained. HRMS calculated for C13H11N3O: 225.0902; found 226.098 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.08 (brs, 1 H), 7.95 (d, 1 H), 7.52 (brs, 1 H), 7.49 (dm, 1 H), 7.46 (d, 1 H), 7.41 (t, 1 H), 7.22 (brd., 1 H), 6.67 (d, 1 H), 2.39 (s, 3 H). 13C-NMR (125 MHz, MSM-d6): δ (ppm) 158.8, 147.3, 144.6, 139.2, 137.8, 129.5, 128.1 , 125.2, 124.2, 121.8, 109.7, 103.5, 21.4. Preparation R2ab: 7-(4-methylphenyl)-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4-one
Using General Procedure 3 starting from Preparation Rib and 4-iodotoluene as reagents, Preparation R2ab was obtained. HRMS calculated for Ci3HnN30: 225,0902; found 226.0987 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.06 (brs, 1 H), 7.93 (s, 1 H), 7.58 (dm, 1 H), 7.44 (d, 1 H), 7.33 (dm, 1 H), 6.66 (d, 1 H), 2.37 (s, 3 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 158.8, 147.3, 144.5, 136.8, 135.4, 130.1 , 124.5, 124.1 , 109.6, 103.4, 21.
Preparation R2ac: 7-benzyl-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4-one
Using General Procedure 1 starting from Preparation Rla and benzyl bromide as reagents, Preparation R2ac was obtained. HRMS calculated for Ci3HnN30: 225.0902; found 226.0986 [(M+H)+ form].
1H-NMR (400 MHz, MSM-d6): δ (ppm) 1 1.91 (brs, 1 H), 7.91 (s, 1 H), 7.36-7.17 (m, 5 H), 7.2 (d, 1 H), 6.49 (d, 1 H), 5.34 (s, 2 H).
13C-NMR (100 MHz, MSM-d6): δ (ppm) 144.1 , 124.3, 102.2, 48.1.
Preparation R2ad: 6-methyl-7-phenyl-3H-pyrrolo [2,3-d] pyrimidin-4-one
Using General Procedure 3 starting from Preparation Rib and iodobenzene as reagents, 4-methoxy-7-phenyl-pyrrolo[2,3-d]pyrimidine was obtained (without hydrolysis).
This crude product (450 mg, 2 mmol) was dissolved in THF (18 ml) stirred at -78 °C, then LDA solution (1.8 M, 1.7 ml, 3 mmol) was added. After one hour of stirring at -78 °C, iodomethane (190 μΐ, 3 mmol) solution in THF (5 ml) was added, and continued stirring for 90 minutes. Then the reaction mixture was diluted with brine (10 ml), evaporated to Celite and purified by flash chromatography (Hexane-EEO=7-l).
The resulted crude product (400 mg, 1.6 mmol) was dissolved in cc. HC1 aqueous solution (330 μΐ, -12.2 M, 4 mmol) and PDO (5 ml) was stirred at 100 °C for 2 hours. After the reaction completed, the mixture was partially evaporated and the formed suspension was filtered. The solid on the filter was washed with water and dried to give Preparation R2de. HRMS calculated for Ci3H„N30: 225.0902; found 226.0985 [(M+H)+ form]. 1H-NMR(500 MHz, MSM-d6) δ ppm 11.94 (s, 1 H), 7.76 (d, 1 H), 7.55 (tm, 2 H), 7.49 (tm, 1 H), 7.4 (dm, 2 H), 6.41 (d, 1 H), 2.17 (d, 3 H).
13C-NMR(125 MHz, MSM-d6) δ ppm 158.4, 143.6, 136.2, 132.6, 129.6, 128.7, 128.5, 100.9, 13.3. Preparation R2ae: 7-(4-fluorophenyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one
Using General Procedure 3 starting from Preparation Rib and 4-fluoroiodobenzene as reagents, Preparation R2ae was obtained. HRMS calculated for C12H8FN3O: 229.0651; found 230.0714 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.12 (brs, 1 H), 7.95 (d, 1 H), 7.74 (m, 2 H), 7.48 (d, 1 H), 7.39 (m, 2 H), 6.68 (d, 1 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 144.7, 126.8, 124.2, 116.4, 103.5.
Preparation R2ai: 6-chloro-7-phenyl-3H-pyrrolo [2,3-d] pyrimidin-4-one
Using General Procedure 3 starting from Preparation Rib and iodobenzene as reagents,
4-methoxy-7-phenyl-pyrrolo[2,3-d]pyrimidine was obtained (without hydrolysis).
The crude product (394 mg, 1.75 mmol) was dissolved in THF (14 ml) stirred at -78 °C, then LDA solution (1.8 M, 1.2 ml, 2.16 mmol) was added. After one hour of stirring at -78 °C, hexachloroethane (632 mg, 2.63 mmol) solution in THF (5 ml) was added, and continued stirring for 90 minutes. Then the reaction mixture was diluted with brine (10 ml), evaporated to Celite and purified by flash chromatography (Hexane-EEO=9-l). The resulted crude product (110 mg, 0.42 mmol) was dissolved in cc. HC1 aqueous solution (82 μΐ, -12.2 M, 1 mmol) and PDO (5 ml) was stirred at 100 °C for 2 hours. After the reaction completed, the mixture was partially evaporated and the formed suspension was filtered. The solid on the filter was washed with water and dried to give Preparation R2dh. HRMS calculated for Ci2H8N3OCl: 245.0356; found 246.043 [(M+H)+ form].
1H-NMR(500 MHz, MSM-d6) δ ppm 12.16 (s, 1 H), 7.88 (s, 1 H), 7.6-7.52 (m, 5 H), 6.78 (s, 1 H).
13C-NMR(125 MHz, MSM-d6) δ ppm 157.6, 148.2, 145.3, 101.6. Preparation R2aj: 6-iodo-7-methyl-3H-pyrrolo [2,3-d] pyrimidin-4-one To a stirred solution of Preparation Rla (8 g, 52.1 mmol) in abs. DMF (50 ml) was cooled down to 0 °C, then sodium-hydride (3.13 g, 60 % disp. in mineral oil, 78.2 mmol, 1.5 eq.) was added, and stirred for 20 minutes at r.t. under Ar. Methyl iodide (8.2 g, 57.2 mmol, d=2.28, 3.6 ml) was added to the reaction mixture and stirred for 1.5 hours at r.t. The mixture was poured into water (50 ml). Solid compound was formed, which was filtered off.
A part of the resulted N-methylated compound (500 mg, 2.98 mmol) was dissolved in 5 ml abs. THF and cooled down to -78 °C. Then 2M LDA (1.7 ml, 3.4 mmol) was added dropwise. The mixture was stirred at -78°C for 1 hour, then iodide (757 mg, 2.98 mmol) was added. The solution was allowed to warm to r.t. and stirred for 22 hours, then 5 ml water was added. Solid compound was formed and filtered off to give Preparation R2aj . HRMS calculated for C7H6IN30: 274.9556; found 275.9634 [(M+H)+ form].
1H-NMR(500 MHz, dmso-d6) δ ppm 1 1.97 (s, 1 H), 7.85 (s, 1 H), 6.79 (s, 1 H), 3.64 (s, 3 H)
13C-NMR(500 MHz, dmso-d6) δ ppm 157.3, 149.1 , 144.2, 1 1 1.4, 1 10.3, 80.4, 33.2
Preparation R2al: 6-iodo-7-(2-trimethylsilylethoxymethyl)-3H-pyrrolo [2,3-d] pyrimidin-4-one
233 mg (0.82mmol) 2-[(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)methoxy]ethyl-trimethyl- silane was dissolved in 4 ml dry THF and cooled down to -78 °C and 500 μΐ, (1.8 M stock solution, 0.9 mmol, 1.1 eq.) LDA was added. The mixture was stirred under nitrogen for 40 minutes at -78 °C then 208 mg iodine (0.82 mmol, 1 eq.) was added and allowed to warm to r.t. It was stirred for 40 minutes, then water was added. The solution was extracted with EEO (2 x 15 ml), combined organic phase was dried (magnesium sulfate) and evaporated. The residue was purified by flash chromatography (Eluent: heptane-EEO gradient).
Resulted crude 2-[(4-chloro-6-iodo-pyrrolo[2,3-d]pyrimidin-7-yl)methoxy]ethyl-trimethyl- silane was solved in 3 ml PDO and 3 ml water and 166 mg (3.98 mmol) lithium hydroxide hydrate was added. The mixture was heated and stirred at 1 10 °c for 5 hours. The solution was cooled to r.t., then 1 N HCl was added till pH 3-4. Solid compound was formed, which was filted off, and washed with water, Preparation R2al was obtained.
HRMS calculated for Ci2Hi8IN302Si: 391.0213; found 392.0298 [(M+H)+ form]. 1H-NMR(500 MHz, DMSO-d6) δ ppm 12.1 (brs, 1 H), 7.91 (d, 1 H), 6.84 (s, 1 H), 5.45 (s, 2H), 3.5 l(m, 2H), 0.82 (m, 2H), -0.08 (s, 9H).
13C-NMR(500 MHz, DMSO-d6) δ ppm 157.3, 149.9, 144.8, 112.9, 1 10.5, 79.3, 73.7, 66.0, 17.5. Preparation R2am: 7-(3,4,5-trimethoxyphenyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4- one
Using General Procedure 3 starting from Preparation Rib and 5-iodo- 1,2,3- trimethoxybenzene as reagents, Preparation R2am was obtained. HRMS calculated for CI SHI SNBC : 301.1063; found 302.1138 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.07 (brs, 1 H), 7.95 (d, 1 H), 7.49 (d, 1 H), 6.99 (s, 2 H), 6.66 (d, 1 H), 3.82 (s, 6 H), 3.7 (s, 3 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 144.5, 124.6, 103.2, 103, 60.6, 56.6.
Preparation R2an: 7-(3,5-dichlorophenyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one Using General Procedure 2 starting from Preparation Rla and 3,5-dichlorophenylboronic acid as reagents, Preparation R2an was obtained. HRMS calculated for C12H7CI2N3O: 278.9966; found 280.0040 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.03 (vbrs, 1 H), 8.03 (s, 1 H), 7.95 (d, 2 H), 7.64 (t, 1 H), 7.63 (d, 1 H), 6.71 (d, 1 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 145.3, 126.7, 123.8, 122.7, 104.4 Preparation R2ao: 7-(3-chloro-5-methoxyphenyl)-3H,4H,7H-pyrrolo[2,3- d] pyrimidin-4-one
Using General Procedure 2 starting from Preparation Rla and 3-chloro-5- methoxyphenylboronic acid as reagents, Preparation R2ao was obtained. HRMS calculated for C13H10CIN3O2: 275.0461; found 276.0541 [(M+H)+ form].
1H-NMR (400 MHz, MSM-d6): δ (ppm) 12.18 (s, 1 H), 8 (d, 1 H), 7.6 (d, 1 H), 7.51 (t, 1 H), 7.33 (t, 1 H), 7.08 (t, 1 H), 6.69 (d, 1 H), 3.85 (s, 3 H).
13C-NMR (100 MHz, MSM-d6): δ (ppm) 161, 158.7, 147.5, 145, 139.7, 134.5, 124, 1 16.3, 112.7, 110.2, 109.4, 104, 56.4 Preparation R2ap: 7-(3,5-dimethoxyphenyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4- one
Using General Procedure 2 starting from Preparation Rla and 2-(3,5-dimethoxy)- phenyl-4,4,5,5-tetramethyl-(l,3,2)-dioxaborolane as reagents, Preparation R2ap was obtained. HRMS calculated for C14H13N3O3 : 271.0957; found 272.1030 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.11 (s, 1 H), 7.95 (d, 1 H), 7.52 (d, 1 H), 6.91 (d, 2 H), 6.66 (d, 1 H), 6.54 (t, 1 H), 3.8 (s, 6 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 144.5, 124.2, 103.5, 103.1, 98.9.
Preparation R2aq: 7-(3,4-dichlorophenyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one Using General Procedure 2 starting from Preparation Rib and
3,4-dichlorophenylboronic acid as reagents, Preparation R2aq was obtained. HRMS calculated for C12H7CI2N3O: 278.9966; found 280.003 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.21 (brs, 1 H), 8.15 (t, 1 H), 8.02 (brs, 1 H), 7.82 (d, 1 H), 7.82 (d, 1 H), 7.61 (d, 1 H), 6.72 (d, 1 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 145.1, 131.5, 125.9, 124.3, 123.8, 104.2.
Preparation R2ar: 7-(4-chloro-3-fluorophenyl)-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4- one
Using General Procedure 3 starting from Preparation Rib and 4-chloro-3- fluoroiodobenzene as reagents, Preparation R2ar was obtained. HRMS calculated for Ci2H7ClFN30: 263.0262; found 264.0339 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.21 (s, 1 H), 8.02 (d, 1 H), 7.97 (dd, 1 H), 7.77 (dd, 1 H), 7.72 (dd, 1 H), 7.6 (d, 1 H), 6.72 (d, 1 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 145.1, 131.5, 123.7, 121.5, 112.8, 104.2.
Preparation R2as: 7-(4-chloro-3-methoxyphenyl)-3H,4H,7H-pyrrolo [2,3-d] pyrimidin- 4-one
Using General Procedure 3 starting from Preparation Rib and 2-chloro-5-iodoanisole as reagents, Preparation R2as was obtained. HRMS calculated for C13H10CI 3O2: 275.0461; found 276.0537 [(M+H)+ form]. 1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.15 (brs, 1 H), 7.98 (brs, 1 H), 7.58 (d, 1 H), 7.57 (d, 1 H), 7.49 (d, 1 H), 7.36 (dd, 1 H), 6.7 (d, 1 H), 3.93 (s, 3 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 158.7, 155.3, 147.4, 144.8, 137.7, 130.5, 124.2, 119.8, 117.3, 110, 109.4, 103.7, 56.9. Preparation R2at: 7-(3,4-dimethoxyphenyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one Using General Procedure 2 starting from Preparation Rib and
3,4-dimethoxyphenylboronic acid pinacol ester as reagents, Preparation R2at was obtained. HRMS calculated for C14H13N3O3 : 271.0957; found 272.103 [(M+H)+ form]. 1H-NMR (500 MHz, MSM-d6): δ (ppm) 7.92 (d, 1 H), 7.43 (d, 1 H), 7.25 (d, 1 H), 7.19 (dd, 1 H), 7.08 (d, 1 H), 6.65 (d, 1 H), 3.8 (s, 6 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 144.5, 124.6, 116.9, 112.2, 109.3, 103.1, 56.3.
Preparation R2au: 4- {4-oxo-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-7-yl}benzonitrile Using General Procedure 3 starting from Preparation Rib and 4-iodobenzonitrile as reagents, Preparation R2au was obtained. HRMS calculated for C13H8N4O: 236,0698; found 237.0775 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.25 (brs, 1 H), 8.05 (m, 2 H), 8.03 (m, 2 H), 8.02 (brs, 1 H), 7.66 (d, 1 H), 6.75 (d, 1 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 147.6, 145.2, 141.5, 134, 124.6, 123.6, 119, 110.6, 109.4, 104.7. Preparation R2av: 7- [4-(trifluoromethyl)phenyl] -3H,4H,7H-pyrrolo [2,3-d] pyrimidin- 4-one
Using General Procedure 3 starting from Preparation Rib and 4-iodobenzotrifluoride as reagents, Preparation R2av was obtained. HRMS calculated for C13H8F3N3O: 279,0619; found 280.0691 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.23 (brs, 1 H), 8.02 (m, 2 H), 8.01 (d, 1 H), 7.92 (m, 2 H), 7.63 (d, 1 H), 6.74 (d, 1 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 158.7, 147.6, 145.1, 126.9, 124.7, 123.8, 110.4, 104.5 15N-NMR (50.6 MHz, MSM-d6): δ (ppm) 170.9. Preparation R2aw: 7- [4-(difluoromethyl)phenyl] -3H,4H,7H-pyrrolo [2,3-d] pyrimidin- 4-one
Using General Procedure 3 starting from Preparation Rib and l-(difluoromethyl)-4- iodobenzene as reagents, Preparation R2aw was obtained. HRMS calculated for C13H9F2N3O: 261.0714; found 262.0784 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.17 (brs, 1 H), 7.99 (d, 1 H), 7.91 (m, 2 H), 7.75 (m, 2 H), 7.58 (d, 1 H), 7.12 (t, 1 H), 6.72 (d, 1 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 144.9, 127.2, 124.7, 123.9, 115.1, 104.1.
Preparation R2ax: 7- [4-(hydroxymethyl)phenyl] -3H,4H,7H-pyrrolo [2,3-d] pyrimidin- 4-one
Using General Procedure 3 starting from Preparation Rib and 4-iodobenzyl alcohol as reagents, Preparation R2ax was obtained. HRMS calculated for C13H11N3O2: 241.0851; found 242.0925 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.07 (brs, 1 H), 7.94 (s, 1 H), 7.66 (m, 2 H), 7.47 (m, 2 H), 7.45 (d, 1 H), 6.67 (d, 1 H), 5.31 (t, 1 H), 4.56 (d, 2 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 158.9, 147.4, 144.6, 142.2, 136.6, 127.6, 124.3, 124.2, 109.9, 103.5, 62.8.
Preparation R2ay: 7-(4-chlorophenyl)-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4-one
Using General Procedure 3 starting from Preparation Rib and l-chloro-4-iodobenzene as reagents, Preparation R2ay was obtained. HRMS calculated for C12H8CIN3O: 245.0356; found 246.0427 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.15 (brs, 1 H), 7.97 (d, 1 H), 7.78 (dm, 1 H), 7.61 (dm, 1 H), 7.53 (d, 1 H), 6.7 (d, 1 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 158.7, 147.3, 144.8, 136.7, 131.7, 129.6, 126.1, 123.9, 109.9, 103.9.
Preparation R2az: 7- [4-(dimethylamino)phenyl] -3H,4H,7H-pyrrolo [2,3-d] pyrimidin- 4-one Using General Procedure 2 starting from Preparation Rla and
4-(dimethylamino)phenylboronic acid as reagents, Preparation R2az was obtained. HRMS calculated for C14H14N4O: 254.1168; found 255.1243 [(M+H)+ form].
1H-NMR (400 MHz, MSM-d6): δ (ppm) 11.98 (brs, 1 H), 7.89 (d, 1 H), 7.43 (m, 2 H), 7.33 (d, 1 H), 6.82 (m, 2 H), 6.61 (d, 1 H), 2.94 (s, 6 H).
13C-NMR (100 MHz, MSM-d6): δ (ppm) 144.1, 125.6, 124.3, 112.7, 102.7, 40.6.
Preparation R2ba: 7- [4-(trifluoromethoxy)phenyl] -3H,4H,7H-pyrrolo [2,3- d] pyrimidin-4-one
Using General Procedure 3 starting from Preparation Rib and l-iodo-4- (trifluoromethoxy)benzene as reagents, Preparation R2ba was obtained. HRMS calculated for Ci3H8F3N302: 295.0569; found 296.0648 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.15 (s, 1 H), 7.97 (d, 1 H), 7.86 (m, 2 H), 7.56 (m, 2 H), 7.54 (m, 1 H), 6.71 (d, 1 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 144.8, 126.4, 124.1, 122.5, 103.9. Preparation R2bb: 7- [4-(benzyloxy)phenyl] -3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4-one Using General Procedure 3 starting from Preparation Rib and 4-benzyloxyiodobenzene as reagents, Preparation R2bb was obtained. HRMS calculated for Ci9Hi5N302: 317.1164; found 318.1243 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.05 (brs, 1 H), 7.92 (d, 1 H), 7.59 (dm, 2 H), 7.48 (dm, 2 H), 7.41 (d, 1 H), 7.41 (tm, 2 H), 7.35 (tm, 1 H), 7.16 (dm, 2 H), 6.65 (d, 1 H), 5.18 (s, 2 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 158.8, 157.6, 147.3, 144.4, 137.4, 131, 129, 128.4, 128.2, 126.1, 124.3, 115.7, 109.4, 103.1, 69.9.
Preparation R2bc: 7-(5-methylthiophen-2-yl)-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4- one
Using General Procedure 3 starting from Preparation Rib and 2-iodo-5- methylthiophene as reagents, Preparation R2bc was obtained. HRMS calculated for CiiH9N3OS: 231.0466; found 232.0541 [(M+H)+ form]. Ή-NMR (400 MHz, MSM-d6): δ (ppm) 12.17 (brs, 1 H), 7.99 (d, 1 H), 7.49 (d, 1 H), 7.14 (d, 1 H), 6.76 (dq, 1 H), 6.67 (d, 1 H), 2.46 (d, 3 H).
13C-NMR (100 MHz, MSM-d6): δ (ppm) 145, 124.2, 123.9, 1 19.4, 103.9, 15.4.
Preparation R2bd: 7-(5-chlorothiophen-2-yl)-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4- one
Using General Procedure 3 starting from Preparation Rib and 2-chloro-5- iodothiophene as reagents, Preparation R2bd was obtained. HRMS calculated for Cio¾N3OSCl: 250.9920; found 252.0005 ((M+H)+ form].
1H-NMR (500 MHz, dmso-d6) δ ppm 12.28 (brs, 1 H), 8.07 (d, 1 H), 7.67 (d, 1 H), 7.3 (d, 1 H), 7.13 (d, 1 H), 6.72 (d, 1 H).
13C-NMR (500 MHz, dmso-d6) δ ppm 158.4, 146.8, 145.6, 136.4, 125.5, 124.6, 123.3, 1 17.5, 109.3, 104.6 .
Preparation R2be: 7-(2,3-dihydro- 1 ,4-benzodioxin-6-yl)-3H,4H,7H-pyrrolo [2,3- d] pyrimidin-4-one
Using General Procedure 2 starting from Preparation Rla and 1 ,4-benzodioxane-6- boronic acid as reagents, Preparation R2be was obtained. HRMS calculated for C14H11N3O3 : 269,0800; found 270.0881 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.05 (brs, 1 H), 7.92 (d, 1 H), 7.4 (d, 1 H), 7.22 (d, 1 H), 7.13 (dd, 1 H), 6.99 (d, 1 H), 6.63 (d, 1 H), 4.33-4.25 (m, 4 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 144.4, 124.3, 1 17.7, 1 17.6, 1 13.8, 103.2.
Preparation R2bf: 7-(2H- 1 ,3-benzodioxol-5-yl)-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4- one
Using General Procedure 2 starting from Preparation Rla and
3,4-methylenedioxyphenylboronic acid as reagents, Preparation R2bf was obtained. HRMS calculated for C13H9N3O3 : 255,0644; found 256.0719 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.05 (brs, 1 H), 7.92 (d, 1 H), 7.4 (d, 1 H), 7.29 (d, 1 H), 7.12 (dd, 1 H), 7.05 (d, 1 H), 6.63 (d, 1 H), 6.1 1 (s, 2 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 144.5, 124.5, 1 18.2, 108.7, 106.5, 103.1 , 102.2. Preparation R2bg: 7-(naphthalen-2-yl)-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4-one Using General Procedure 2 starting from Preparation Rla and 2-naphthaleneboronic acid as reagents, Preparation R2bg was obtained. HRMS calculated for C16H11N3O: 261 ,0902; found 262.0982 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.14 (s, 1 H), 8.25 (d, 1 H), 8.09 (d, 1 H), 8.01 (m, 1 H), 8.01 (m, 1 H), 8 (s, 1 H), 7.91 (dd, 1 H), 7.63 (d, 1 H), 7.6 (tm, 1 H), 7.57 (tm, 1 H), 6.74 (d, 1 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 158.8, 147.6, 144.8, 135.4, 133.4, 132, 129.4, 128.4, 128.2, 127.4, 126.9, 124.4, 123.5, 122.3, 109.9, 103.8. Preparation R2bh: 7- [3-(trifluoromethyl)phenyl] -3H,4H,7H-pyrrolo [2,3-d] pyrimidin- 4-one
Using General Procedure 3 starting from Preparation Rib and 3-iodobenzotrifluoride as reagents, Preparation R2bh was obtained. HRMS calculated for Ci3H8F3N30: 279.0620; found 280.0699 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.19 (brs, 1 H), 8.18 (brs, 1 H), 8.07 (dm, 1 H), 8.02 (d, 1 H), 7.79 (t, 1 H), 7.77 (dm, 1 H), 7.65 (d, 1 H), 6.73 (d, 1 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 145.1 , 131.1 , 128.3, 124, 123.9, 121 , 104.1.
Preparation R2bi: 7-{3-[(4-methylpiperazin-l-yl)methyl]phenyl}-3H,4H,7H- pyrrolo [2,3-d] pyrimidin-4-one
Using General Procedure 2 starting from Preparation Rib and 3-(4-methyl-l- piperazinylmethyl)benzeneboronic acid pinacol ester as reagents, Preparation R2bi was obtained. HRMS calculated for Ci8H2iN50: 323.1746; found 324.1828 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.37/12.2/1 1.95 (brs, 3 H), 8.04 (brs, 1 H), 7.98
(s, 1 H), 7.91 (dm, 1 H), 7.67 (dm, 1 H), 7.63 (d, 1 H), 7.62 (t, 1 H), 6.72 (d, 1 H), 4.49 (brs, 2 H), 3.8-3.3 (brm, 8 H), 2.8 (brs, 3 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 144.8, 130.3, 130, 127.3, 125.7, 124, 103.9, 58.7,
42.7.
Preparation R2bj : 7- [3-(hydroxymethyl)phenyl] -3H,4H,7H-pyrrolo [2,3-d] pyrimidin- 4-one Using General Procedure 3 starting from Preparation Rib and 3-iodobenzyl alcohol as reagents, Preparation R2bj was obtained. HRMS calculated for C13H11N3O2: 241.0851 ; found 242.0935 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.1 1 (brs, 1 H), 7.95 (d, 1 H), 7.64 (brt, 1 H), 7.55 (dm, 1 H), 7.48 (t, 1 H), 7.46 (d, 1 H), 7.35 (dm, 1 H), 6.68 (d, 1 H), 4.58 (s, 2 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 158.8, 147.4, 144.6, 144.4, 137.7, 129.4, 125.4, 124.2, 123, 122.5, 109.7, 103.5, 62.9.
Preparation R2bk: 7-(3-chlorophenyl)-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4-one
Using General Procedure 3 starting from Preparation Rib and l-chloro-3-iodobenzene as reagents, Preparation R2bk was obtained. HRMS calculated for C12H8CI 3O : 245.0356; found 246.0437 [(M+H)+ form].
1H-NMR (400 MHz, MSM-d6): δ (ppm) 12.17 (brs, 1 H), 8 (d, 1 H), 7.92 (m, 1 H), 7.74
(dm, 1 H), 7.58 (d, 1 H), 7.57 (t, 1 H), 7.47 (dm, 1 H), 6.7 (d, 1 H).
13C-NMR (100 MHz, MSM-d6): δ (ppm) 145, 131.3, 127.2, 124.1 , 123.9, 122.9, 104. Preparation R2bl: 7-(3-fluorophenyl)-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4-one
Using General Procedure 3 starting from Preparation Rib and l-fluoro-3-iodobenzene as reagents, Preparation R2bl was obtained. HRMS calculated for C12H8N3OF: 229.0651 ; found 230.0729 [(M+H)+ form].
1H-NMR (400 MHz, MSM-d6): δ (ppm) 12.17 (brs, 1 H), 7.99 (d, 1 H), 7.72 (dm, 1 H), 7.64 (m, 1 H), 7.58 (d, 1 H), 7.58 (m, 1 H), 7.25 (m, 1 H), 6.71 (d, 1 H).
13C-NMR (100 MHz, MSM-d6): δ (ppm) 144.9, 131.4, 130.9, 123.9, 120.2, 1 14, 1 1 1.6. 19F-NMR (376.5 MHz, MSM-d6): δ (ppm) -1 1 1.7.
Preparation R2bm: 7- [3-(dimethylamino)phenyl] -3H,4H,7H-pyrrolo [2,3-d] pyrimidin- 4-one
Using General Procedure 2 starting from Preparation Rla and 3-(N,N- dimethylamino)phenylboronic acid as reagents, Preparation R2bm was obtained. HRMS calculated for C14H14N4O: 254.1 168; found 255.1229 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.04 (brs, 1 H), 7.92 (d, 1 H), 7.45 (d, 1 H), 7.3 (t, 1 H), 6.94 (m, 1 H), 6.93 (dm, 1 H), 6.74 (dm, 1 H), 6.65 (d, 1 H), 2.95 (s, 6 H). 13C-NMR (125 MHz, MSM-d6): δ (ppm) 144.3, 129.9, 124.4, 112.4, 111.4, 108.6, 103.1, 40.5.
Preparation R2bn: 7- [3-(morpholin-4-yl)phenyl] -3H,4H,7H-pyrrolo [2,3-d] pyrimidin- 4-one
Using General Procedure 2 starting from Preparation Rla and
3-(morpholino)phenylboronic acid as reagents, Preparation R2bn was obtained. 1H-NMR (400 MHz, MSM-d6): δ (ppm) 12.05 (brs, 1 H), 7.93 (s, 1 H), 7.47 (d, J=3.53 Hz, 1 H), 7.36 (t, J=8.13 Hz, 1 H), 7.19 (t, J=2.20 Hz, 1 H), 7.11 (dd, J=1.27, 7.93 Hz, 1 H), 6.98 (dd, J=1.96, 8.49 Hz, 1 H), 6.65 (d, J=3.5 Hz, 1 H), 3.75 (t, J=4.61 Hz, 4 H), 3.18 (t, J=4.61 Hz, 4 H).
Preparation R2bo: 7- [3-(trifluoromethoxy)phenyl] -3H,4H,7H-pyrrolo [2,3- d] pyrimidin-4-one
Using General Procedure 3 starting from Preparation Rib and
3-(trifluoromethoxy)iodobenzene as reagents, Preparation R2bo was obtained. HRMS calculated for CisHgFsNsCh: 295.0569; found 296.0651 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.91 (s, 1 H), 8 (s, 1 H), 7.87 (t, 1 H), 7.82 (ddd, 1 H), 7.68 (t, 1 H), 7.6 (d, 1 H), 7.41 (ddd, 1 H), 6.71 (d, 1 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 145.1, 131.5, 123.9, 123.2, 119.5, 117.1, 104.1.
Preparation R2bp: 7-(3-methoxyphenyl)-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4-one Using General Procedure 3 starting from Preparation Rib and 3-iodoanisole as reagents, Preparation R2bp was obtained. HRMS calculated for C13H11N3O2: 241.0851; found 242.0928 [(M+H)+ form].
1H-NMR (400 MHz, MSM-d6): δ (ppm) 12.1 (brs, 1 H), 7.95 (d, 1 H), 7.51 (d, 1 H), 7.44 (t, 1 H), 7.31 (m, 1 H), 7.3 (m, 1 H), 6.98 (dm, 1 H), 6.67 (d, 1 H), 3.82 (s, 3 H).
13C-NMR (100 MHz, MSM-d6): δ (ppm) 144.6, 130.4, 124.2, 116.7, 112.9, 110.5, 103.5.
Preparation R2bq: 7- [3-(benzyloxy)phenyl] -3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4-one Using General Procedure 3 starting from Preparation Rib and l-benzyloxy-3- iodobenzene as reagents, Preparation R2bq was obtained. HRMS calculated for Ci9Hi5N302: 317.1 164; found 318.1235 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.1 (brs, 1 H), 7.95 (d, 1 H), 7.51 (d, 1 H), 7.51- 7.31 (m, 5 H), 7.44 (t, 1 H), 7.41 (m, 1 H), 7.32 (dm, 1 H), 7.05 (dm, 1 H), 6.68 (d, 1 H), 5.18 (s, 2 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 144.6, 130.5, 124.1 , 1 16.8, 1 13.6, 1 1 1.4, 103.6, 70.
Preparation R2br: 7-(6-methylpyridin-2-yl)-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4-one Using General Procedure 3 starting from Preparation Rib and 2-iodo-6-methylpyridine as reagents, Preparation R2br was obtained. HRMS calculated for C12H10N4O: 226.0855; found 227.0933 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12 (brs, 1 H), 8.25 (dm, 1 H), 8.05 (s, 1 H), 7.9 (t, 1 H), 7.88 (d, 1 H), 7.25 (dm, 1 H), 6.68 (d, 1 H), 2.52 (s, 3 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 144.9, 139.5, 122, 121.8, 1 13.8, 103.7, 24.4.
Preparation R2bs: 7-(6-methoxypyridin-2-yl)-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4- one
The mixture of Preparation Rla (1.0 g, 6.51 mmol) ), 2-iodo-6-methoxy-pyridine (2.35 g, 9.77 mmol, 1.5 eq.), copper(I)-iodide (125 mg, 0.65 mmol, 0.1 eq.), potassium-phosphate tribasic (2.76 g, 13 mmol, 2 eq.), (li?,2i?)-(-)-l ,2-diaminocyclohexane (74 mg, 0.65 mmol, 0.1 eq.) in PDO (50 ml) was stirred under inert atmosphere for 4 hours at 100 °C. The inorganics was filtered off and the filtrate was evaporated. The resulted residue was purified by flash chromatography (DCM).
The arylated product (920 mg, 3.5 mmol) and lithium-hydroxide monohydrate (1.48 g, 35 mmol) were stirred in the mixture of PDO (15 ml) and water (15 ml) at 1 10 °C for 24 hours. The residue was acidified by aq. HC1 solution (1 N, 50 ml) and the resulted precipitate was filtered off and dried to give Preparation R2bs. HRMS calculated for C12H10N4O2: 242.0804; found 243.0884 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.21 (brs, 1 H), 8.08 (dd, 1 H), 8.03 (s, 1 H), 7.94 (d, 1 H), 7.9 (t, 1 H), 6.78 (dd, 1 H), 6.7 (d, 1 H), 3.94 (s, 3 H). 13C-NMR (125 MHz, MSM-d6): δ (ppm) 163.2, 158.5, 147.6, 147.4, 144.9, 141.9, 121.9, 111.2, 108.4, 108.4, 103.8, 53.9.
Preparation R2bt: 7-(naphthalen-l-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one
Using General Procedure 2 starting from Preparation Rla and 1-naphthaleneboronic acid as reagents, Preparation R2bt was obtained. HRMS calculated for C16H1 1N3O: 261.0902; found 262.0984 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.04 (s, 1 H), 8.12 (d, 1 H), 8.09 (d, 1 H), 7.78 (d, 1 H), 7.67 (t, 1 H), 7.61 (dm, 1 H), 7.6 (t, 1 H), 7.51 (tm, 1 H), 7.39 (d, 1 H), 7.21 (t, 1 H), 6.77 (d, 1 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 158.9, 149.2, 144.6, 134.2, 134.1, 130.4, 129.5, 128.7, 127.8, 127.2, 126.4, 126.3, 126, 123, 108.7, 103.1
Preparation R2bu: 7-(pyridin-3-yl)-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4-one
Using General Procedure 2 starting from Preparation Rla and pyridine-3-boronic acid as reagents, Preparation R2bu was obtained. HRMS calculated for CnH8N40: 212.0698; found 213.0774 [(M+H)+ form] .
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.29 (s, 1 H), 8.55 (dd, 1 H), 8.47 (dd, 1 H), 8.06 (brs, 1 H), 8.03 (t, 1 H), 7.9 (d, 1 H), 7.4 (t, 1 H), 6.7 (d, 1 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 149.1, 145, 139.4, 122.5, 122, 116.9, 104.
15N-NMR (50.6 MHz, MSM-d6): δ (ppm) 171.2. Preparation R2bv: 7-(pyridin-4-yl)-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4-one
Using General Procedure 2 starting from Preparation Rla and pyridine-4-boronic acid pinacol ester as reagents, Preparation R2bv was obtained. HRMS calculated for CiiH8N40: 212.0698; found 213.0773 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ ppm 12.31 (brs, 1 H), 8.69 (m, 2 H), 8.05 (s, 1 H), 7.99 (m, 2 H), 7.73 (d, 1 H), 6.76 (d, 1 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 151.3, 145.6, 122.8, 117.3, 105.
Preparation R2bw: 7-[l-(difluoromethyl)-lH-pyrazol-4-yl]-3H,4H,7H-pyrrolo[2,3- d] pyrimidin-4-one Using General Procedure 3 starting from Preparation Rib and l-(difluoromethyl)-4- iodo-lH-pyrazole as reagents, Preparation R2bw was obtained. HRMS calculated for CioH7F2N50: 251.0619; found 252.0682 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 11.88 (brs, 1 H), 8.83 (d, 1 H), 8.4 (d, 1 H), 8.03 (s, 1 H), 7.91 (t, 1 H), 7.58 (d, 1 H), 6.69 (d, 1 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 145.2, 136.2, 123.2, 121.3, 111, 104.
Preparation R2bx: 7-(l-methyl-lH-pyrazol-4-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin- 4-one
Using General Procedure 3 starting from Preparation Rib and 4-iodo-l -methyl- 1H- pyrazole as reagents, Preparation R2bx was obtained. HRMS calculated for C10H9N5O: 215.0807; found 216.0889 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 12.12 (brs, 1 H), 8.27 (s, 1 H), 7.96 (s, 1 H), 7.91 (d, 1 H), 7.42 (d, 1 H), 6.63 (d, 1 H), 3.89 (s, 3 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 158.6, 146.9, 144.7, 132.1, 124.3, 123.4, 121.4, 109, 103.4, 38.5.
Preparation R2by: 7-(propan-2-yl)-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4-one
Using General Procedure 1 starting from Preparation Rla and 2-iodopropane as reagents, Preparation R2by was obtained. HRMS calculated for C9HnN30: 177.0902; found 178.0979 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 11.83 (brs, 1 H), 7.87 (s, 1 H), 7.24 (d, 1 H), 6.47 (d, 1 H), 4.85 (sept., 1 H), 1.42 (d, 6 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 158.8, 146.8, 143.5, 120.7, 108.2, 102, 46.5, 23. 15N-NMR (50.6 MHz, MSM-d6): δ (ppm) 168.
Preparation R2ca: 7-cyclobutyl-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4-one
Using General Procedure 1 starting from Preparation Rla and cyclo butyl bromide as reagents, Preparation R2ca was obtained. HRMS calculated for C10H1 1N3O: 189.0902; found 190.0974 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 11.85 (brs, 1 H), 7.88 (brs, 1 H), 7.09 (d, 1 H), 6.44 (d, 1 H), 3.70 (m, 1 H) 13C-NMR (125 MHz, MSM-d6): δ (ppm) 158.7, 147.7, 143.8, 125.1, 108.1, 101.7, 31.8.
Preparation R2cb: 7-(l-methylpiperidin-4-yl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4- one
Using General Procedure 4 starting from Preparation Rla and 4-hydroxy-l- methylpiperidine as reagents, Preparation R2cb was obtained. HRMS calculated for Ci2Hi6N40: 232.1324; found 233.1405 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 11.82 (brs, 1 H), 7.86 (d, 1 H), 7.29 (d, 1 H), 6.46 (d, 1 H), 4.44 (m, 1 H), 2.89/2.05 (m, 4 H), 2.22 (s, 3 H), 2.02/1.82 (m, 4 H).
13C-NMR (125 MHz, MSM-d6): δ (ppm) 143.9, 121.2, 102.1, 55.1, 52.1, 46.1, 32.3. Preparation R2cc: 7-(2,2-difluoroethyl)-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4-one
Using General Procedure 1 starting from Preparation Rla and 2-iodo-l,l- difluoroethane as reagents, Preparation R2cc was obtained. HRMS calculated for C8H7N3OF2: 199.0557; found 200.0634 ((M+H)+ form].
1H-NMR (400 MHz, DMSO-d6) δ ppm 11.99 (brs, 1 H), 7.93 (s, 1 H), 7.16 (d, 1 H), 6.53 (d, 1 H), 6.37 (tt, 1 H), 4.6 (td, 2 H).
13C-NMR (400 MHz, DMSO-d6) δ ppm 144.4, 124.8, 114.3, 102.5, 46.2 .
Preparation R2cd: 7-(2-fluoroethyl)-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4-one
Using General Procedure 1 starting from Preparation Rla and l-fluoro-2-iodoethane as reagents, Preparation R2cd was obtained. HRMS calculated for CsHsNOF: 181.0651; found 182.0728 ((M+H)+ form] .
1H-NMR (400 MHz, dmso-d6) δ ppm 11.91 (brs, 1 H), 7.9 (s, 1 H), 7.17 (d, 1 H), 6.49 (d, 1 H), 4.74 (dt, 2 H), 4.43 (dt, 2 H).
13C-NMR (400 MHz, dmso-d6) δ ppm 144, 124.3, 102, 83.1, 45.1.
Preparation R2ce: 7-(2-hydroxyethyl)-3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4-one
Using General Procedure 1 starting from Preparation Rla and 2-chloroethanol as reagents, Preparation R2ce was obtained. 1H-NMR (400 MHz, MSM-d6): δ (ppm) 11.83 (brs, 1 H), 7.86 (d, J=2.4 Hz, 1 H), 7.12 (d, J=3.92 Hz, 1 H), 6.43 (d, J=3.14 Hz, 1 H), 4.92 (t, J=5.49 Hz, 1 H), 4.15 (t, J=6.28 Hz, 2 H), 3.68 (q, J=5.49 Hz, 2 H). Preparation R2cg: 7- [(4-chlorophenyl)methyl] -3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4- one
Using General Procedure 1 starting from Preparation Rla and 4-chlorobenzyl bromide as reagents, Preparation R2cg was obtained. HRMS calculated for C13H10CI 3O: 259.0512; found 260.0583 [(M+H)+ form].
1H-NMR (400 MHz, MSM-d6): δ (ppm) 11.93 (s, 7.9 (s, 1 H), 7.39 (m, 2 H), 7.23 (m, 2 H), 7.22 (d, 1 H), 6.51 (d, 1 H), 5.34 (s, 2 H).
13C-NMR (100 MHz, MSM-d6): δ (ppm) 158.7, 147.4, 144.2, 137.5, 132.5, 129.5, 129, 124.2, 108.3, 102.4, 47.5. Preparation R2ch: 7- [(3-chlorophenyl)methyl] -3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4- one
Using General Procedure 1 starting from Preparation Rla and 3-chlorobenzyl bromide as reagents, Preparation R2ch was obtained. HRMS calculated for C13H10CIN3O: 259.0512; found 260.0580 [(M+H)+ form].
1H-NMR (500 MHz, MSM-d6): δ (ppm) 11.94 (brs, 1 H), 7.92 (d, 1 H), 7.35 (m, 1 H), 7.35 (m, 1 H), 7.28 (t, 1 H), 7.25 (d, 1 H), 7.16 (dm, 1 H), 6.51 (d, 1 H), 5.35 (s, 2 H). 13C-NMR (125 MHz, MSM-d6): δ (ppm) 158.7, 147.6, 144.3, 140.9, 133.6, 131.1, 128, 127.5, 126.4, 124.3, 108.4, 102.4, 47.5.
Preparation R2ci: 7- [(2-chlorophenyl)methyl] -3H,4H,7H-pyrrolo [2,3-d] pyrimidin-4- one
Using General Procedure 1 starting from Preparation Rla and 2-chlorobenzyl bromide as reagents, Preparation R2ci was obtained. HRMS calculated for C13H10CI 3O: 259.0512; found 260.0587 [(M+H)+ form].
1H-NMR (400 MHz, MSM-d6): δ (ppm) 11.95 (brs, 1 H), 7.89 (d, 1 H), 7.5 (dm, 1 H), 7.32 (m, 1 H), 7.26 (m, 1 H), 7.17 (d, 1 H), 6.72 (dm, 1 H), 6.55 (d, 1 H), 5.44 (s, 2 H).
13C-NMR (100 MHz, MSM-d6): δ (ppm) 144.3, 129.8, 129.8, 128.8, 128.1, 124.5, 102.5, 46. EXAMPLES
The following Examples illustrate the invention but do not limit it in any way.
■ tert-butyl (3R,4R)-4- [4-hydroxy-4- [(7-methyl-4-oxo-pyrrolo [2,3-d] pyrimidin-3- yl)methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 1) Using General Procedure 5 starting from Preparation R2g and Preparation Rlc as reagents, EXAMPLE 1 was obtained. HRMS calculated for C30H39N5O5 : 549.2951; found 550.3021 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4-hydroxy-4- [(4-oxothieno [2,3-d] pyrimidin-3- yl)methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 2) Using General Procedure 5 starting from 3H-thieno[2,3-d]pyrimidin-4-one and Preparation Rlc as reagents, EXAMPLE 2 was obtained. HRMS calculated for C29H36N405S: 552.2406; found 553.2479 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4- [(7-ethyl-4-oxo-pyrrolo [2,3-d] pyrimidin-3-yl)methyl] -4- hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 3) Using General Procedure 5 starting from Preparation R2h and Preparation Rlc as reagents, EXAMPLE 3 was obtained. HRMS calculated for C3iH4iN505: 563.3108; found 564.319 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4-hydroxy-4- [(4-oxo-7-prop-2-ynyl-pyrrolo [2,3-d] pyrimidin-3- yl)methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 4) Using General Procedure 5 starting from Preparation R2i and Preparation Rlc as reagents, EXAMPLE 4 was obtained. HRMS calculated for C32H39N505: 573.2951; found 574.3024 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4- [(7-cyclopr opyl-4-oxo-pyrrolo [2,3-d] pyrimidin-3-yl)methyl] - 4-hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 5) Using General Procedure 5 starting from Preparation R2j and Preparation Rlc as reagents, EXAMPLE 5 was obtained. HRMS calculated for C32H4iN505: 575.3108; found 576.3189 [(M+H) form]. ■ tert-butyl (3R,4R)-4- [4- [(7-chloro-4-oxo-thieno [3,4-d] yrimidin-3-yl)methyl] -4- hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 6) Using General Procedure 5 starting from 7-chloro-3H-thieno[3,4-d]pyrimidin-4-one and Preparation Rlc as reagents, EXAMPLE 6 was obtained. HRMS calculated for C29H35C1N405S: 586.2017; found 609.1912 [(M+Na) form].
■ tert-butyl (3R,4R)-4- [4- [(7-buta-2,3-dienyl-4-oxo-pyrrolo [2,3-d] pyrimidin-3- yl)methyl]-4-hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate
(EXAMPLE 7)
Using General Procedure 5 starting from Preparation R2k and Preparation Rlc as reagents, EXAMPLE 7 was obtained. HRMS calculated for C33H4iN505: 587.3108; found 588.318 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4- [ [7-(cyclopropylmethyl)-4-oxo-pyrrolo [2,3-d] pyrimidin-3- yl]methyl]-4-hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate
(EXAMPLE 8)
Using General Procedure 5 starting from Preparation R21 and Preparation Rlc as reagents, EXAMPLE 8 was obtained. HRMS calculated for C33H43N505 : 589.3264; found 590.3342 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4-hydroxy-4- [(7-isobutyl-4-oxo-pyrrolo [2,3-d] pyrimidin-3- yl)methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 9) Using General Procedure 5 starting from Preparation R2m and Preparation Rlc as reagents, EXAMPLE 9 was obtained. HRMS calculated for C33H45N505 : 591.342; found 592.3501 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4-hydroxy-4- [(9-methyl-4-oxo-pyrimido [4,5-b] indol-3- yl)methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 10) Using General Procedure 5 starting from Preparation R2n and Preparation Rlc as reagents, EXAMPLE 10 was obtained. HRMS calculated for C34H4iN505: 599.3108; found 600.3181 [(M+H) form]. ■ tert-butyl (3R,4R)-4- [4- [ [7-(cyclobutylmethyl)-4-oxo-pyrrolo [2,3-d] pyrimidin-3- yl]methyl]-4-hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate
(EXAMPLE 11)
Using General Procedure 5 starting from Preparation R2o and Preparation Rlc as reagents, EXAMPLE 11 was obtained. HRMS calculated for C34H45N505 : 603.342; found 604.3502 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4- [ [7-(2-dimethylaminoethyl)-4-oxo-pyrrolo [2,3-d] pyrimidin- 3-yl]methyl]-4-hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate
(EXAMPLE 12)
Using General Procedure 5 starting from Preparation R2p and Preparation Rlc as reagents, EXAMPLE 12 was obtained. HRMS calculated for C33H46N6O5 : 606.353; found 607.36 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4-hydroxy-4- [(4-oxo-7-phenyl-pyrrolo [2,3-d] pyrimidin-3- yl)methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 13) Using General Procedure 5 starting from Preparation R2q and Preparation Rlc as reagents, EXAMPLE 13 was obtained. HRMS calculated for C35H41N5O5 : 611.3108; found 612.3192 [(M+H) form].
■ tert-butyl (3R,4R)-4-[4-hydroxy-4-[(4-oxo-7-phenyl-5H-pyrrolo[3,2-d]pyrimidin-3- yl)methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 14) Using General Procedure 5 starting from 7-phenyl-3,5-dihydropyrrolo[3,2-(i]pyrimidin-4- one and Preparation Rlc as reagents, EXAMPLE 14 was obtained. HRMS calculated for C35H4iN505 : 611.3108; found 612.3182 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4-hydroxy-4- [ [4-oxo-7-(2-pyridyl)pyrrolo [2,3-d] pyrimidin-3- yl] methyl] piperidine- 1-carbonyl] -3-phenyl-piperidine- 1-carboxylate (EXAMPLE 15) Using General Procedure 5 starting from Preparation R2b and Preparation Rlc as reagents, EXAMPLE 15 was obtained. HRMS calculated for C34H40N6O5 : 612.306; found 613.3132 [(M+H) form]. ■ tert-butyl (3R,4R)-4-[4-hydroxy-4-[(4-oxo-l-phenyl-pyrazolo[3,4-d]pyrimidin-5- yl)methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 16) Using General Procedure 5 starting from l-phenyl-5H-pyrazolo[3,4-d]pyrimidin-4-one and Preparation Rlc as reagents, EXAMPLE 16 was obtained. HRMS calculated for C34H4oN605: 612.306; found 613.312 [(M+H) form].
■ tert-butyl (3R,4R)-4-[4-hydroxy-4-[(6-oxo-9-phenyl-purin-l-yl)methyl]piperidine-l- carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 17)
Using General Procedure 5 starting from 9-phenyl-lH-purin-6-one and Preparation Rlc as reagents, EXAMPLE 17 was obtained. HRMS calculated for C34H4oN605: 612.306; found 613.3142 [(M+H) form].
■ tert-butyl (3R,4R)-4-[4-[(7-bromo-4-oxo-pyrrolo[2,l-f| [l,2,4]triazin-3-yl)methyl]-4- hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 18) Using General Procedure 5 starting from 7-bromo-3H-pyrrolo[2,lT/][l,2,4]triazin-4-one and Preparation Rlc as reagents, EXAMPLE 18 was obtained. HRMS calculated for C29H36BrN505: 613.19; found 612.1851 [(M-H) form].
■ tert-butyl (3R,4R)-4- [4-hydroxy-4- [(7-oxo-3-phenyl-isoxazolo [4,5-d] pyrimidin-6- yl)methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 19) Using General Procedure 5 starting from 3-phenyl-6H-isoxazolo[4,5-d]pyrimidin-7-one and Preparation Rlc as reagents, EXAMPLE 19 was obtained. HRMS calculated for C34H39N506: 613.29; found 636.2782 [(M+Na) form].
■ tert-butyl (3R,4R)-4- [4-hydroxy-4- [(4-oxo-7-pyrimidin-2-yl-pyrrolo [2,3-d] pyrimidin-3-yl)methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate
(EXAMPLE 20)
Using General Procedure 5 starting from Preparation R2s and Preparation Rlc as reagents, EXAMPLE 20 was obtained. HRMS calculated for C33H39N705: 613.3013; found 614.3102 [(M+H) form]. ■ tert-butyl (3R,4R)-4- [4-hydroxy-4- [(7-oxo-3-phenyl-triazolo [4,5-d] pyrimidin-6- yl)methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 21) Using General Procedure 5 starting from 3-phenyl-6H-triazolo[4,5-d]pyrimidin-7-one and Preparation Rlc as reagents, EXAMPLE 21 was obtained. HRMS calculated for CssHsgNyOs: 613.3013; found 614.3095 [(M+H) form].
■ tert-butyl (3R,4R)-4-({4-[(6,8-dimethyl-4-oxopyrimido[5,4-6]indolizin-3(4H)- yl)methyl]-4-hydroxypiperidin-l-yl}carbonyl)-3-phenylpiperidine-l-carboxylate
(EXAMPLE 22)
Using General Procedure 5 starting from Preparation R2t and Preparation Rlc as reagents, EXAMPLE 22 was obtained. HRMS calculated for C34H42N6O5 : 614.3217; found 615.3301 [(M+H) form].
■ tert-butyl (3R,4R)-4-[4-hydroxy-4-[[7-(l-methylimidazol-4-yl)-4-oxo-pyrrolo[2,3-d] pyrimidin-3-yl]methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate
(EXAMPLE 23)
Using General Procedure 5 starting from Preparation R2u and Preparation Rlc as reagents, EXAMPLE 23 was obtained. HRMS calculated for C33H41N7O5 : 615.3169; found 616.324 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4-hydroxy-4- [ [4-oxo-7-(3-thienyl)pyrrolo [2,3-d] pyrimidin-3- yl]methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 24) Using General Procedure 5 starting from Preparation R2v and Preparation Rlc as reagents, EXAMPLE 24 was obtained. HRMS calculated for C33H39N5O5S: 617.2672; found 618.2736 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4-hydroxy-4- [ [4-oxo-7-(2-thienyl)pyrrolo [2,3-d] pyrimidin-3- yl]methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 25) Using General Procedure 5 starting from Preparation R2w and Preparation Rlc as reagents, EXAMPLE 25 was obtained. HRMS calculated for C33H39N5O5S: 617.2672; found 618.2744 [(M+H) form]. ■ tert-butyl (3R,4R)-4- [4-hydroxy-4- [ [4-oxo-7-(2,2,2-trifluoroethyl)pyrrolo [2,3-d] pyrimidin-3-yl]methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate
(EXAMPLE 26)
Using General Procedure 5 starting from Preparation R2x and Preparation Rlc as reagents, EXAMPLE 26 was obtained. HRMS calculated for C31H38F3N5O5 : 617.2825; found 618.2912 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4-hydroxy-4- [(4-oxo-7-thiazol-2-yl-pyrrolo [2,3-d] pyrimidin-3- yl)methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 27) Using General Procedure 5 starting from Preparation R2y and Preparation Rlc as reagents, EXAMPLE 27 was obtained. HRMS calculated for C32H38N6O5S : 618.2625; found 641.251 [(M+Na) form].
■ tert-butyl (3R,4R)-4- [4- [ [7- [3-(dimethylamino)propyl] -4-oxo-pyrrolo [2,3-d] pyrimidin-3-yl]methyl]-4-hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l- carboxylate (EXAMPLE 28)
Using General Procedure 5 starting from Preparation R2z and Preparation Rlc as reagents, EXAMPLE 28 was obtained. HRMS calculated for C34H48N6O5 : 620.3686; found 621.3731 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4-hydroxy-4- [ [7-(m-tolyl)-4-oxo-pyrrolo [2,3-d] pyrimidin-3- yl]methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 29) Using General Procedure 5 starting from Preparation R2aa and Preparation Rlc as reagents, EXAMPLE 29 was obtained. HRMS calculated for C36H43N5O5 : 625.3264; found
626.3357 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4-hydroxy-4- [ [4-oxo-7-(p-tolyl)pyrrolo [2,3-d] pyrimidin-3- yl]methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 30) Using General Procedure 5 starting from Preparation R2ab and Preparation Rlc as reagents, EXAMPLE 30 was obtained. HRMS calculated for C36H43N5O5 : 625.3264; found
626.3358 [(M+H) form]. ■ tert-butyl (3R,4R)-4- [4- [(7-benzyl-4-oxo-pyrrolo [2,3-d] pyrimidin-3-yl)methyl] -4- hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 31) Using General Procedure 5 starting from Preparation R2ac and Preparation Rlc as reagents, EXAMPLE 31 was obtained. HRMS calculated for C36H43N5O5: 625.3264; found 626.3343 [(M+H) form].
■ tert-butyl (3R,4R)-4-[4-hydroxy-4-[(6-methyl-4-oxo-7-phenyl-pyrrolo [2,3-d] pyrimidin-3-yl)methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate
(EXAMPLE 32)
Using General Procedure 5 starting from Preparation R2ad and Preparation Rlc as reagents, EXAMPLE 32 was obtained. HRMS calculated for C36H43N5O5: 625.3264; found 626.3335 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4-hydroxy-4- [(7-oxo-3-phenyl-isothiazolo [4,5-d] pyrimidin-6- yl)methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 33) Using General Procedure 5 starting from 3-phenyl-6H-isothiazolo[4,5-<i]pyrimidin-7-one and Preparation Rlc as reagents, EXAMPLE 33 was obtained. HRMS calculated for C34H39N505S: 629.2672; found 652.2559 [(M+Na) form].
■ tert-butyl (3R,4R)-4- [4- [ [7-(4-fluorophenyl)-4-oxo-pyrrolo [2,3-d] pyrimidin-3- yl]methyl]-4-hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate
(EXAMPLE 34)
Using General Procedure 5 starting from Preparation R2ae and Preparation Rlc as reagents, EXAMPLE 34 was obtained. HRMS calculated for C35H40FN5O5: 629.3013; found 530.2568 [(M+H-Boc) form].
■ tert-butyl (3R,4R)-4- [4- [ [7-(3-fluorophenyl)-4-oxo-pyrrolo [2,3-d] pyrimidin-3- yl]methyl]-4-hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 35)
Using General Procedure 5 starting from Preparation R2bl and Preparation Rlc as reagents, EXAMPLE 35 was obtained. HRMS calculated for C35H40FN5O5: 629.3013; found 652.2909 [(M+Na) form]. ■ tert-butyl (3R,4R)-4- [4- [(7-bromo-4-oxo-thieno [3,2-d] yrimidin-3-yl)methyl] -4- hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 36) Using General Procedure 5 starting from 7-bromo-3H-thieno[3,2-d]pyrimidin-4-one and Preparation Rlc as reagents, EXAMPLE 36 was obtained. HRMS calculated for C29H35BrN405S: 630.1511; found 653.1419 [(M+Na) form].
■ tert-butyl (3R,4R)-4- [4-hydroxy-4- [ [7-(5-methyl-2-thienyl)-4-oxo-pyrrolo [2,3-d] pyrimidin-3-yl]methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate
(EXAMPLE 37)
Using General Procedure 5 starting from Preparation R2bc and Preparation Rlc as reagents, EXAMPLE 37 was obtained. HRMS calculated for C34H41N5O5S : 631.2828; found 654.2719 [(M+Na) form].
■ tert-butyl (3R,4R)-4-[4-hydroxy-4-[[7-(l-methyl-4-piperidyl)-4-oxo-pyrrolo[2,3-d] pyrimidin-3-yl]methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate
(EXAMPLE 38)
Using General Procedure 5 starting from Preparation R2cb and Preparation Rlc as reagents, EXAMPLE 38 was obtained. HRMS calculated for C35H48N6O5 : 632.3686; found 633.3766 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4- [ [7-(4-cyanophenyl)-4-oxo-pyrrolo [2,3-d] pyrimidin-3- yl]methyl]-4-hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 39)
Using General Procedure 5 starting from Preparation R2au and Preparation Rlc as reagents, EXAMPLE 39 was obtained. HRMS calculated for C36H40N6O5 : 636.306; found 637.3127 [(M+H) form].
■ tert-butyl (3R,4R)-4-[4-hydroxy-4-[[7-(4-methoxyphenyl)-4-oxo-pyrrolo [2,3-d] pyrimidin-3-yl]methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate
(EXAMPLE 40) Using General Procedure 5 starting from Preparation R2c and Preparation Rlc as reagents, EXAMPLE 40 was obtained. HRMS calculated for C36H43N5O6: 641.3214; found 642.3297 [(M+H) form].
■ tert-butyl (3R,4R)-4-[4-hydroxy-4-[[7-(3-methoxyphenyl)-4-oxo-pyrrolo[2,3-d] pyrimidin-3-yl]methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate
(EXAMPLE 41)
Using General Procedure 5 starting from Preparation R2bp and Preparation Rlc as reagents, EXAMPLE 41 was obtained. HRMS calculated for C36H43N5O6: 641.3214; found 642.3313 [(M+H) form]. ■ tert-butyl (3R,4R)-4-[4-hydroxy-4-[[7-[4-(hydroxymethyl)phenyl]-4-oxo- pyrrolo [2,3-d] pyrimidin-3-yl] methyl] piperidine- 1-carbonyl] -3-phenyl-piperidine- 1- carboxylate (EXAMPLE 42)
Using General Procedure 5 starting from Preparation R2ax and Preparation Rlc as reagents, EXAMPLE 42 was obtained. HRMS calculated for C36H43N5O6: 641.3214; found 642.3288 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4-hydroxy-4- [ [6-(hydr oxymethyl)-4-oxo-7-phenyl-pyrrolo
[2,3-d] pyrimidin-3-yl] methyl] piperidine- 1-carbonyl] -3-phenyl-piperidine- 1- carboxylate (EXAMPLE 43)
Preparation Rib (10 g, 67.05 mmol, 1 eq.), iodobenzene (87.2 mmol, 1.3 eq.), Cul (1.28 g, 190.45, 6,705 mmol, 0.1 eq.), DMEDA (1.45 ml, 13,4 mmol, 1,18 g, 0.2 eq.), anhydrous K2CO3 (12.05 g, 87.16 mmol, 1.3 eq.) was suspended in dry acetonitrile (50 ml), flushed with N2 and stirred at 80 °C for 1.5 h. After the reaction completed, the mixture was diluted with water (200 ml) and cooled to r.t. The mixture was filtered, and washed with water (3 x 30 ml), aq. NH3 solution (40 ml, 25%), water (3 x 50 ml), heptane (50 then 30 ml) and dried in vacuum.
A flame dried 3-necked round flask was charged with 5 ml dry THF under N2 atmosphere. 420 μΐ (1.5 eq.) iPr2NH was added via a syringe and the round flask was cooled to -78°C. 1.25 ml (1.5 eq.) n-BuLi was added via a syringe and stirred for 30 minutes. Then 4-methoxy-7-phenyl-pyrrolo[2,3-d]pyrimidine obtained in previous step (450 mg, 2 mmol, 1 eq.) dissolved in 20 ml dry THF was added dropwise and stirred for 1 hour. Then methyl formate (360 mg, 3 eq.) was added dissolved in 10 ml dry THF. After the reaction was completed 40 ml sat. NH4C1 was added and extracted with 3 x 40 ml EEO, dried, filtered and evaporated. Flash chromatography with Hexane:EEO gave (4-methoxy-7-phenyl- pyrrolo[2,3-(i]pyrimidin-6-yl)methanol.
A part of the crude product (127 mg, 0.5 mmol) was dissolved in 2.5 ml PDO and cc. HC1 (82 μΕ, 1 mmol, 2 eq.) was added. The solution was heated, stirred at 100 °C for 2 hours, and it was evaporated to give 6-(hydroxymethyl)-7-phenyl-3H-pyrrolo[2,3-<i]pyrimidin-4- one which was reacted according to General Procedure 5 with Preparation Rlc as reagents to give EXAMPLE 43. HRMS calculated for C36H43N5O6: 641.3214; found 642.3295 [(M+H) form].
■ tert-butyl (3R,4R)-4-[4-hydroxy-4-[[l-(4-methoxyphenyl)-4-oxo-pyrazolo[3,4-d] pyrimidin-5-yl]methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate
(EXAMPLE 44)
Using General Procedure 5 starting from l-(4-methoxyphenyl)-5H-pyrazolo[3,4-<i] pyrimidin-4-one and Preparation Rlc as reagents, EXAMPLE 44 was obtained. HRMS calculated for
Figure imgf000059_0001
642.3166; found 665.3057 [(M+Na) form].
■ tert-butyl (3R,4R)-4- [4-hydroxy-4- [ [7-(6-methoxy-2-pyridyl)-4-oxo-pyrrolo [2,3-d] pyrimidin-3-yl]methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 45)
Using General Procedure 5 starting from Preparation R2bs and Preparation Rlc as reagents, EXAMPLE 45 was obtained. HRMS calculated for C35H42N6O6: 642.3166; found 643.3231 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4- [ [7-(4-chlorophenyl)-4-oxo-pyrrolo [2,3-d] pyrimidin-3- yl]methyl]-4-hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate
(EXAMPLE 46)
Using General Procedure 5 starting from Preparation R2ay and Preparation Rlc as reagents, EXAMPLE 46 was obtained. HRMS calculated for C35H40CI 5O5: 645.2718; found 646.2787 [(M+H) form]. ■ tert-butyl (3R,4R)-4- [4- [ [7-(3-chlorophenyl)-4-oxo-pyrrolo [2,3-d] pyrimidin-3- yl]methyl]-4-hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate
(EXAMPLE 47)
Using General Procedure 5 starting from Preparation R2bk and Preparation Rlc as reagents, EXAMPLE 47 was obtained. HRMS calculated for C35H40CI 5O5 : 645.2718; found 646.2821 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4- [(6-chloro-4-oxo-7-phenyl-pyrrolo [2,3-d] pyrimidin-3- yl)methyl]-4-hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate
(EXAMPLE 48)
Using General Procedure 5 starting from Preparation R2ai and Preparation Rlc as reagents, EXAMPLE 48 was obtained. HRMS calculated for C35H40CI 5O5 : 645.2718; found 646.2782 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4- [ [7-(5-chloro-2-thienyl)-4-oxo-pyrrolo [2,3-d] pyrimidin-3- yl]methyl]-4-hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 49)
Using General Procedure 5 starting from Preparation R2bd and Preparation Rlc as reagents, EXAMPLE 49 was obtained. HRMS calculated for C33H38CIN5O5S: 651.2282; found 652.2348 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4- [ [7- [ l-(difluor omethyl)pyrazol-4-yl] -4-oxo-pyrrolo [2,3-d] pyrimidin-3-yl]methyl]-4-hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l- carboxylate (EXAMPLE 50)
Using General Procedure 5 starting from Preparation R2bw and Preparation Rlc as reagents, EXAMPLE 50 was obtained. HRMS calculated for C33H39F2N7O5: 651.2981; found 674.2867 [(M+Na) form]. ■ tert-butyl (3R,4R)-4-[4-[[7-(4-dimethylaminophenyl)-4-oxo-pyrrolo[2,3-d] pyrimidin-3-yl]methyl]-4-hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l- carboxylate (EXAMPLE 51) Using General Procedure 5 starting from Preparation R2az and Preparation Rlc as reagents, EXAMPLE 51 was obtained. HRMS calculated for C37H46N6O5 : 654.353; found 655.3589 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4- [ [7- [3-(dimethylamino)phenyl] -4-oxo-pyrrolo [2,3-d] pyrimidin-3-yl]methyl]-4-hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l- carboxylate (EXAMPLE 52)
Using General Procedure 5 starting from Preparation R2bm and Preparation Rlc as reagents, EXAMPLE 52 was obtained. HRMS calculated for C37H46N6O5 : 654.353; found 655.3602 [(M+H) form]. ■ tert-butyl (3R,4R)-4-[4-[[7-(l,3-benzodioxol-5-yl)-4-oxo-pyrrolo[2,3-d]pyrimidin-3- yl]methyl]-4-hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate
(EXAMPLE 53)
Using General Procedure 5 starting from Preparation R2bf and Preparation Rlc as reagents, EXAMPLE 53 was obtained. HRMS calculated for C36H41N5O7: 655.3006; found 655.3006 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4- [ [7- [(2-chlorophenyl)methyl] -4-oxo-pyrrolo [2,3-d] pyrimidin-3-yl]methyl]-4-hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l- carboxylate (EXAMPLE 54)
Using General Procedure 5 starting from Preparation R2ci and Preparation Rlc as reagents, EXAMPLE 54 was obtained. HRMS calculated for C36H42N5O5CI: 659.2875; found 660.2949 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4- [ [7- [(3-chlorophenyl)methyl] -4-oxo-pyrrolo [2,3-d] pyrimidin-3-yl]methyl]-4-hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l- carboxylate (EXAMPLE 55)
Using General Procedure 5 starting from Preparation R2ch and Preparation Rlc as reagents, EXAMPLE 55 was obtained. HRMS calculated for C36H42CI 5O5 : 659.2875; found 660.2933 [(M+H) form]. ■ tert-butyl (3R,4R)-4- [4- [ [7- [(4-chlorophenyl)methyl] -4-oxo-pyrrolo [2,3-d] pyrimidin-3-yl]methyl]-4-hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l- carboxylate (EXAMPLE 56)
Using General Procedure 5 starting from Preparation R2cg and Preparation Rlc as reagents, EXAMPLE 56 was obtained. HRMS calculated for C36H42CI 5O5 : 659.2875; found 660.2949 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4- [ [7-(4-fluoro-3-methoxy-phenyl)-4-oxo-pyrrolo [2,3-d] pyrimidin-3-yl]methyl]-4-hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l- carboxylate (EXAMPLE 57)
Using General Procedure 5 starting from Preparation R2e and Preparation Rlc as reagents, EXAMPLE 57 was obtained. HRMS calculated for C36H42FN5O6: 659.31 19; found 660.3194 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4- [ [7- [4-(difluoromethyl)phenyl] -4-oxo-pyrrolo [2,3-d] pyrimidin-3-yl]methyl]-4-hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l- carboxylate (EXAMPLE 58)
Using General Procedure 5 starting from Preparation R2aw and Preparation Rlc as reagents, EXAMPLE 58 was obtained. HRMS calculated for C36H41F2N5O5 : 661.3076; found 662.3141 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4-hydroxy-4- [ [7-(l-naphthyl)-4-oxo-pyrrolo [2,3-d] pyrimidin- 3-yl]methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 59)
Using General Procedure 5 starting from Preparation R2bt and Preparation Rlc as reagents, EXAMPLE 59 was obtained. HRMS calculated for C39H43N5O5 : 661.3264; found 662.3345 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4-hydroxy-4- [ [7-(2-naphthyl)-4-oxo-pyrrolo [2,3-d] pyrimidin- 3-yl]methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 60)
Using General Procedure 5 starting from Preparation R2bg and Preparation Rlc as reagents, EXAMPLE 60 was obtained. HRMS calculated for C35H35N505 : 661.3264; found 606.2715 [(M+H-C(CH3)3) form]. ■ tert-butyl (3R,4R)-4- [4- [ [7-(4-chloro-3-fluoro-phenyl)-4-oxo-pyrrolo [2,3-d] pyrimidin-3-yl]methyl]-4-hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l- carboxylate (EXAMPLE 61)
Using General Procedure 5 starting from Preparation R2ar and Preparation Rlc as reagents, EXAMPLE 61 was obtained. HRMS calculated for C35H39CIFN5O5: 663.2624; found 564.218 [(M+H-Boc) form].
■ tert-butyl (3R,4R)-4-[4-hydroxy-4-[[4-oxo-7-(2- trimethylsilylethoxymethyl)pyr rolo [2,3-d] pyrimidin-3-yl] methyl] piperidine- 1- carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 62)
Using General Procedure 5 starting from 7-(2-trimethylsilylethoxymethyl)-3H- pyrrolo[2,3-d]pyrimidin-4-one and Preparation Rlc as reagents, EXAMPLE 62 was obtained. HRMS calculated for C35H5iN506Si: 665.3609; found 666.3696 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4- [ [7-(2,3-dihydro- 1 ,4-benzodioxin-6-yl)-4-oxo-pyrrolo [2,3-d] pyrimidin-3-yl]methyl]-4-hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l- carboxylate (EXAMPLE 63)
Using General Procedure 5 starting from Preparation R2be and Preparation Rlc as reagents, EXAMPLE 63 was obtained. HRMS calculated for C37H43N5O7: 669.3162; found 670.3238 [(M+H) form].
■ tert-butyl (3R,4R)-4-[4-[[l-(2,3-dihydro-l,4-benzodioxin-6-yl)-4-oxo-pyrazolo[3,4-d] pyrimidin-5-yl]methyl]-4-hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l- carboxylate (EXAMPLE 64)
Using General Procedure 5 starting from l -(2,3-dihydro-l ,4-benzodioxin-6-yl)-5H- pyrazolo[3,4-d]pyrimidin-4-one and Preparation Rlc as reagents, EXAMPLE 64 was obtained. HRMS calculated for C36H42N607: 670.31 15; found 693.3019 [(M+Na) form]. ■ tert-butyl (3R,4R)-4-[4-[[7-(3,4-dimethoxyphenyl)-4-oxo-pyrrolo[2,3-d]pyrimidin-3- yl]methyl]-4-hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate
(EXAMPLE 65) Using General Procedure 5 starting from Preparation R2at and Preparation Rlc as reagents, EXAMPLE 65 was obtained. HRMS calculated for C37H45N507: 671.3319; found 672.3396 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4- [ [7-(3,5-dimethoxyphenyl)-4-oxo-pyrrolo [2,3-d] pyrimidin-3- yl]methyl]-4-hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate
(EXAMPLE 66)
Using General Procedure 5 starting from Preparation R2ap and Preparation Rlc as reagents, EXAMPLE 66 was obtained. HRMS calculated for C37H45N507: 671.3319; found 672.3401 [(M+H) form]. ■ tert-butyl (3R,4R)-4-[4-hydroxy-4-[(6-iodo-7-methyl-4-oxo-pyrrolo [2,3-d] pyrimidin- 3-yl)methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 67) Using General Procedure 5 starting from Preparation R2aj and Preparation Rlc as reagents, EXAMPLE 67 was obtained. HRMS calculated for C30H38IN5O5 : 675.1918; found 676.1994 [(M+H) form]. ■ tert-butyl (3R,4R)-4- [4- [ [7-(3-chloro-5-methoxy-phenyl)-4-oxo-pyrrolo [2,3-d] pyrimidin-3-yl]methyl]-4-hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l- carboxylate (EXAMPLE 68)
Using General Procedure 5 starting from Preparation R2ao and Preparation Rlc as reagents, EXAMPLE 68 was obtained. HRMS calculated for C36H42CrN506: 675.2823; found 676.2891 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4- [ [7-(4-chloro-3-methoxy-phenyl)-4-oxo-pyrrolo [2,3-d] pyrimidin-3-yl]methyl]-4-hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l- carboxylate (EXAMPLE 69)
Using General Procedure 5 starting from Preparation R2as and Preparation Rlc as reagents, EXAMPLE 69 was obtained. HRMS calculated for C36H42CrN506: 675.2823; found 676.2885 [(M+H) form]. ■ tert-butyl (3R,4R)-4- [4- [ [7-(3,4-dichlorophenyl)-4-oxo-pyrrolo [2,3-d] pyrimidin-3- yl]methyl]-4-hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate
(EXAMPLE 70)
Using General Procedure 5 starting from Preparation R2aq and Preparation Rlc as reagents, EXAMPLE 70 was obtained. HRMS calculated for C35H39CI2N5O5 : 679.2328; found 680.2399 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4- [ [7-(3,5-dichlorophenyl)-4-oxo-pyrrolo [2,3-d] pyrimidin-3- yl]methyl]-4-hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate
(EXAMPLE 71)
Using General Procedure 5 starting from Preparation R2an and Preparation Rlc as reagents, EXAMPLE 71 was obtained. HRMS calculated for C35H39CI2N5O5: 679.2328; found 680.2399 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4-hydroxy-4- [ [4-oxo-7- [4-(trifluor omethyl)phenyl] pyrrolo
[2,3-d] pyrimidin-3-yl] methyl] piperidine- 1-carbonyl] -3-phenyl-piperidine- 1- carboxylate (EXAMPLE 72)
Using General Procedure 5 starting from Preparation R2av and Preparation Rlc as reagents, EXAMPLE 72 was obtained. HRMS calculated for C36H40F3N5O5: 679.2982; found 680.3068 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4-hydroxy-4- [ [4-oxo-7- [3-(trifluor omethyl)phenyl] pyrrolo
[2,3-d] pyrimidin-3-yl] methyl] piperidine- 1-carbonyl] -3-phenyl-piperidine- 1- carboxylate (EXAMPLE 73)
Using General Procedure 5 starting from Preparation R2bh and Preparation Rlc as reagents, EXAMPLE 73 was obtained. HRMS calculated for C36H40F3N5O5: 679.2982; found 702.2875 [(M+Na) form]. ■ tert-butyl (3R,4R)-4- [4-hydroxy-4- [ [6-iodo-4-oxo-7-(2- trimethylsilylethoxymethyl)pyr rolo [2,3-d] pyrimidin-3-yl] methyl] piperidine- 1- carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 74) Using General Procedure 5 starting from Preparation R2al and Preparation Rlc as reagents, EXAMPLE 74 was obtained. HRMS calculated for C35H5oIN506Si: 791.2575; found 792.265 [(M+H) form].
■ tert-butyl (3R,4R)-4-[4-hydroxy-4-[[4-oxo-7-[3- (trifluoromethoxy)phenyl] pyrrolo [2,3-d] pyrimidin-3-yl] methyl] piperidine- 1- carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 75)
Using General Procedure 5 starting from Preparation R2bo and Preparation Rlc as reagents, EXAMPLE 75 was obtained. HRMS calculated for C36H4oF3N506: 695.2931; found 696.2997 [(M+H) form]. ■ tert-butyl (3R,4R)-4- [4-hydroxy-4- [ [4-oxo-7- [4-
(trifluoromethoxy)phenyl] pyrrolo [2,3-d] pyrimidin-3-yl] methyl] piperidine- 1- carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 76)
Using General Procedure 5 starting from Preparation R2ba and Preparation Rlc as reagents, EXAMPLE 76 was obtained. HRMS calculated for C36H4oF3N506: 695.2931; found 696.3006 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4-hydroxy-4- [ [7-(3-morpholinophenyl)-4-oxo-pyrrolo [2,3-d] pyrimidin-3-yl]methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate
(EXAMPLE 77)
Using General Procedure 5 starting from Preparation R2bn and Preparation Rlc as reagents, EXAMPLE 77 was obtained. HRMS calculated for ^^sNeOe: 696.3635; found 697.3708 [(M+H) form].
■ tert-butyl (3R,4R)-4-[4-hydroxy-4-[[4-oxo-7-(3,4,5-trimethoxyphenyl)pyrrolo[2,3-d] pyrimidin-3-yl]methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate
(EXAMPLE 78)
Using General Procedure 5 starting from Preparation R2am and Preparation Rlc as reagents, EXAMPLE 78 was obtained. HRMS calculated for C38H47N508 : 701.3425; found 702.3487 [(M+H) form]. ■ tert-butyl (3R,4R)-4- [4- [ [7-(4-benzyloxyphenyl)-4-oxo-pyrrolo [2,3-d] pyrimidin-3- yl]methyl]-4-hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate
(EXAMPLE 79)
Using General Procedure 5 starting from Preparation R2bb and Preparation Rlc as reagents, EXAMPLE 79 was obtained. HRMS calculated for C42H47N5O6: 717.3527; found 718.3603 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4- [ [7-(3-benzyloxyphenyl)-4-oxo-pyrrolo [2,3-d] pyrimidin-3- yl]methyl]-4-hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate
(EXAMPLE 80)
Using General Procedure 5 starting from Preparation R2bq and Preparation Rlc as reagents, EXAMPLE 80 was obtained. HRMS calculated for C42H47N5O6: 717.3527; found 740.3423 [(M+Na) form].
■ tert-butyl (3R,4R)-4- [4-hydroxy-4- [ [7- [3- [(4-methylpiperazin- l-yl)methyl] phenyl] -4- oxo-pyrrolo [2,3-d] pyrimidin-3-yl] methyl] piperidine- 1-carbonyl] -3-phenyl-piperidine- 1-carboxylate (EXAMPLE 81)
Using General Procedure 5 starting from Preparation R2bi and Preparation Rlc as reagents, EXAMPLE 81 was obtained. HRMS calculated for C4iH53N705 : 723.4108; found 724.4175 [(M+H) form].
■ tert-butyl (3R,4R)-4-[4-[[6-cyano-4-oxo-7-(2- trimethylsilylethoxymethyl)py rrolo [2,3-d] pyrimidin-3-yl] methyl] -4-hydroxy- piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 82)
EXAMPLE 74 was dissolved in PDO and copper cyanide (4.2 eq), tetraethylammonium cyanide (1.05 eq.), Pd2(dba)3 (0.1 eq.), and 1 , -bis(diphenylphosphino)ferrocene (0.4 eq.) were added. The mixture was heated and stirred at 1 10 °C till the reaction was completed. The residue was purified by flash chromatography in DCM-MeOH gradient to give EXAMPLE 82. HRMS calculated for CseHsoNgOgSi: 690.3561; found 691.3637 [(M+H) form]. ■ 3- [ [4-hydroxy- 1- [(3R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7H- pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 83)
Using General Procedure 5 starting from 3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one and Preparation Rlc as reagents, the resulted Boc-protected crude product was reacted using General Procedure 6, to give EXAMPLE 83 as HC1 salt. HRMS calculated for C24H29N503: 435.2271 ; found 436.2345 [(M+H) form].
■ 3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7- methyl-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 84)
Using General Procedure 6 starting from EXAMPLE 1 as reagent, EXAMPLE 84 was obtained as HC1 salt. HRMS calculated for C25H3iN503: 449.2427; found 450.2517 [(M+H) form].
■ 3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4- piperidyl] methyl] thieno[2,3-d]pyrimidin-4-one (EXAMPLE 85)
Using General Procedure 6 starting from EXAMPLE 2 as reagent, EXAMPLE 85 was obtained as HC1 salt. HRMS calculated for C24H28N403S: 452.1882; found 453.1933 [(M+H) form].
■ 7-ethyl-3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4- piperidyl] methyl] pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 86)
Using General Procedure 6 starting from EXAMPLE 3 as reagent, EXAMPLE 86 was obtained as HC1 salt. HRMS calculated for C26H33N503: 463.2583; found 464.2654 [(M+H) form].
■ 3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7- prop-2-ynyl-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 87)
Using General Procedure 6 starting from EXAMPLE 4 as reagent, EXAMPLE 87 was obtained as HC1 salt. HRMS calculated for C27H3iN503: 473.2427; found 474.2502 [(M+H) form]. ■ 7-cyclopr opyl-3- [ [4-hydroxy- 1- [(3R,4R)-3-phenylpiperidine-4-carbonyl] -4- piperidyl] methyl] pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 88)
Using General Procedure 6 starting from EXAMPLE 5 as reagent, EXAMPLE 88 was obtained as HC1 salt. HRMS calculated for CzyHssNjOs: 475.2583; found 476.2668 [(M+H) form].
■ 3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7- isopropyl-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 89)
Using General Procedure 5 starting from Preparation R2by and Preparation Rlc as reagents, the resulted Boc-protected crude product was reacted using General Procedure 6, to give EXAMPLE 89 as HC1 salt. HRMS calculated for C27H35N503 : 477.274; found 478.2819 [(M+H) form].
■ 7-(2-hydroxyethyl)-3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4- piperidyl] methyl] pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 90)
Using General Procedure 5 starting from Preparation R2ce and Preparation Rlc as reagents, the resulted Boc-protected crude product was reacted using General Procedure 6, to give EXAMPLE 90 as HC1 salt. HRMS calculated for C26H33N5O4: 479.2533; found (NMR available form].
■ 7-(2-fluoroethyl)-3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4- piperidyl] methyl] pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 91)
Using General Procedure 5 starting from Preparation R2cd and Preparation Rlc as reagents, the resulted Boc-protected crude product was reacted using General Procedure 6, to give EXAMPLE 91 as HC1 salt. HRMS calculated for C26H32N5O3F: 481.2489; found 482.2555 [(M+H) form].
■ 7-chloro-3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4- piperidyl]methyl]thieno[3,4-d]pyrimidin-4-one (EXAMPLE 92)
Using General Procedure 6 starting from EXAMPLE 6 as reagent, EXAMPLE 92 was obtained as HC1 salt. HRMS calculated for C24H27CI 4O3S: 486.1492; found 487.1544 [(M+H) form]. ■ 7-buta-2,3-dienyl-3- [ [4-hydroxy- 1- [(3R,4R)-3-phenylpiperidine-4-carbonyl] -4- piperidyl] methyl] pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 93)
Using General Procedure 6 starting from EXAMPLE 7 as reagents, EXAMPLE 93 was obtained as HC1 salt. HRMS calculated for C28H33N503: 487.2583; found 488.2657 [(M+H) form].
■ 7-cyclobutyl-3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4- piperidyl] methyl] pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 94)
Using General Procedure 5 starting from Preparation R2ca and Preparation Rlc as reagents, the resulted Boc-protected crude product was reacted using General Procedure 6, to give EXAMPLE 94 as HC1 salt. HRMS calculated for C28H35N503 : 489.274; found 490.2796 [(M+H) form].
■ 7-(cyclopropylmethyl)-3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4- piperidyl] methyl] pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 95)
Using General Procedure 6 starting from EXAMPLE 8 as reagent, EXAMPLE 95 was obtained as HC1 salt. HRMS calculated for C28H35N503: 489.274; found 490.2817 [(M+H) form].
■ 3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7- isobutyl-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 96)
Using General Procedure 6 starting from EXAMPLE 9 as reagent, EXAMPLE 96 was obtained as HC1 salt. HRMS calculated for C28H37N503: 491.2896; found 492.2963 [(M+H) form].
■ 7-(2,2-difluoroethyl)-3- [ [4-hydroxy- 1- [(3R,4R)-3-phenylpiperidine-4-carbonyl] -4- piperidyl] methyl] pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 97)
Using General Procedure 5 starting from Preparation R2cc and Preparation Rlc as reagents, the resulted Boc-protected crude product was reacted using General Procedure 6, to give EXAMPLE 97 as HC1 salt. HRMS calculated for C26H3iN503F2: 499.2395; found 500.2485 [(M+H) form]. ■ 3- [ [4-hydroxy- 1- [(3R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -9- methyl-pyrimido[4,5-b]indol-4-one (EXAMPLE 98)
Using General Procedure 6 starting from EXAMPLE 10 as reagent, EXAMPLE 98 was obtained as HC1 salt. HRMS calculated for C29H33N5O3 : 499.2583; found 500.2677 [(M+H) form].
■ 7-(cyclobutylmethyl)-3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4- piperidyl] methyl] pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 99)
Using General Procedure 6 starting from EXAMPLE 11 as reagent, EXAMPLE 99 was obtained as HC1 salt. HRMS calculated for C29H37N5O3 : 503.2896; found 504.2957 [(M+H) form].
■ 7-(2-dimethylaminoethyl)-3-[[4-hydroxy-l-[(3R,4R)-3-phenylpiperidine-4- carbonyl] -4-piperidyl] methyl] pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 100)
Using General Procedure 6 starting from EXAMPLE 12 as reagent, EXAMPLE 100 was obtained as HC1 salt. HRMS calculated for C28H38N6O3 : 506.3005; found 254.1581 [(M+2H)2+ form].
■ 3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7- phenyl-pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 101)
Using General Procedure 6 starting from EXAMPLE 13 as reagent, EXAMPLE 101 was obtained as HC1 salt. HRMS calculated for C3oH33N503: 511.2583; found 512.2648 [(M+H) form].
■ 3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7- phenyl-5H-pyrrolo[3,2-d]pyrimidin-4-one (EXAMPLE 102)
Using General Procedure 6 starting from EXAMPLE 14 as reagents, EXAMPLE 102 was obtained as HC1 salt. HRMS calculated for C3oH33N503: 511.2583; found 512.2647 [(M+H) form]. ■ 5- [ [4-hydroxy- 1- [(3R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] - 1- phenyl-pyrazolo[3,4-d]pyrimidin-4-one (EXAMPLE 103)
Using General Procedure 6 starting from EXAMPLE 16 as reagent, EXAMPLE 103 was obtained as HC1 salt. HRMS calculated for C29H32N6O3 : 512.2536; found 513.2623 [(M+H) form].
■ 3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7-(2- pyridyl)pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 104)
Using General Procedure 6 starting from EXAMPLE 15 as reagent, EXAMPLE 104 was obtained as HC1 salt. HRMS calculated for C29H32N6O3 : 512.2536; found 257.134 [(M+2H)2+ form].
■ 3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7-(3- pyridyl)pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 105)
Using General Procedure 5 starting from Preparation R2bu and Preparation Rlc as reagents, the resulted Boc-protected crude product was reacted using General Procedure 6, to give EXAMPLE 105 as HC1 salt. HRMS calculated for C2 H32N6O3 : 512.2536; found 513.261 [(M+H) form].
■ 3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7-(4- pyridyl)pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 106)
Using General Procedure 5 starting from Preparation R2bv and Preparation Rlc as reagents, the resulted Boc-protected crude product was reacted using General Procedure 6, to give EXAMPLE 106 as HC1 salt. HRMS calculated for C2 H32N6O3 : 512.2536; found 513.2609 [(M+H) form].
■ 1- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -9- phenyl-purin-6-one (EXAMPLE 107)
Using General Procedure 6 starting from EXAMPLE 17 as reagent, EXAMPLE 107 was obtained as HC1 salt. HRMS calculated for C29H32N6O3 : 512.2536; found 513.2616 [(M+H) form]. ■ 7-bromo-3- [ [4-hydroxy- 1- [(3R,4R)-3-phenylpiperidine-4-carbonyl] -4- piperidyl]methyl]pyrrolo[2,l-f| [l,2,4]triazin-4-one (EXAMPLE 108)
Using General Procedure 6 starting from EXAMPLE 18 as reagent, EXAMPLE 108 was obtained as HC1 salt. HRMS calculated for C24H28BrN503 : 513.1376; found 514.1462 [(M+H) form].
■ 6- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -3- phenyl-isoxazolo[4,5-d]pyrimidin-7-one (EXAMPLE 109)
Using General Procedure 6 starting from EXAMPLE 19 as reagent, EXAMPLE 109 was obtained as HC1 salt. HRMS calculated for C29H31N5O4: 513.2376; found 514.2451 [(M+H) form].
■ 3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7- pyrimidin-2-yl-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 110)
Using General Procedure 6 starting from EXAMPLE 20 as reagent, EXAMPLE 110 was obtained as HC1 salt. HRMS calculated for C28H31N7O3 : 513.2488; found 257.6326 [(M+2H)2+ form].
■ 6- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -3- phenyl-triazolo[4,5-d]pyrimidin-7-one (EXAMPLE 111)
Using General Procedure 6 starting from EXAMPLE 21 as reagent, EXAMPLE 111 was obtained as HC1 salt. HRMS calculated for C28H31N7O3 : 513.2488; found 514.2576 [(M+H) form].
■ 3-[(4-hydroxy-l-{[(3R,4R)-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl]- 6,8-dimethylpyrimido [5,4-b] indolizin-4(3H)-one (EXAMPLE 112)
Using General Procedure 6 starting from EXAMPLE 22 as reagent, EXAMPLE 112 was obtained as HC1 salt. HRMS calculated for C29H34N6O3 : 514.2692; found 515.2757 [(M+H) form].
■ 3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7-(l- methylimidazol-4-yl)pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 113) Using General Procedure 6 starting from EXAMPLE 23 as reagent, EXAMPLE 113 was obtained as HC1 salt. HRMS calculated for C28H33N7O3: 515.2645; found 516.2728 [(M+H) form].
■ 3- [ [4-hydroxy- 1- [(3R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7-(l- methylpyrazol-4-yl)pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 114)
Using General Procedure 5 starting from Preparation R2bx and Preparation Rlc as reagents, the resulted Boc-protected crude product was reacted using General Procedure 6, to give EXAMPLE 114 as HC1 salt. HRMS calculated for C28H33N7O3: 515.2645; found 516.2716 [(M+H) form]. ■ 3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7-(2- thienyl)pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 115)
Using General Procedure 6 starting from EXAMPLE 25 as reagent, EXAMPLE 115 was obtained as HC1 salt. HRMS calculated for C28H3iN503S: 517.2148; found 518.2231 [(M+H) form]. ■ 3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7-(3- thienyl)pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 116)
Using General Procedure 6 starting from EXAMPLE 24 as reagent, EXAMPLE 116 was obtained as HC1 salt. HRMS calculated for C28H3iN503S: 517.2148; found 518.2233 [(M+H) form]. ■ 3-[[4-hydroxy-l-[(3R,4R)-3-phenyl-l-(2,2,2-trifluoroethyl)piperidine-4-carbonyl]-4- piperidyl] methyl] -7H-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 117)
EXAMPLE 62 (610 mg, 0.92 mmol) was dissolved in 12 ml DCM, then TFA (211 μΐ, 2.73 mmol, 3 eq.) and formic acid (399 μΐ, 10.6 mmol, 1 1.5 eq.) were added. The mixture was stirred at r.t. for 118 hours, then potassium carbonate (2.22g 16.1 mmol) was added. The solution was extrated with DCM (2x70 ml) and organic phase was dried (MgS04) and evaporated.
112 mg (0.2 mmol) of crude 3-[[4-hydroxy-l-[(3i?,4i?)-3-phenylpiperidine-4-carbonyl]-4- piperidyl]methyl]-7-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-(i]pyrimidin-4-one product was solved in 2 ml dry THF, then triethyl amine (42 μΐ, 0.3 mmol, 1.5 eq.) and 2,2,2-trifluoroethyl trifluoromethanesulfonate (32 μΐ, 0.22 mol, 1.2 eq.) were added. The mixture was stirred at r.t. for 141 hours, then 5 ml water was added. The solution was extracted with DCM (2x10 ml) and organic phase was dried (MgS04) and evaporated The obtained 3-[[4-hydroxy-l-[(3i?,4i?)-3-phenyl-l-(2,2,2-trifluoroethyl)piperidine-4- carbonyl]-4-piperidyl]methyl]-7-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-(i]pyrimidin-4- one was solved in 270 μΐ dry THF, and tetrabutylammonium fluoride (270 μΐ, 1M in THF, 0.27 mmol) and molecular sieves were added and stirred at 75 °C for 20 hours, then the molecular sieves was filtered off and the residue was purified by preparative HPLC in 25mM NH4HC03-acetonitrile gradient method, to give EXAMPLE 117. HRMS calculated for C26H3oF3N503: 517.2301; found 518.2361 [(M+H) form].
■ 3- [ [4-hydroxy- 1- [(3R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7- (2,2,2-trifluoroethyl)pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 118)
Using General Procedure 6 starting from EXAMPLE 26 as reagent, EXAMPLE 118 was obtained as HC1 salt. HRMS calculated for C26H3oF3N503: 517.2301; found 518.2386 [(M+H) form].
■ 3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7- thiazol-2-yl-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 119)
Using General Procedure 6 starting from EXAMPLE 27 as reagent, EXAMPLE 119 was obtained as HC1 salt. HRMS calculated for C27H3oN603S: 518.21; found 519.2181 [(M+H) form].
■ 7- [3-(dimethylamino)propyl] -3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4- carbonyl] -4-piperidyl] methyl] pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 120)
Using General Procedure 6 starting from EXAMPLE 28 as reagent, EXAMPLE 120 was obtained as HC1 salt. HRMS calculated for C29H40N6O3: 520.3162; found 261.1666 [(M+2H)2+ form].
■ 3- [ [4-hydroxy- 1- [(3 R,4R)- l-methyl-3-phenyl-piperidine-4-carbonyl] -4- piperidyl] methyl] -7-phenyl-pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 121) Using General Procedure 7 starting from EXAMPLE 101 and methyl iodide as reagents, EXAMPLE 121 was obtained as HC1 salt. HRMS calculated for C31H35N5O3 : 525.274; found 526.2802 [(M+H) form].
■ 7-benzyl-3- [ [4-hydroxy- 1- [(3R,4R)-3-phenylpiperidine-4-carbonyl] -4- piperidyl] methyl] pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 122)
Using General Procedure 6 starting from EXAMPLE 31 as reagent, EXAMPLE 122 was obtained as HC1 salt. HRMS calculated for C31H35N5O3 : 525.274; found 526.2822 [(M+H) form].
■ 3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7-(p- tolyl)pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 123)
Using General Procedure 6 starting from EXAMPLE 30 as reagent, EXAMPLE 123 was obtained as HC1 salt. HRMS calculated for C3iH35N503: 525.274; found 526.2816 [(M+H) form].
■ 3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7-(m- tolyl)pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 124)
Using General Procedure 6 starting from EXAMPLE 29 as reagent, EXAMPLE 124 was obtained as HC1 salt. HRMS calculated for C3iH35N503: 525.274; found 526.2825 [(M+H) form].
■ 3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -6- methyl-7-phenyl-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 125)
Using General Procedure 6 starting from EXAMPLE 32 as reagent, EXAMPLE 125 was obtained as HC1 salt. HRMS calculated for C3iH35N503: 525.274; found 526.2827 [(M+H) form].
■ 3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7-(6- methyl-2-pyridyl)pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 126)
Using General Procedure 5 starting from Preparation R2br and Preparation Rlc as reagents, the resulted Boc-protected crude product was reacted using General Procedure 6, to give EXAMPLE 126 as HC1 salt. HRMS calculated for C30H34N6O3 : 526.2692; found 527.2764 [(M+H) form].
■ tert-butyl (3R,4R)-4-[4-hydroxy-4-[(4-oxo-7-phenyl-thieno[3,4-d]pyrimidin-3- yl)methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 127) EXAMPLE 6 (370 mg, 0.63 mmol) was dissolved in 2 ml THF and 2 ml water, then phenyl boronic acid (308 mg, 2.52 mmol, 4 eq.), AtaPhos*PdCl2 (8.6 mg, 0.012 mmol, 0.2 eq.), cesium carbonate (617 mg, 1.89 mmol, 3 eq.) were added. The mixture was heated and stirred in Anton Paar microwave reactor for 1 hour at 100 °C. The residue was purified by preparative HPLC in 5mM NH4HC03-MeCN gradient method, to give EXAMPLE 127. HRMS calculated for C35H40N4O5S: 628.2719; found 629.2788 [(M+H) form].
■ 3- [ [4-hydroxy- 1- [(3R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7-(6- oxo-lH-pyridin-2-yl)pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 128)
Using General Procedure 6 starting from EXAMPLE 45 as reagents, EXAMPLE 128 was obtained. HRMS calculated for C29H32N604: 528.2485; found 529.2567 [(M+H) form].
■ 6- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -3- phenyl-isothiazolo[4,5-d]pyrimidin-7-one (EXAMPLE 129)
Using General Procedure 6 starting from EXAMPLE 33 as reagent, EXAMPLE 129 was obtained. HRMS calculated for C29H3iN503S: 529.2148; found 530.2223 [(M+H) form].
■ 7-(4-fluorophenyl)-3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4- piperidyl] methyl] pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 130)
Using General Procedure 6 starting from EXAMPLE 34 as reagent, EXAMPLE 130 was obtained. HRMS calculated for C30H30FN5O3 : 529.2489; found 530.2584 [(M+H) form].
■ 7-(3-fluorophenyl)-3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4- piperidyl] methyl] pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 131)
Using General Procedure 6 starting from EXAMPLE 35 as reagents, EXAMPLE 131 was obtained. HRMS calculated for C30H32FN5O3 : 529.2489; found 530.2571 [(M+H) form]. ■ 3- [ [4-hydroxy- 1- [(3R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7-(5- methyl-2-thienyl)pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 132)
Using General Procedure 6 starting from EXAMPLE 37 as reagent, EXAMPLE 132 was obtained. HRMS calculated for C29H33N5O3S : 531.2304; found 532.2361 [(M+H) form]. ■ 3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7-(l- methyl-4-piperidyl)pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 133)
Using General Procedure 6 starting from EXAMPLE 38 as reagent, EXAMPLE 133 was obtained. HRMS calculated for C30H40N6O3: 532.3162; found 267.1658 [(M+2H)2+ form].
■ 4- [3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -4- oxo-pyrrolo[2,3-d]pyrimidin-7-yl]benzonitrile (EXAMPLE 134)
Using General Procedure 6 starting from EXAMPLE 39 as reagent, EXAMPLE 134 was obtained. HRMS calculated for C31H32N6O3: 536.2536; found 537.2599 [(M+H) form].
■ 3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7-(4- methoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 135)
Using General Procedure 6 starting from EXAMPLE 40 as reagents, EXAMPLE 135 was obtained. HRMS calculated for C3iH35N504: 541.2689; found 542.2784 [(M+H) form].
■ 3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7-(3- methoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 136)
Using General Procedure 6 starting from EXAMPLE 41 as reagents, EXAMPLE 136 was obtained. HRMS calculated for C3iH35N504: 541.2689; found 542.2777 [(M+H) form].
■ 7- [4-(hydroxymethyl)phenyl] -3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4- carbonyl] -4-piperidyl] methyl] pyrrolo [2,3-d]pyrimidin-4-one (EXAMPLE 137)
Using General Procedure 6 starting from EXAMPLE 42 as reagents, EXAMPLE 137 was obtained. HRMS calculated for C3iH35N504: 541.2689; found 542.2787 [(M+H) form]. " 7- [3-(hydroxymethyl)phenyl] -3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4- carbonyl] -4-piperidyl] methyl] pyrrolo [2,3-d]pyrimidin-4-one (EXAMPLE 138) Using General Procedure 5 starting from Preparation R2bj and Preparation Rlc as reagents, the resulted Boc-protected crude product was reacted using General Procedure 6, to give EXAMPLE 138. HRMS calculated for C31H35N5O4: 541.2689; found 542.2769 [(M+H) form]. ■ 6-(hydroxymethyl)-3- [ [4-hydroxy- 1- [(3R,4R)-3-phenylpiperidine-4-carbonyl] -4- piperidyl] methyl] -7-phenyl-pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 139)
Using General Procedure 6 starting from EXAMPLE 43 as reagent, EXAMPLE 139 was obtained. HRMS calculated for C3iH35N504: 541.2689; found 542.2763 [(M+H) form].
■ 3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7-(6- methoxy-2-pyridyl)pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 140)
Using General Procedure 6 starting from EXAMPLE 45 as reagent, EXAMPLE 140 was obtained. HRMS calculated for C30H34N6O4: 542.2642; found 543.2698 [(M+H) form].
■ 7-(4-fluorophenyl)-3-[[4-hydroxy-l-[(3R,4R)-l-methyl-3-phenyl-piperidine-4- carbonyl] -4-piperidyl] methyl] pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 141)
Using General Procedure 7 starting from EXAMPLE 130 and methyl iodide as reagents, EXAMPLE 141 was obtained. HRMS calculated for C31H34N5O3F: 543.2646; found 544.2721 [(M+H) form].
■ 7-(3-chlorophenyl)-3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4- piperidyl] methyl] pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 142)
Using General Procedure 6 starting from EXAMPLE 47 as reagent, EXAMPLE 142 was obtained. HRMS calculated for C30H32ClN5O3 : 545.2194; found 546.2248 [(M+H) form].
■ 7-(4-chlorophenyl)-3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4- piperidyl] methyl] pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 143)
Using General Procedure 6 starting from EXAMPLE 46 as reagent, EXAMPLE 143 was obtained. HRMS calculated for C3oH32Cl 503: 545.2194; found 546.2262 [(M+H) form]. ■ 6-chloro-3- [ [4-hydroxy- 1- [(3R,4R)-3-phenylpiperidine-4-carbonyl] -4- piperidyl] methyl] -7-phenyl-pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 144)
Using General Procedure 6 starting from EXAMPLE 48 as reagent, EXAMPLE 144 was obtained. HRMS calculated for C3oH32ClN503: 545.2194; found 546.2277 [(M+H) form]. ■ 7-(5-chloro-2-thienyl)-3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4- piperidyl] methyl] pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 145)
Using General Procedure 6 starting from EXAMPLE 49 as reagent, EXAMPLE 145 was obtained. HRMS calculated for C28H30ClN5O3S: 551.1758; found 552.1844 [(M+H) form].
■ 7- [ l-(difluor omethyl)pyrazol-4-yl] -3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4- carbonyl]-4-piperidyl] methyl] pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 146)
Using General Procedure 6 starting from EXAMPLE 50 as reagent, EXAMPLE 146 was obtained. HRMS calculated for C28H3iF2N703: 551.2457; found 552.254 [(M+H) form].
■ 3-[[l-[(3R,4R)-l-acetyl-3-phenyl-piperidine-4-carbonyl]-4-hydroxy-4- piperidyl] methyl] -7-phenyl-pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 147)
Using General Procedure 8 starting from EXAMPLE 101 and acetic acid as reagents, EXAMPLE 147 was obtained. HRMS calculated for C32H35N504: 553.2689; found 554.2757 [(M+H) form].
■ 7-(4-dimethylaminophenyl)-3-[[4-hydroxy-l-[(3R,4R)-3-phenylpiperidine-4- carbonyl] -4-piperidyl] methyl] pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 148)
Using General Procedure 6 starting from EXAMPLE 51 as reagent, EXAMPLE 148 was obtained. HRMS calculated for C32H38N603: 554.3005; found 555.3076 [(M+H) form].
■ 7- [3-(dimethylamino)phenyl] -3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4- carbonyl] -4-piperidyl] methyl] pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 149)
Using General Procedure 6 starting from EXAMPLE 52 as reagent, EXAMPLE 149 was obtained. HRMS calculated for C32H38N603: 554.3005; found 555.3086 [(M+H) form]. ■ 7-(l,3-benzodioxol-5-yl)-3-[[4-hydroxy-l-[(3R,4R)-3-phenylpiperidine-4-carbonyl]- 4-piperidyl] methyl] pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 150)
Using General Procedure 6 starting from EXAMPLE 53 as reagent, EXAMPLE 150 was obtained. HRMS calculated for C3iH33N505: 555.2482; found 556.2556 [(M+H) form]. ■ 3- [ [4-hydroxy- 1- [(3R,4R)- l-methyl-3-phenyl-piperidine-4-carbonyl] -4- piperidyl] methyl] -7-(4-methoxyphenyl)pyr rolo [2,3-d] pyrimidin-4-one (EXAMPLE 151) Using General Procedure 7 starting from EXAMPLE 135 and methyl iodide as reagents, EXAMPLE 151 was obtained. HRMS calculated for C32H37N5O4: 555.2845; found 556.2922 [(M+H) form]. ■ 7-(3-chlorophenyl)-3-[[4-hydroxy-l-[(3R,4R)-l-methyl-3-phenyl-piperidine-4- carbonyl] -4-piperidyl] methyl] pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 152)
Using General Procedure 7 starting from EXAMPLE 142 and methyl iodide as reagents, EXAMPLE 152 was obtained. HRMS calculated for C31H34N5O3CI: 559.235; found 560.2425 [(M+H) form]. ■ 7-(4-chlorophenyl)-3-[[4-hydroxy-l-[(3R,4R)-l-methyl-3-phenyl-piperidine-4- carbonyl] -4-piperidyl] methyl] pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 153)
Using General Procedure 7 starting from EXAMPLE 143 and methyl iodide as reagents, EXAMPLE 153 was obtained. HRMS calculated for C31H34N5O3CI: 559.235; found 560.2423 [(M+H) form]. " 7- [(4-chlorophenyl)methyl] -3- [ [4-hydroxy- 1- [(3R,4R)-3-phenylpiperidine-4- carbonyl] -4-piperidyl] methyl] pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 154)
Using General Procedure 6 starting from EXAMPLE 56 as reagent, EXAMPLE 154 was obtained. HRMS calculated for C3iH34ClN503: 559.235; found 560.2418 [(M+H) form].
■ 7- [(3-chlorophenyl)methyl] -3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4- carbonyl] -4-piperidyl] methyl] pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 155)
Using General Procedure 6 starting from EXAMPLE 55 as reagent, EXAMPLE 155 was obtained. HRMS calculated for C3iH34ClN503: 559.235; found 560.2432 [(M+H) form]. ■ 7- [(2-chlorophenyl)methyl] -3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4- carbonyl] -4-piperidyl] methyl] pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 156)
Using General Procedure 6 starting from EXAMPLE 54 as reagent, EXAMPLE 156 was obtained. HRMS calculated for CsiffeClNjOs: 559.235; found 560.2429 [(M+H) form]. ■ 7-(4-fluoro-3-methoxy-phenyl)-3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4- carbonyl] -4-piperidyl] methyl] pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 157)
Using General Procedure 6 starting from EXAMPLE 57 as reagent, EXAMPLE 157 was obtained. HRMS calculated for C3iH34FN504: 559.2595; found 560.2638 [(M+H) form].
■ 7- [4-(difluoromethyl)phenyl] -3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4- carbonyl] -4-piperidyl] methyl] pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 158)
Using General Procedure 6 starting from EXAMPLE 58 as reagent, EXAMPLE 158 was obtained. HRMS calculated for C3iH33F2N503: 561.2551; found 562.2636 [(M+H) form].
■ 3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7-(2- naphthyl)pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 159)
Using General Procedure 6 starting from EXAMPLE 60 as reagent, EXAMPLE 159 was obtained. HRMS calculated for C34H35N503: 561.274; found 562.2831 [(M+H) form].
■ 3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7-(l- naphthyl)pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 160)
Using General Procedure 6 starting from EXAMPLE 59 as reagent, EXAMPLE 160 was obtained. HRMS calculated for C34H35N503: 561.274; found 562.2827 [(M+H) form].
■ 7-(4-chloro-3-fluoro-phenyl)-3-[[4-hydroxy-l-[(3R,4R)-3-phenylpiperidine-4- carbonyl] -4-piperidyl] methyl] pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 161)
Using General Procedure 6 starting from EXAMPLE 61 as reagent, EXAMPLE 161 was obtained. HRMS calculated for C30H31N5O3FCI: 563.21; found 564.2181 [(M+H) form]. ■ 3- [ [4-hydroxy- 1- [(3R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7-(2- trimethylsilylethoxymethyl)pyr rolo [2,3-d] pyrimidin-4-one (EXAMPLE 162)
EXAMPLE 62 (1.6 g, 2.4 mmol) was dissolved in 30 ml DCM, then TFA (3 ml) and formic acid (550 μΐ, 7.2 mmol, 3 eq.) were added. The mixture was stirred at r.t. for 4 days, then potassium carbonate (15 g, 108 mmol) was added. The solution was extrated with DCM and organic phase was dried (MgS04) and evaporated to give EXAMPLE 162. HRMS calculated for C3oH43N504Si: 565.3084; found 566.3138 [(M+H) form].
■ 3- [ [4-hydroxy- 1- [(3 R,4R)- l-isobutyl-3-phenyl-piperidine-4-carbonyl] -4- piperidyl] methyl] -7-phenyl-pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 163)
Using General Procedure 7 starting from EXAMPLE 101 and l-bromo-2-methyl-propane as reagents, EXAMPLE 163 was obtained. HRMS calculated for C34H41N5O3: 567.3209; found 568.328 [(M+H) form].
■ 7-(2,3-dihydro- 1 ,4-benzodioxin-6-yl)-3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine- 4-carbonyl] -4-piperidyl] methyl] pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 164)
Using General Procedure 6 starting from EXAMPLE 63 as reagent, EXAMPLE 164 was obtained. HRMS calculated for C32H35N505: 569.2638; found 570.2709 [(M+H) form].
■ l-(2,3-dihydro-l,4-benzodioxin-6-yl)-5-[[4-hydroxy-l-[(3R,4R)-3-phenylpiperidine- 4-carbonyl] -4-piperidyl] methyl] pyrazolo [3,4-d] pyrimidin-4-one (EXAMPLE 165)
Using General Procedure 6 starting from EXAMPLE 64 as reagent, EXAMPLE 165 was obtained. HRMS calculated for C3iH34N605: 570.2591; found 571.2663 [(M+H) form].
■ 3-[[l-[(3R,4R)-l-acetyl-3-phenyl-piperidine-4-carbonyl]-4-hydroxy-4- piperidyl] methyl] -7-(4-fluorophenyl)pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 166) Using General Procedure 8 starting from EXAMPLE 130 and acetic acid as reagents, EXAMPLE 166 was obtained. HRMS calculated for C32H34FN504: 571.2595; found 572.2679 [(M+H) form].
■ 7-(3,5-dimethoxyphenyl)-3-[[4-hydroxy-l-[(3R,4R)-3-phenylpiperidine-4-carbonyl]- 4-piperidyl] methyl] pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 167) Using General Procedure 6 starting from EXAMPLE 66 as reagent, EXAMPLE 167 was obtained. HRMS calculated for C32H37N505: 571.2795; found 572.2881 [(M+H) form].
■ 7-(3,4-dimethoxyphenyl)-3-[[4-hydroxy-l-[(3R,4R)-3-phenylpiperidine-4-carbonyl]- 4-piperidyl] methyl] pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 168)
Using General Procedure 6 starting from EXAMPLE 65 as reagent, EXAMPLE 168 was obtained. HRMS calculated for C32H37N505: 571.2795; found 572.2892 [(M+H) form].
■ 5- [ [1- [(3R,4R)- 1 , l-dimethyl-3-phenyl-piperidin- l-ium-4-carbonyl] -4-hydroxy-4- piperidyl]methyl]-l-(4-methoxyphenyl)pyrazolo[3,4-d]pyrimidin-4-one
(EXAMPLE 169)
Using General Procedure 7 starting from EXAMPLE 135 and methyl iodide as reagents, EXAMPLE 169 was obtained. HRMS calculated for C32H39N604: 571.3027; found 571.3038 [(M+) form].
■ 3- [ [4-hydroxy- 1- [(3R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -6- iodo-7-methyl-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 170)
Using General Procedure 6 starting from EXAMPLE 67 as reagent, EXAMPLE 170 was obtained. HRMS calculated for C25H3oIN503: 575.1393; found 576.1455 [(M+H) form].
■ 7-(3-chloro-5-methoxy-phenyl)-3-[[4-hydroxy-l-[(3R,4R)-3-phenylpiperidine-4- carbonyl] -4-piperidyl] methyl] pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 171)
Using General Procedure 6 starting from EXAMPLE 68 as reagent, EXAMPLE 171 was obtained. HRMS calculated for C3iH34ClN504: 575.2299; found 576.2382 [(M+H) form].
■ 7-(4-chloro-3-methoxy-phenyl)-3-[[4-hydroxy-l-[(3R,4R)-3-phenylpiperidine-4- carbonyl] -4-piperidyl] methyl] pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 172)
Using General Procedure 6 starting from EXAMPLE 69 as reagents, EXAMPLE 172 was obtained. HRMS calculated for C3iH34ClN504: 575.2299; found 576.2382 [(M+H) form]. ■ 7-(3,5-dichlorophenyl)-3-[[4-hydroxy-l-[(3R,4R)-3-phenylpiperidine-4-carbonyl]-4- piperidyl] methyl] pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 173) Using General Procedure 6 starting from EXAMPLE 71 as reagent, EXAMPLE 173 was obtained. HRMS calculated for C30H31N5O3CI2: 579.1804; found 580.1891 [(M+H) form].
■ 7-(3,4-dichlorophenyl)-3-[[4-hydroxy-l-[(3R,4R)-3-phenylpiperidine-4-carbonyl]-4- piperidyl] methyl] pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 174)
Using General Procedure 6 starting from EXAMPLE 70 as reagent, EXAMPLE 174 was obtained. HRMS calculated for C30H31CI2N5O3: 579.1804; found 580.187 [(M+H) form].
■ 3- [ [4-hydroxy- 1- [(3R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7- [4- (trifluoromethyl)phenyl] pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 175)
Using General Procedure 6 starting from EXAMPLE 72 as reagent, EXAMPLE 175 was obtained. HRMS calculated for
Figure imgf000085_0001
579.2457; found 580.2529 [(M+H) form].
■ 3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7- [3- (trifluoromethyl)phenyl] pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 176)
Using General Procedure 6 starting from EXAMPLE 73 as reagent, EXAMPLE 176 was obtained. HRMS calculated for
Figure imgf000085_0002
579.2457; found 580.2509 [(M+H) form]. ■ 3-[[4-hydroxy-l-[(3R,4R)-l-(2-methylpropanoyl)-3-phenyl-piperidine-4-carbonyl]- 4-piperidyl] methyl] -7-phenyl-pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 177)
Using General Procedure 8 starting from EXAMPLE 101 and 2-methylpropanoic acid as reagents, EXAMPLE 177 was obtained. HRMS calculated for C34H39N5O4: 581.3002; found 582.3072 [(M+H) form]. ■ 3-[[l-[(3R,4R)-l-acetyl-3-phenyl-piperidine-4-carbonyl]-4-hydroxy-4- piperidyl] methyl] -7-(4-methoxyphenyl)pyr rolo [2,3-d] pyrimidin-4-one (EXAMPLE 178) Using General Procedure 8 starting from EXAMPLE 135 and acetic acid as reagents, EXAMPLE 178 was obtained. HRMS calculated for C33H37N5O5 : 583.2795; found 584.2868 [(M+H) form]. ■ 3-[[l-[(3R,4R)-l-acetyl-3-phenyl-piperidine-4-carbonyl]-4-hydroxy-4- piperidyl] methyl] -7-(3-methoxyphenyl)pyr rolo [2,3-d] pyrimidin-4-one (EXAMPLE 179) Using General Procedure 8 starting from EXAMPLE 136 and acetic acid as reagents, EXAMPLE 179 was obtained. HRMS calculated for C33H37N5O5: 583.2795; found 584.2863 [(M+H) form].
■ 3-[[l-[(3R,4R)-l-acetyl-3-phenyl-piperidine-4-carbonyl]-4-hydroxy-4- piperidyl] methyl] -7-(3-chlorophenyl)pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 180)
Using General Procedure 8 starting from EXAMPLE 142 and acetic acid as reagents, EXAMPLE 180 was obtained. HRMS calculated for C32H34CIN5O4: 587.2299; found 588.238 [(M+H) form].
■ 3-[[l-[(3R,4R)-l-acetyl-3-phenyl-piperidine-4-carbonyl]-4-hydroxy-4- piperidyl] methyl] -7-(4-chlorophenyl)pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 181)
Using General Procedure 8 starting from EXAMPLE 143 and acetic acid as reagents, EXAMPLE 181 was obtained. HRMS calculated for C32H34CIN5O4: 587.2299; found 588.2366 [(M+H) form].
■ 3- [ [4-hydroxy- 1- [(3R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7- [4- (trifluoromethoxy)phenyl]pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 182)
Using General Procedure 6 starting from EXAMPLE 76 as reagent, EXAMPLE 182 was obtained. HRMS calculated for C3iH32N504F3: 595.2407; found 596.2494 [(M+H) form].
■ 3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7- [3- (trifluor omethoxy)phenyl] pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 183)
Using General Procedure 6 starting from EXAMPLE 75 as reagent, EXAMPLE 183 was obtained. HRMS calculated for C3iH32N504F3: 595.2407; found 596.2491 [(M+H) form].
■ 3- [ [1- [(3R,4R)-l-(2,2-dimethylpropanoyl)-3-phenyl-piperidine-4-carbonyl] -4- hydroxy-4-piperidyl] methyl] -7-phenyl-pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 184) Using General Procedure 8 starting from EXAMPLE 101 and 2,2-dimethylpropanoic acid as reagents, EXAMPLE 184 was obtained. HRMS calculated for C35H41N5O4: 595.3159; found 596.3221 [(M+H) form]. ■ 3- [ [4-hydroxy- 1- [(3R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7-(3- morpholinophenyl)pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 185)
Using General Procedure 6 starting from EXAMPLE 77 as reagent, EXAMPLE 185 was obtained. HRMS calculated for C34H40N6O4: 596.3111; found 597.3187 [(M+H) form]. ■ 3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7- (3,4,5-trimethoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 186)
Using General Procedure 6 starting from EXAMPLE 78 as reagent, EXAMPLE 186 was obtained. HRMS calculated for CssHsgNjOg: 601.29; found 602.296 [(M+H) form].
■ 3- [ [1- [(3R,4R)-l-(3,3-dimethylbutanoyl)-3-phenyl-piperidine-4-carbonyl] -4- hydroxy-4-piperidyl] methyl] -7-phenyl-pyrrolo[2,3-d]pyrimidin-4-one (EXAMPLE 187) Using General Procedure 8 starting from EXAMPLE 101 and 3,3-dimethylbutanoic acid as reagents, EXAMPLE 187 was obtained. HRMS calculated for C36H43N5O4: 609.3315; found 610.3384 [(M+H) form].
■ 7-(4-benzyloxyphenyl)-3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4- piperidyl] methyl] pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 188)
Using General Procedure 6 starting from EXAMPLE 79 as reagent, EXAMPLE 188 was obtained. HRMS calculated for C37H39N5O4: 617.3002; found 618.3083 [(M+H) form].
■ 7-(3-benzyloxyphenyl)-3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4- piperidyl] methyl] pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 189)
Using General Procedure 6 starting from EXAMPLE 80 as reagent, EXAMPLE 189 was obtained. HRMS calculated for C37H39N5O4: 617.3002; found 618.3051 [(M+H) form].
■ 3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7- [3- [(4-methylpiperazin- l-yl)methyl] phenyl] pyrrolo [2,3-d] pyrimidin-4-one
(EXAMPLE 190)
Using General Procedure 6 starting from EXAMPLE 81 as reagent, EXAMPLE 190 was obtained. HRMS calculated for
Figure imgf000087_0001
623.3584; found 624.3656 [(M+H) form]. ■ 3- [ [4-hydroxy- 1- [(3R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -7- phenyl-thieno[3,4-d]pyrimidin-4-one (EXAMPLE 191)
Using General Procedure 6 starting from EXAMPLE 127 as reagent, EXAMPLE 191 was obtained. HRMS calculated for C30H32N4O3S: 528.2195; found 529.2265 [(M+H) form]. ■ 3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -6- iodo-7-(2-trimethylsilylethoxymethyl)pyrrolo [2,3-d] pyrimidin-4-one (EXAMPLE 192) EXAMPLE 74 (647 mg, 0.82 mmol) was dissolved in 13 ml DCM, then TFA (188 μΐ, 2.46 mmol, 3 eq.) and formic acid (356 μΐ, 9.43 mmol, 11.5 eq.) were added. The mixture was stirred at r.t. for 214 hours, then potassium carbonate (1.99 g, 14.3 mmol) was added. The solution was extrated with DCM (2x70 ml) and organic phase (MgSC^) was dried and evaporated to give EXAMPLE 192. HRMS calculated for C30H42IN5O4S1: 691.2051; found 692.2155 [(M+H) form].
■ tert-butyl (3R,4R)-4- [4-hydroxy-4- [(4-oxopyrido [3,2-d] pyrimidin-3- yl)methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 193) Using General Procedure 5 starting from 3H-pyrido[3,2-d]pyrimidin-4-one and Preparation Rlc as reagents, EXAMPLE 193 was obtained. HRMS calculated for C3oH37N505: 547.2795; found 548.2870 [(M+H) form].
■ 3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4- piperidyl]methyl]pyrido[3,2-d]pyrimidin-4-one (EXAMPLE 194)
Using General Procedure 6 starting from EXAMPLE 193 as reagent, EXAMPLE 194 was obtained as HC1 salt. HRMS calculated for C25H29N503: 447.227; found 448.2365 [(M+H)+ form].
■ tert-butyl (3R,4R)-4- [4- [(6-chloro-4-oxo-pyrido [3,2-d] pyrimidin-3-yl)methyl] -4- hydroxy-piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 195) Using General Procedure 5 starting from 6-chloro-3H-pyrido[3,2-d]pyrimidin-4-one and Preparation Rlc as reagents, EXAMPLE 195 was obtained. HRMS calculated for C3oH36ClN505: 581.2405; found 604.2239 [(M+Na) form]. ■ 6-chloro-3- [ [4-hydroxy- 1- [(3R,4R)-3-phenylpiperidine-4-carbonyl] -4- piperidyl]methyl]pyrido[3,2-d]pyrimidin-4-one (EXAMPLE 196)
Using General Procedure 6 starting from EXAMPLE 195 as reagent, EXAMPLE 196 was obtained as HC1 salt. HRMS calculated for CzsftsClNjOs: 481.1881; found 482.1949 [(M+H)+ form].
■ tert-butyl (3R,4R)-4-[4-hydroxy-4-[(6-methoxy-4-oxo-pyrido[3,2-d]pyrimidin-3- yl)methyl]piperidine-l-carbonyl]-3-phenyl-piperidine-l-carboxylate (EXAMPLE 197) Using General Procedure 5 starting from 6-methoxy-3H-pyrido[3,2-d]pyrimidin-4-one and Preparation Rlc as reagents, EXAMPLE 197 was obtained. HRMS calculated for C3iH39N506: 577.29; found 578.2976 [(M+H) form].
■ 3- [ [4-hydroxy- 1- [(3 R,4R)-3-phenylpiperidine-4-carbonyl] -4-piperidyl] methyl] -6- methoxy-pyrido[3,2-d]pyrimidin-4-one (EXAMPLE 198)
Using General Procedure 6 starting from EXAMPLE 197 as reagent, EXAMPLE 198 was obtained as HC1 salt. HRMS calculated for C26H3iN504: 477.2376; found 478.2458 [(M+H)+ form].
PHARMACOLOGICAL STUDY
EXAMPLE A: Evaluation of the inhibition of USP7 by the Fluorescence Intensity (FLINT) readings
USP7 activity was measured using Rhodamine-110 c-terminal labelled Ubiquitin as a substrate (Viva Biosciences). Incubation with USP7 results in the release of Rhodamine-110 leading to an increase in fluorescence which can be used in the continuous measurement of USP7 activity.
The USP7 reactions were performed in a 50 μΐ, volume, in 384 well black solid low binding plates (Corning #3575). The reaction buffer consisted of 100 mM Bicine pH 8.0, 0.01 % TritonXlOO, 1 mM TCEP, and 10 % DMSO.
0.25 nM His-His-USP7 (aa208-560, [C315A]) was incubated with compound (final concentration 10 % DMSO) for 60 minutes at 30 °C. The reaction was then initiated by the addition of 500 nM Ubiquitin- Rhodamine-110 substrate and the plate read every 3 minutes for 21 minutes to measure the release of Rhodamine-110. Fluorescence Intensity (FLINT) readings were measured using a Biomek Neo plate reader (Ex.485 nm, Em.535 nm).
The inhibition of increasing doses of compound was expressed as a percentage reduction in kinetic rate compared to the kinetic rates established between 'DMSO only' and 'total inhibition' controls (no USP7). The inhibitory concentrations that gave a 50 % reduction in kinetic rate (IC50) were determined, from 11 -point dose response curves, in XL-Fit using a 4-Parameter Logistic Model (Sigmoidal Dose-Response Model).
The results presented in Table 1 below show that compounds of the invention inhibit interaction between USP7 protein and the fluorescent peptide described hereinbefore. EXAMPLE B: In vitro cytotoxicity
The cytotoxicity studies were carried out on the MM IS multiple myeloma tumour cell line. The cells are distributed onto microplates and exposed to the test compounds for 96 hours. The cell viability is then quantified by a colorimetric assay, the Microculture Tetrazolium Assay (Cancer Res., 1987, 47, 939-942).
The results are expressed in IC50 (the concentration of compound that inhibits cell viability by 50%) and are presented in Table 1 below.
The results show that the compounds of the invention are cytotoxic.
Table 1: ICsn of USP7 inhibition and of cytotoxicity for MM1S cells
Figure imgf000091_0001
ND: not determined EXAMPLE C: Anti-tumor activity in vivo
The anti-tumour activity of the compounds of the invention is evaluated in a xenograft model of multiple myeloma and/or acute lymphoblastic leukaemia cells.
Human tumour cells are grafted subcutaneously into immunosuppressed mice.
When the tumour volume (TV) reaches about 200 mm3, the mice are treated per os with the various compounds once a day for 5 days on/2 days off during 3 weeks. The tumour mass is measured twice weekly from the start of treatment.
The compounds of the invention display anti-tumour activities represented by the TGI (tumor growth inhibition) at the end of the treatment period. The TGI is defined as follows:
( Median (DTV at Dx in treated group) \
1 I x 100 ,
Median (DTV at Dx in control group) J
with:
DTV (delta tumoral volume) at Dx = (TV at Dx) - (TV at randomization for each animal).
EXAMPLE D: Pharmaceutical composition: Tablets
1000 tablets containing a dose of 5 mg of a compound selected from Examples 1 to 198 5 g Wheat starch 20 g
Maize starch 20 g
Lactose 30 g
Magnesium stearate 2 g
Silica 1 g Hydroxypropylcellulose 2 g

Claims

1. Compound of formula (I):
Figure imgf000093_0001
wherein:
♦ Ri represents an aryl group or a heteroaryl group,
♦ R2 represents a hydrogen atom or a halogen atom,
♦ R3 represents a hydrogen atom, a linear or branched (Ci-Ce)alkyl group, a linear or branched halo(Ci-C6)alkyl, a -C(0)-Rs group, a -C(0)-ORs group,
♦ n is an integer equal to 0, 1 or 2,
♦ W represents the group
Figure imgf000093_0002
■ A represents a heteroaryl ring,
■ X represents a carbon atom or a nitrogen atom,
■ R4 represents a hydrogen atom, a halogen atom, a linear or branched (Ci-C6)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-Ce)alkynyl group, a -Y1-NR6R7 group, a -Y1-OR6 group, a linear or branched halo(Ci-C6)alkyl group, an oxo group, a -Yi-Cyi group, a -Cyi-R7 group, a -Cyi-OR7 group, or a -Yi-NR6-C(0)-R7 group,
■ R5 represents a hydrogen atom, a halogen atom, a linear or branched (Ci-Ce)alkyl group, a cyano group, or a -hydroxy(Ci-Ce)alkyl group,
■ 5 represents a hydrogen atom or a linear or branched (Ci-C6)alkyl group, or a -Y2-Si[(Ci-C4)alkyl]3 group, ■ R7 represents a hydrogen atom, a linear or branched (Ci-Ce)alkyl group, or a -Y2-Cy2 group,
■ Yi and Y2 independently of one another represent a bond or a linear or branched (Ci-C4)alkylene group,
♦ Rs represents a hydrogen atom, or a linear or branched (Ci-Ce)alkyl group,
♦ Cyi and Cy2 independently of one another, represent a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, it being understood that:
- "aryl" means a phenyl, naphthyl, or indanyl group,
- "heteroaryl" means any mono- or fused bi-cyclic group composed of from 5 to 10 ring members, having at least one aromatic moiety and containing from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen,
- "cycloalkyl" means any mono- or fused bi-cyclic non-aromatic carbocyclic group containing from 3 to 7 ring members,
- "heterocycloalkyl" means any non-aromatic mono- or fused bi-cyclic group containing from 3 to 10 ring members, and containing from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, it being possible for the aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups so defined to be substituted by from 1 to 4 groups selected from linear or branched (Ci-Ce)alkyl, linear or branched (C2-Ce)alkenyl, linear or branched (C2-Ce)alkynyl, linear or branched halo(Ci-C6)alkyl, -Yj-OR', -Yi-NR'R", -Yi-S(0)m-R', oxo (or N-oxide where appropriate), nitro, cyano, -C(0)-R', -C(0)-OR', -0-C(0)-R', -C(0)-NR'R", -Yi-NR'-C(0)-R", -Yi-NR'-C(0)-OR", halogen, cyclopropyl, and pyridinyl which can be substituted by a linear or branched (Ci-C6)alkyl group, it being understood that R' and R' ' independently of one another represent a hydrogen atom, a linear or branched (Ci-Ce)alkyl group, a linear or branched (C2-Ce)alkenyl group, a linear or branched (Ci-Ce)alkoxy group, a linear or branched halo(Ci-C6)alkyl, a linear or branched hydroxy(Ci-C6)alkyl group, a linear or branched (Ci-C6)alkoxy(Ci-C6)alkyl group, a phenyl group, a cyclopropylmethyl group, a tetrahydropyranyl group,
or the substituents of the pair (R', R") form together with the nitrogen atom carrying them a non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen a second heteroatom selected from oxygen and nitrogen, it being understood that the nitrogen in question may be substituted by from 1 to 2 groups representing a hydrogen atom, or a linear or branched (Ci-Ce)alkyl group, and it being understood that m is an integer equal to 0, 1 and 2, their enantiomers, diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.
2. Compounds according to claim 1 , wherein W represents the group
Figure imgf000095_0001
wherein R4, R5 and A are as defined in claim 1.
3. Compounds according to claim 1 , wherein W represents the group
Figure imgf000095_0002
wherein R4, R5 and A are as defined in claim 1.
4. Compounds according to claim 1, wherein Ri represents a phenyl group.
5. Compounds according to claim 1 , wherein R2 represents a hydrogen atom.
6. Compounds according to claim 1, wherein R3 represents a hydrogen atom, a methyl group, a -CH2-CH(CH3)2 group, a -CH2-CF3 group, a -C(0)-CH3 group, a -C(0)-CH(CH3)2 group, a -C(0)-CH2-C(CH3)3 group, or a -C(0)-OC(CH3)3 group.
7. Compounds according to claim 1 , wherein R4 represents a hydrogen atom, a linear or branched (Ci-C6)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, a -Yi-NReR7 group, a -Y1-OR6 group, a linear or branched halo(Ci-C6)alkyl group, a -Yi-Cyi group, a -Cyi-R7 group, or a -Cyi-OR7 group.
8. Compound according to claim 1, wherein R5 represents a hydrogen atom, an iodine atom, a chlorine atom, a methyl group or a -CH2-OH group.
9. Compounds according to claim 1, wherein R^ represents a hydrogen atom, a methyl group, or a -(CH2)2-Si(CH3)3 group.
10. Compounds according to claim 1, wherein R7 represents a hydrogen atom, a methyl group, or a -CH2-Cy2 group.
11. Compounds according to claim 1, which are:
- tert-butyl (3S,4S)-4-( {4-hydroxy-4-[(4-oxothieno[2,3-60p imidin-3(4H)- yl)methyl]piperidin- 1 -yl} carbonyl)-3-phenylpiperidine- 1 -carboxylate;
- tert-butyl (3i?,4i?)-4-[(4-hydroxy-4- {[4-oxo-7-(pyridin-2-yl)-4,7-dihydro-3H- pyrrolo[2,3-(i]pyrimidin-3-yl]methyl}piperidin- 1 -yl)carbonyl]-3-phenylpiperidine- 1 - carboxylate;
- tert-butyl (3i?,4i?)-4-[(4-hydroxy-4- {[7-(4-methoxyphenyl)-4-oxo-4,7-dihydro-3H- pyrrolo[2,3-(i]pyrimidin-3-yl]methyl}piperidin- 1 -yl)carbonyl]-3-phenylpiperidine- 1 - carboxylate;
- tert-butyl (3i?,4i?)-4-[(4-hydroxy-4- { [ 1 -(4-methoxyphenyl)-4-oxo- 1 ,4-dihydro-5H- pyrazo lo [3 ,4- ]pyrimidin-5 -yljmethyl} piperidin- 1 -yl)carbonyl] -3 -phenylpiperidine- 1 - carboxylate; - tert-butyl (3R,4R)-4-[(4- {[7-(4-fluoro-3-methoxyphenyl)-4-oxo-4,7-dihydro-3H- pyrrolo[2,3-d]pyrimidin-3-yl]methyl} -4-hydroxypiperidin- 1 -yl)carbonyl]-3- phenylpiperidine- 1 -carboxylate;
- tert-butyl (3R,4R)-4-[(4- { [ 1 -(2,3-dihydro- 1 ,4-benzodioxin-6-yl)-4-oxo- 1 ,4-dihydro- 5H-pyrazo lo [3 ,4- ]pyrimidin-5 -yljmethyl} -4-hydroxypiperidin- 1 -yl)carbonyl] -3 - phenylpiperidine- 1 -carboxylate;
- 3-[(4-hydroxy-l-{[(3i?,4i?)-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl] 7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-(i]pyrimidin-4-one;
- 5-[(4-hydroxy-l-{[(3i?,4i?)-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl] l-phenyl-l,5-dihydro-4H-pyrazolo[3,4-(i]pyrimidin-4-one;
- 3-[(4-hydroxy-l-{[(3i?,4i?)-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl] 7-(pyridin-2-yl)-3,7-dihydro-4H-pyrrolo[2,3-(i]pyrimidin-4-one;
- 3-[(4-hydroxy- 1 - { [(3i?,4i?)-3-phenyl- 1 -(2,2,2-trifluoroethyl)piperidin-4- yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3- ]pyrimidin-4-one;
- 3-[(4-hydroxy-l-{[(3i?,4i?)-l-methyl-3-phenylpiperidin-4-yl]carbonyl}piperidin-4- yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-(i]pyrimidin-4-one;
- 7-(4-fluorophenyl)-3-[(4-hydroxy-l-{[(3i?,4i?)-3-phenylpiperidin-4- yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3- ]pyrimidin-4-one;
- 3-[(4-hydroxy-l-{[(3i?,4i?)-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl] 7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-(i]pyrimidin-4-one;
- 3-[(4-hydroxy-l-{[(3i?,4i?)-3-phenylpiperidin-4-yl]carbonyl}piperidin-4-yl)methyl] 7-(3-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-(i]pyrimidin-4-one;
- 7-(4-fluorophenyl)-3- [(4-hydroxy- 1 - {[(3R,4R)- 1 -methyl-3 -phenylpiperidin-4- yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3- ]pyrimidin-4-one;
- 7-(3-chlorophenyl)-3-[(4-hydroxy-l-{[(3i?,4i?)-3-phenylpiperidin-4- yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3- ]pyrimidin-4-one;
- 7-(4-chlorophenyl)-3-[(4-hydroxy-l-{[(3i?,4i?)-3-phenylpiperidin-4- yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3- ]pyrimidin-4-one;
- 3-[(l - {[(3R,4R)- 1 -acetyl-3-phenylpiperidin-4-yl]carbonyl} -4-hydroxypiperidin-4- yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3-(i]pyrimidin-4-one;
- 3-[(4-hydroxy-l-{[(3i?,4i?)-l-methyl-3-phenylpiperidin-4-yl]carbonyl}piperidin-4- yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3-(i]pyrimidin-4-one; - 7-(3-chlorophenyl)-3-[(4-hydroxy-l-{[(3i?,4i?)-l-m
yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3- ]pyrimidin-4-one
- 7-(4-chlorophenyl)-3-[(4-hydroxy-l-{[(3i?,4i?)-l-methyl-3-phenylpiperidin-4- yl]carbonyl}piperidin-4-yl)methyl]-3,7-dihydro-4H-pyrrolo[2,3- ]pyrimidin-4-on^
- 7-(4-fluoro-3-methoxyphenyl)-3-[(4-hydroxy-l-{[(3i?,4i?)-3-phenylpiperidin-4- yl]carbonyl}piperidin-4-yl)methyl]-3
- 3-[(4-hydroxy-l-{[(3i?,4i?)-l-(2-methylpropyl)-3-phenylpiperidin-4-yl]carbonyl} piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3- ]pyrimidin-4-one
- 1 -(2,3-dihydro- 1 ,4-benzodioxin-6-yl)-5-[(4-hydroxy- 1 - {[(3i?,4i?)-3-phenylpiperidin- 4-yl]carbonyl}piperidin-4-yl)methyl]-l,5-dihydro-4H-pyrazolo[3,4- ]pyrimidin^
- 3-[( 1 - { [(3R,4R)- 1 -acetyl-3-phenylpiperidin-4-yl]carbonyl} -4-hydroxypiperidin-4- yl)methyl]-7-(4-fluorophenyl)-3,7-d^
- (3i?,4i?)-4-[(4-hydroxy-4- { [ 1 -(4-methoxyphenyl)-4-oxo- 1 ,4-dihydro-5H- pyrazolo[3,4-(i]pyrimidin-5-yl]methyl}piperidin- 1 -yl)carbonyl]- 1 , 1 -dimethyl-3- phenylpiperidinium;
- 3-[(4-hydroxy-l-{[(3i?,4i?)-l-(2-methylpropanoyl)-3-phenylpiperidin-4-yl]carbonyl} piperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3- ]pyrimidm^
- 3-[( 1 - { [(3R,4R)- 1 -acetyl-3-phenylpiperidin-4-yl]carbonyl} -4-hydroxypiperidin-4- yl)methyl]-7-(4-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3- ]pyrim
- 3-[( 1 - { [(3R,4R)- 1 -acetyl-3-phenylpiperidin-4-yl]carbonyl} -4-hydroxypiperidin-4- yl)methyl]-7-(3-methoxyphenyl)-3,7-dihydro-4H-pyrrolo[2,3- ]pyrim
- 3-[( 1 - { [(3R,4R)- 1 -acetyl-3-phenylpiperidin-4-yl]carbonyl} -4-hydroxypiperidin-4- yl)methyl]-7-(3-chlorophenyl)-3,7-dihydro-4H-pyrrolo[2,3- ]pyrimidin^
- 3-[( 1 - { [(3R,4R)- 1 -acetyl-3-phenylpiperidin-4-yl]carbonyl} -4-hydroxypiperidin-4- yl)methyl]-7-(4-chlorophenyl)-3,7-dihydro-4H-pyrrolo[2,3- ]pyrimidin^
- 3-[( 1 - { [(3R,4R)- 1 -(2,2-dimethylpropanoyl)-3-phenylpiperidin-4-yl] carbonyl} -4- hydroxypiperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3- ]pyrimid one;
- 3-[( 1 - { [(3R,4R)- 1 -(3 ,3-dimethylbutanoyl)-3-phenylpiperidin-4-yl]carbonyl} -4- hydroxypiperidin-4-yl)methyl]-7-phenyl-3,7-dihydro-4H-pyrrolo[2,3- ]pyrimidin-4- one.
12. Process for the preparation of a compound of formula (I) according to claim 1 , characterised in that there is used as starting material the compound of formula (II):
Figure imgf000099_0001
wherein R2 and n are as defined for formula (I), which is subjected to coupling with a compound of formula (III):
Figure imgf000099_0002
wherein Ri is as defined for formula (I), and R3' represents a -C(0)-ORs group wherein R8 is as defined for formula (I), to yield the compound of formula (IV):
Figure imgf000099_0003
wherein Rl s R2, R3' and n are as defined hereinbefore, compound of formula (IV) which is further converted to an epoxide compound of formula (V):
Figure imgf000100_0001
wherein Rl s R2, R3' and n are as defined hereinbefore, compound of formula (V) which is further subjected to coupling with compound of formula (VI):
Figure imgf000100_0002
wherein W is as defined for formula (I), to yield the compound of formula (I-a), a particular case of the compounds of formula (I):
Figure imgf000100_0003
wherein Rl s R2, R3', n and W are as defined hereinbefore, which compound of formula (I/a) may then, if required, be subjected to a reaction removing the R3' group, to yield the compound of formula (I-b), a particular case of the compounds of formula (I):
Figure imgf000101_0001
wherein Rl s R2, n and W are as defined hereinbefore, which compound of formula (I/b) may then, if required, be subjected to a coupling reaction with compound of formula R3"-C1 wherein R3 " represents a linear or branched (Ci-Ce)alkyl group, a linear or branched halo(Ci-C6)alkyl, or a -C(0)-Rs group wherein R8 is as defined for formula (I), to yield the compound of formula (I-c), a particular case of the compounds of formula
(I):
Figure imgf000101_0002
wherein Rl s R2, R3", n and W are as defined hereinbefore, which compounds of formulae (I/a) to (I/c), which constitute the totality of the compounds of formula (I), may then be purified according to a conventional separation technique, which is converted, if desired, into its addition salts with a pharmaceutically acceptable acid or base and which is optionally separated into its isomers according to a conventional separation technique,
it being understood that at any moment considered appropriate during the course of the process described above, some groups (hydroxy, amino...) of the starting reagents or of the synthesis intermediates can be protected, subsequently deprotected and functionalized, as required by the synthesis.
13. Pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to 11 or an addition salt thereof with a pharmaceutically acceptable acid or base in combination with one or more pharmaceutically acceptable excipients.
14. Pharmaceutical composition according to claim 13 for use as pro-apoptotic and/or anti-proliferative agents.
15. Pharmaceutical composition according to claim 14 for use in the treatment of cancers and of auto-immune and immune system diseases.
16. Pharmaceutical composition according to claim 15 for use in the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukemia, cancer of the colon, esophagus and liver, lymphoblastic leukemia, acute myeloid leukemia, lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non- small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer.
17. Use of a pharmaceutical composition according to claim 13 in the manufacture of medicaments for use as pro-apoptotic and/or anti-proliferative agents.
18. Use of a pharmaceutical composition according to claim 13 in the manufacture of medicaments for use in the treatment of cancers and of auto-immune and immune system diseases.
19. Use of a pharmaceutical composition according to claim 13 in the manufacture of medicaments for use in the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukemia, cancer of the colon, esophagus and liver, lymphoblastic leukemia, acute myeloid leukemia, lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer.
20. Compound of formula (I) according to any one of claims 1 to 11 , or an addition salt thereof with a pharmaceutically acceptable acid or base, for use in the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukemia, cancer of the colon, esophagus and liver, lymphoblastic leukemia, acute myeloid leukemia, lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non- small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer.
21. Use of a compound of formula (I) according to any one of claims 1 to 11 or an addition salt thereof with a pharmaceutically acceptable acid or base, in the manufacture of medicaments for use in the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukemia, cancer of the colon, esophagus and liver, lymphoblastic leukemia, acute myeloid leukemia, lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer.
22. Combination of a compound of formula (I) according to any one of claims 1 to 11 with anti-cancer agents selected from genotoxic agents, mitotic poisons, anti-metabolites, proteasome inhibitors, kinase inhibitors, protein-protein interaction inhibitors, immunomodulators, E3 ligase inhibitors, chimeric antigen receptor T-cell therapy and antibodies.
23. Pharmaceutical composition comprising a combination according to claim 22 in combination with one or more pharmaceutically acceptable excipients.
24. Combination according to claim 22 for use in the treatment of cancers.
25. Use of a combination according to claim 22 in the manufacture of medicaments for use in the treatment of cancers.
26. Compound of formula (I) according to any one of claims 1 to 11 for use in the treatment of cancers requiring radiotherapy.
PCT/EP2017/064067 2016-06-10 2017-06-09 New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them WO2017212012A1 (en)

Priority Applications (33)

Application Number Priority Date Filing Date Title
SI201730260T SI3468974T1 (en) 2016-06-10 2017-06-09 New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
KR1020197000834A KR20190016106A (en) 2016-06-10 2017-06-09 Novel piperidinyl derivatives, processes for their preparation and pharmaceutical compositions containing them
MYPI2018002416A MY196562A (en) 2016-06-10 2017-06-09 New Piperidinyl Derivatives, a Process for Their Preparation and Pharmaceutical Compositions Containing Them
ES17727927T ES2775789T3 (en) 2016-06-10 2017-06-09 Novel piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
UAA201900217A UA123794C2 (en) 2016-06-10 2017-06-09 New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
RS20200266A RS60029B1 (en) 2016-06-10 2017-06-09 New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
CU2018000145A CU20180145A7 (en) 2016-06-10 2017-06-09 DERIVATIVE COMPOUNDS (PIPERIDIN-1-IL) (PIPERIDIN-4-IL) METANONE, METHOD OF PREPARATION OF THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
LTEP17727927.0T LT3468974T (en) 2016-06-10 2017-06-09 New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
RU2018147430A RU2743163C2 (en) 2016-06-10 2017-06-09 Novel piperidinyl derivatives, a method for production thereof and pharmaceutical compositions containing them
MX2018015216A MX2018015216A (en) 2016-06-10 2017-06-09 New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them.
CA3027014A CA3027014C (en) 2016-06-10 2017-06-09 Piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
AU2017277734A AU2017277734B2 (en) 2016-06-10 2017-06-09 New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
CR20180564A CR20180564A (en) 2016-06-10 2017-06-09 NEW PIPERIDINYL DERIVATIVES, A PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
MA45222A MA45222B1 (en) 2016-06-10 2017-06-09 Novel piperidinyl derivatives, process for their preparation and pharmaceutical compositions containing them
DK17727927.0T DK3468974T3 (en) 2016-06-10 2017-06-09 NEW PIPERIDINYL DERIVATIVES, A PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JP2018564356A JP6928005B2 (en) 2016-06-10 2017-06-09 Novel piperidinyl derivatives, their preparation methods and pharmaceutical compositions containing them
TNP/2018/000410A TN2018000410A1 (en) 2016-06-10 2017-06-09 New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
US16/306,933 US11046681B2 (en) 2016-06-10 2017-06-09 Substituted piperidines for the treatment of cancer
SG11201810629QA SG11201810629QA (en) 2016-06-10 2017-06-09 New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
CN201780035584.8A CN109311888B (en) 2016-06-10 2017-06-09 Piperidinyl derivatives, process for their preparation and pharmaceutical compositions containing them
EA201892838A EA037211B1 (en) 2016-06-10 2017-06-09 Piperidinyl derivatives, process for their preparation and pharmaceutical compositions containing them
MDE20190460T MD3468974T2 (en) 2016-06-10 2017-06-09 New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
EP17727927.0A EP3468974B1 (en) 2016-06-10 2017-06-09 New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
PE2018003159A PE20220567A1 (en) 2016-06-10 2017-06-09 NEW PIPERIDINIL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
PL17727927T PL3468974T3 (en) 2016-06-10 2017-06-09 New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
BR112018075433-1A BR112018075433A2 (en) 2016-06-10 2017-06-09 piperidinyl derivatives, processes for their preparation and pharmaceutical compositions containing them
MEP-2020-47A ME03670B (en) 2016-06-10 2017-06-09 New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12018502515A PH12018502515A1 (en) 2016-06-10 2018-11-28 New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
IL263463A IL263463B (en) 2016-06-10 2018-12-03 New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
ECSENADI201890144A ECSP18090144A (en) 2016-06-10 2018-12-04 NEW PIPERIDINYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CONC2018/0013210A CO2018013210A2 (en) 2016-06-10 2018-12-06 New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
HRP20200361TT HRP20200361T1 (en) 2016-06-10 2020-03-04 New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
CY20201100414T CY1122870T1 (en) 2016-06-10 2020-05-06 NEW PIPERIDINYL DERIVATIVES, METHOD FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1655392A FR3052452B1 (en) 2016-06-10 2016-06-10 NOVEL PIPERIDINYL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
FR1655392 2016-06-10

Publications (1)

Publication Number Publication Date
WO2017212012A1 true WO2017212012A1 (en) 2017-12-14

Family

ID=56943687

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2017/064067 WO2017212012A1 (en) 2016-06-10 2017-06-09 New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them

Country Status (45)

Country Link
US (1) US11046681B2 (en)
EP (1) EP3468974B1 (en)
JP (1) JP6928005B2 (en)
KR (1) KR20190016106A (en)
CN (1) CN109311888B (en)
AR (1) AR108706A1 (en)
AU (1) AU2017277734B2 (en)
BR (1) BR112018075433A2 (en)
CA (1) CA3027014C (en)
CL (1) CL2018003474A1 (en)
CO (1) CO2018013210A2 (en)
CR (1) CR20180564A (en)
CU (1) CU20180145A7 (en)
CY (1) CY1122870T1 (en)
DK (1) DK3468974T3 (en)
DO (1) DOP2018000270A (en)
EA (1) EA037211B1 (en)
EC (1) ECSP18090144A (en)
ES (1) ES2775789T3 (en)
FR (1) FR3052452B1 (en)
GE (1) GEP20207160B (en)
HR (1) HRP20200361T1 (en)
HU (1) HUE049507T2 (en)
IL (1) IL263463B (en)
LT (1) LT3468974T (en)
MA (1) MA45222B1 (en)
MD (1) MD3468974T2 (en)
ME (1) ME03670B (en)
MX (1) MX2018015216A (en)
MY (1) MY196562A (en)
NI (1) NI201800132A (en)
PE (1) PE20220567A1 (en)
PH (1) PH12018502515A1 (en)
PL (1) PL3468974T3 (en)
PT (1) PT3468974T (en)
RS (1) RS60029B1 (en)
RU (1) RU2743163C2 (en)
SG (1) SG11201810629QA (en)
SI (1) SI3468974T1 (en)
SV (1) SV2018005791A (en)
TN (1) TN2018000410A1 (en)
TW (1) TWI620750B (en)
UA (1) UA123794C2 (en)
UY (1) UY37288A (en)
WO (1) WO2017212012A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019105963A1 (en) * 2017-11-29 2019-06-06 Les Laboratoires Servier New piperidinyl derivatives as inhibitors of ubiquitin specific protease 7
WO2019150119A1 (en) * 2018-01-31 2019-08-08 Almac Discovery Limited 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (usp19)
WO2020079205A1 (en) * 2018-10-19 2020-04-23 Les Laboratoires Servier New amino-pyrimidonyl-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
WO2020115501A1 (en) * 2018-12-06 2020-06-11 Almac Discovery Limited Pharmaceutical compounds and their use as inhibitors of ubiquitin specific protease 19 (usp19)
CN112368276A (en) * 2018-07-05 2021-02-12 法国施维雅药厂 Amino-pyrimidinone derivatives, process for their preparation and pharmaceutical compositions containing them
WO2021161047A1 (en) 2020-02-13 2021-08-19 Almac Discovery Limited Usp7 inhibitor for use in the treatment of cancer
US11672800B2 (en) 2017-04-21 2023-06-13 Epizyme, Inc. Combination therapies with EHMT2 inhibitors

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3426245B1 (en) 2016-03-07 2022-12-14 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
IL272941B2 (en) 2017-08-28 2023-03-01 Enanta Pharm Inc Hepatitis b antiviral agents
AR116474A1 (en) 2018-09-21 2021-05-12 Enanta Pharm Inc 6,7-DIHYDRO-2H-BENZOFUR [2,3-a] QUINOLIZIN-3-CARBOXYL ACID DERIVATIVES AS ANTIVIRAL AGENTS FOR THE TREATMENT OR PREVENTION OF HBV INFECTION
KR20210093951A (en) 2018-11-21 2021-07-28 이난타 파마슈티칼스, 인코포레이티드 Functionalized Heterocycles as Antiviral Agents
WO2020247444A1 (en) 2019-06-03 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
WO2020247575A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
WO2020247561A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
US11738019B2 (en) 2019-07-11 2023-08-29 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US11236108B2 (en) 2019-09-17 2022-02-01 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
CN113087718B (en) * 2020-01-09 2024-02-09 四川科伦博泰生物医药股份有限公司 Thienopyrimidinone compounds and medical application thereof
CN112608320B (en) * 2020-01-16 2023-03-17 中国药科大学 Piperidine compound and preparation method and medical application thereof
WO2021188414A1 (en) 2020-03-16 2021-09-23 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008108957A2 (en) * 2007-03-02 2008-09-12 Schering Corporation Piperidinyl-piperidine and piperazinyl-piperidine for use in the treatment of diabetes or pain
WO2013030218A1 (en) * 2011-09-02 2013-03-07 Hybrigenics Sa Selective and reversible inhibitors of ubiquitin specific protease 7

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2634235A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Combination of an h3 antagonist/inverse agonist and an appetite suppressant
TWI770525B (en) * 2014-12-30 2022-07-11 美商瓦洛健康公司 Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors
JP6985299B2 (en) * 2016-06-10 2021-12-22 レ ラボラトワール セルヴィエ A novel (hetero) aryl substituted piperidinyl derivative, a process for preparing it, and a pharmaceutical composition containing it.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008108957A2 (en) * 2007-03-02 2008-09-12 Schering Corporation Piperidinyl-piperidine and piperazinyl-piperidine for use in the treatment of diabetes or pain
WO2013030218A1 (en) * 2011-09-02 2013-03-07 Hybrigenics Sa Selective and reversible inhibitors of ubiquitin specific protease 7

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
CANCER RES., vol. 47, 1987, pages 939 - 942
COLLERAN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 110, 2013, pages 618 - 623
EDELMAN ET AL., EXPERT REV. MOL. MED, vol. 13, 2011, pages 1 - 17
HAO ET AL., MOL. CELL, vol. 59, 2015, pages 956 - 969
HOLOWATY ET AL., BIOCHEM. SOC. TRANS., vol. 32, 2004, pages 731 - 732
KEMP ET AL., PROGRESS IN MEDICINAL CHEMISTRY, vol. 55, 2016, pages 149 - 192
LOOSDREGT ET AL., IMMUNITY, vol. 39, 2013, pages 259 - 27
LUISE ET AL., PLOS ONE, vol. 6, 2011, pages E15891
NICHOLSON ET AL., CELL BIOCHEM. BIOPHYS., vol. 60, 2011, pages 61 - 68
PAL ET AL., CANCER RES., vol. 74, 2014, pages 4955 - 4966
ROLEN ET AL., MOL. CARCINOG, vol. 45, 2006, pages 260 - 269

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11672800B2 (en) 2017-04-21 2023-06-13 Epizyme, Inc. Combination therapies with EHMT2 inhibitors
WO2019105963A1 (en) * 2017-11-29 2019-06-06 Les Laboratoires Servier New piperidinyl derivatives as inhibitors of ubiquitin specific protease 7
US11332472B2 (en) 2017-11-29 2022-05-17 Les Laboratoires Servier Substituted piperidines as inhibitors of ubiquitin specific protease 7
WO2019150119A1 (en) * 2018-01-31 2019-08-08 Almac Discovery Limited 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (usp19)
CN112135818A (en) * 2018-01-31 2020-12-25 阿尔麦克探索有限公司 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin-specific protease 19(USP19)
JP2021525220A (en) * 2018-01-31 2021-09-24 アルマック・ディスカバリー・リミテッドＡｌｍａｃ Ｄｉｓｃｏｖｅｒｙ Ｌｉｍｉｔｅｄ Its use as an inhibitor of 4-hydroxypiperidine derivatives and ubiquitin-specific protease 19 (USP19)
US11807646B2 (en) 2018-01-31 2023-11-07 Almac Discovery Limited 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19)
JP7464526B2 (en) 2018-01-31 2024-04-09 アルマック・ディスカバリー・リミテッド 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 19 (USP19) - Patent application
CN112368276A (en) * 2018-07-05 2021-02-12 法国施维雅药厂 Amino-pyrimidinone derivatives, process for their preparation and pharmaceutical compositions containing them
WO2020079205A1 (en) * 2018-10-19 2020-04-23 Les Laboratoires Servier New amino-pyrimidonyl-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
WO2020115501A1 (en) * 2018-12-06 2020-06-11 Almac Discovery Limited Pharmaceutical compounds and their use as inhibitors of ubiquitin specific protease 19 (usp19)
WO2021161047A1 (en) 2020-02-13 2021-08-19 Almac Discovery Limited Usp7 inhibitor for use in the treatment of cancer

Also Published As

Publication number Publication date
TW201802092A (en) 2018-01-16
HUE049507T2 (en) 2020-09-28
SI3468974T1 (en) 2020-07-31
PE20220567A1 (en) 2022-04-13
TWI620750B (en) 2018-04-11
MD3468974T2 (en) 2020-05-31
MA45222B1 (en) 2020-04-30
DOP2018000270A (en) 2019-05-15
UY37288A (en) 2018-01-02
BR112018075433A2 (en) 2019-03-19
RU2018147430A (en) 2020-07-10
CR20180564A (en) 2019-03-04
NI201800132A (en) 2019-04-08
PH12018502515B1 (en) 2019-09-30
CA3027014A1 (en) 2017-12-14
CN109311888B (en) 2021-09-14
SG11201810629QA (en) 2018-12-28
US11046681B2 (en) 2021-06-29
KR20190016106A (en) 2019-02-15
SV2018005791A (en) 2019-01-16
RU2743163C2 (en) 2021-02-15
IL263463B (en) 2021-01-31
LT3468974T (en) 2020-04-10
JP6928005B2 (en) 2021-09-01
PH12018502515A1 (en) 2019-09-30
CL2018003474A1 (en) 2019-05-24
EA201892838A1 (en) 2019-06-28
PT3468974T (en) 2020-03-25
AU2017277734A1 (en) 2018-12-20
UA123794C2 (en) 2021-06-02
ME03670B (en) 2020-10-20
CY1122870T1 (en) 2021-05-05
PL3468974T3 (en) 2020-07-13
ES2775789T3 (en) 2020-07-28
TN2018000410A1 (en) 2020-06-15
IL263463A (en) 2019-01-31
EP3468974B1 (en) 2020-02-12
US20190144448A1 (en) 2019-05-16
RS60029B1 (en) 2020-04-30
EP3468974A1 (en) 2019-04-17
AR108706A1 (en) 2018-09-19
CO2018013210A2 (en) 2018-12-28
CU20180145A7 (en) 2019-07-04
FR3052452B1 (en) 2018-06-22
GEP20207160B (en) 2020-10-12
MX2018015216A (en) 2019-04-25
CA3027014C (en) 2021-01-05
ECSP18090144A (en) 2019-01-31
JP2019517556A (en) 2019-06-24
RU2018147430A3 (en) 2020-07-10
CN109311888A (en) 2019-02-05
MY196562A (en) 2023-04-19
MA45222A (en) 2019-04-17
DK3468974T3 (en) 2020-05-11
AU2017277734B2 (en) 2021-07-01
HRP20200361T1 (en) 2020-06-12
EA037211B1 (en) 2021-02-19
FR3052452A1 (en) 2017-12-15

Similar Documents

Publication Publication Date Title
AU2017277734B2 (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
US10016438B2 (en) Bicyclic heterocycles as FGFR4 inhibitors
US10654849B2 (en) (Hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
US10214528B2 (en) Bicyclic heterocycles as FGFR4 inhibitors
KR102039764B1 (en) Novel thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof
CA3083320C (en) Piperidinyl derivatives as inhibitors of ubiquitin specific protease 7
OA19084A (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them.
OA19127A (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them.
EA037563B1 (en) New (hetero)aryl-substituted piperidinyl derivatives, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17727927

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2018564356

Country of ref document: JP

Kind code of ref document: A

Ref document number: 3027014

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018075433

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2017277734

Country of ref document: AU

Date of ref document: 20170609

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 14978

Country of ref document: GE

ENP Entry into the national phase

Ref document number: 20197000834

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017727927

Country of ref document: EP

Effective date: 20190110

ENP Entry into the national phase

Ref document number: 112018075433

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20181207